StudyFinder

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
631 Study Matches

Pancreatic Cancer Early Detection Consortium (PRECEDE)

Naveen Fawas, BS - naveen.fawaz@arborresearch.org

NCT04970056
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database: Cohort 1 Individuals without history of PDAC meeting any of the following criteria:
• 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
• 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
• BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
• Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
• Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
• Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+ Cohort 2 Individuals without history of PDAC meeting any of the following criteria:
• ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
• 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
• 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2) Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort. Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort. Cohort 6a Individuals diagnosed with PDAC after enrollment in PRECEDE meeting any of the following criteria:
• Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
• Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11 Cohort 6b Individuals with a personal history of PDAC meeting any of the following criteria:
• Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
• Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
• Diagnosed ≤ age 45 Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)
Exclusion Criteria:
* Individuals not meeting the criteria above.
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
I'm interested
Share via email
Show 60 locations

Study Locations

Hide all locations
Location Contacts
Azienda Ospedaliera Universitaria Integrata Verona Verona, Salvatore Paiella - (salvatore.paiella@univr.it) Erica Secchettin - (erica.secchettin@univr.it)
Beaumont/Corewell Health Royal Oak, Michigan Tara Rangarajan - (tara.rangarajan@corewellhealth.org)
British Columbia Cancer Agency Vancouver, British Columbia Eugene Cheung - (eugene.cheung1@bccancer.bc.ca)
Cedars-Sinai Medical Center Los Angeles, California Liliana Bancila - (liliana.bancila@cshs.org)
City of Hope Duarte, California Diamond Ward - (diward@coh.org)
Columbia University Irving Medical Center New York, New York Katharine Godfrey - (kb3217@cumc.columbia.edu)
Emory University Hospital Atlanta, Georgia
Epworth Healthcare Richmond, Victoria Ashleigh Poh - (ashleigh.poh@epworth.org.au)
Fox Chase Cancer Center Philadelphia, Pennsylvania Sara Snell - (sara.snell@fccc.edu)
Hackensack Meridian Health Hackensack, New Jersey Christianna Torres - (christianna.torres@hmhn.org)
Hoag Newport Beach, California Alexandria Adams - (alexandria.adams@hoag.org) Zulma Loera - (zulma.loera@hoag.org)
Honor Health Research Institute Scottsdale, Arizona Jeanette Dupree - (jdupree@honorhealth.com)
Hospital Clinic de Barcelona Barcelona, Eva Vaquero - (evaquero@clinic.cat)
Hospital Universitari Arnau de Vilanova Lleida, Lerida Xavier Molero - (xmolero@gss.cat)
Huntsman Cancer Institute Salt Lake City, Utah Jo Lyman - (jo.anson@hci.utah.edu)
Icahn School of Medicine at Mount Sinai New York, New York Joyce Serebrenik - (joyce.serebrenik@mountsinai.org) Storey Harbison - (storey.harbison@mssm.edu)
Illinois CancerCare Peoria, Illinois Carrie Geoffroy - (cgeoffroy@illinoiscancercare.com)
Inova Schar Cancer Institute Fairfax, Virginia Stephanie Van Bebber - (Stephanie.VanBebber@inova.org)
Intermountain Health Salt Lake City, Utah Maricel Purcell - (hrcancerprevention@imail.org)
Landspitali University Hospital Reykjavík, Jóhanna Stefansdottir - (johanste@landspitali.is)
MD Anderson Center Houston, Texas
Massachusetts General Hospital Boston, Massachusetts Danielle Lynch - (dlynch22@mgh.harvard.edu)
Mayo Clinic Arizona Phoenix, Arizona Michele Richardson - (richardson.michele@mayo.edu)
Mayo Clinic Jacksonville Jacksonville, Florida Guillermo Pradieu - (Pradieu.Guillermo@mayo.edu)
McGill University Health Centre Montreal, Quebec Adeline Cuggia - (pancreas.surveillance@muhc.mcgill.ca)
Memorial Sloan Kettering Cancer Center New York, New York Jeffin Naduparambil - (naduparj@mskcc.org)
Moffitt Cancer Center Tampa, Florida Toni Basinski - (Toni.Basinski@Moffitt.Org)
National Cancer Centre Singapore Singapore, Caitlin Nicole - (caitlin.nicole.s.v@nccs.com.sg) Meggie Huang Mochao - (meggie.huang.m.c@nccs.com.sg)
National Cheng Kung University Hospital (NCKUH) Tainan, Taiwan T.O.C. Yung-Yeh Su - (yysu@nhri.edu.tw)
National Taiwan University Hospital Taipei, Wei-Chih David Liao - (david.ntuh@gmail.com)
NorthShore University Healthsystem Evanston, Illinois Aram Rojas - (arojas@northshore.org)
Oregon Health & Science University Portland, Oregon Dove Keith - (keithd@ohsu.edu)
Providence Health and Services Burbank, California Miles Picus - (miles.picus@providence.org)
Ramón y Cajal University Hospital Madrid, Julie Earl - (julie.earl@live.co.uk)
Semmelweis University, Institute of Pancreatic Diseases Budapest, Zoltán Hajnády - (hajnady.zoltan@semmelweis.hu)
Sheba Medical Center Ramat Gan, Maria Raitses - (Maria.RaitsesGurevich@sheba.health.gov.il)
The Ohio State University Columbus, Ohio Angela Lontoc - (angela.lontoc@osumc.edu)
The University of Texas Southwestern Medical Center Dallas, Texas
UC Davis Sacramento, California Anthony Martinez - (axmartinez@ucdavis.edu)
UC Irvine Health Orange, California Jennifer Valerin - (ucstudy@hs.uci.edu)
UC San Diego Moores Cancer Center La Jolla, California Emma Vail - (e2brooks@health.ucsd.edu)
UCLA Health Los Angeles, California Aletta Deranteriassian - (aderanteriassian@mednet.ucla.edu)
UMass Memorial Medical Center Worcester, Massachusetts Paige Malone - (paige.malone@umassmed.edu)
University Health Network Toronto, Ontario Spring Holter - (spring.holter@uhn.ca)
University of California, San Francisco (UCSF) San Francisco, California Kurt Giles - (PancreasCRC@ucsf.edu)
University of Chicago Medicine Chicago, Illinois Nia Howard - (nia.howard@bsd.uchicago.edu)
University of Kansas Medical Center Kansas City, Kansas Na Yu - (nyu3@kumc.edu)
University of Liverpool Liverpool, Annabelle Boughey - (europac@liverpool.ac.uk)
University of Miami Miami, Florida Maria Yow - (mvy6@med.miami.edu) Chloe Brown - (cmb482@med.miami.edu)
University of Michigan Ann Arbor, Michigan Sarah Volk - (stomanic@med.umich.edu) Erika Koeppe - (eskoeppe@med.umich.edu)
University of Nebraska Medical Center Omaha, Nebraska Suzanne Wessling - (suzanne.wessling@unmc.edu)
University of Pennsylvania Philadelphia, Pennsylvania Danny Clay - (Daniel.Clay@Pennmedicine.upenn.edu)
University of Pittsburgh Medical Center (UPMC) Pittsburgh, Pennsylvania Beth Dudley - (dudleyre@upmc.edu)
University of Rochester Medical Center Rochester, New York Chelsea DiBella - (chelsea_dibella@urmc.rochester.edu)
University of Tennessee Graduate School of Medicine Knoxville, Tennessee Tiffany Johnson - (thjohnson@utmck.edu)
University of Virginia Charlottesville, Virginia Evelyn Garcia - (ev4pd@uvahealth.org)
University of Washington Seattle, Washington Lisa Ann Lai - (LLai@medicine.washington.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Tyler Phillips - (phillipst5@vcu.edu)
White Plains Hospital White Plains, New York Griselda Cruz - (grcruz@wphospital.org)
Yale University New Haven, Connecticut Scott Merenda - (scott.merenda@yale.edu)

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

Massey IIT Research Operations - masseyepd@vcu.edu

PHASE1
NCT06966388
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years * Self-reports as Black, Asian, Hispanic/Latin, ethnically originating from the Mediterranean rim or Pacific rim, or she/he tans easily in the sun * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Appendix 1, Section 18) * Attestation by the patient that she/he is not pregnant, lactating, or planning to become pregnant during the study period * Histologic confirmation of breast malignancy (with TNM staging) If the patient did not receive adjuvant chemotherapy, adjuvant radiation must start within 180 days of lumpectomy or mastectomy. If the patient received adjuvant chemotherapy, adjuvant radiation should start within 60 days of the last dose of chemotherapy * Treatment plan includes one of the following: * Conventionally fractionated whole breast radiation (45-50 Gray in 25 fractions) * Moderately hypofractionated whole breast radiation (42.56 Gray in 16 fractions or 40 Gray in 15 fractions) * Conventionally fractionated chest wall radiation (45-50 Gray in 25 fractions) * Treatment of the regional lymph nodes, a tumor bed boost (4-8 fractions), and use of tissue-equivalent bolus on the chest wall may be included at the discretion of the treating physician. * Radiation will be photon-based. Note: If the patient receives a boost, photons and/or electrons may be used at the discretion of the treating physician.
Exclusion Criteria:
* Prior radiotherapy to any portion of the planned treatment site * Current inflammatory breast cancer or gross dermal involvement at initiation of radiotherapy * Concomitant immunotherapy or cytotoxic chemotherapy. Concomitant HER2 directed therapy or concomitant endocrine therapy is allowed * Active rash or dermatitis within the treatment field, or a history of any rash or dermatologic condition within the treatment field * Co-existing medical conditions resulting in life expectancy \< 1 years * Active collagen vascular diseases (ie lupus erythematosus, scleroderma, dermatomyositis) * History of organ transplant or bone marrow transplant * History of hypersensitivity or allergic reaction to any ingredients in the topical azelaic acid formulation * Has used within 1 month prior to baseline: * topical retinoids to the breast * oral retinoids * systemic (oral or injectable) antibiotics known to have an impact on the severity of skin rash or sun-sensitivity (eg, containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim) * systemic corticosteroids or immunosuppressive drugs * Has used on treated breast within 2 weeks prior to baseline: * topical corticosteroids * topical antibiotics * topical medications for skin rash (eg, metronidazole, azelaic acid) * Radiation therapy will be proton therapy or carbon therapy * External beam partial breast irradiation, brachytherapy partial breast irradiation, or intraoperative radiation are included in the treatment plan Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
DRUG: Azelaic Acid
Breast Cancer
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Massey CTO CPC Team - (MasseyCPC@vcu.edu)

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

ctrrecruit@vcu.edu

PHASE2
NCT05554328
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N4 based on the presence of an actionable mutation as defined in EAY191 * Patients must be enrolled on the ComboMATCH Master Registration Trial EAY191 * Patients must have RAS pathway mutations as determined by the ComboMATCH screening assessment * Cohort 1: Patients with histologically confirmed RAS pathway mutant ovarian, primary peritoneal, or fallopian tube ("ovarian") cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1) * Cohort 2: Patients with histologically confirmed RAS pathway mutant endometrial cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1). * Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy, if disease cannot be safely biopsied, or have archival tissue available from within 12 months prior to registration on the ComboMATCH Registration Trial (EAY191) * Patients must have progressed after first-line treatment for recurrent or persistent disease * Patients with ovarian cancer should not be eligible for further platinum-based therapy * Patients with endometrial cancer must have received or been offered an immune oncology agent (alone or in combination with lenvatinib) unless there are existing contraindications for immune oncology agents or lenvatinib * Patients may have received unlimited prior therapy * Patients must have measurable and biopsiable disease. Measurable disease is defined by RECIST 1.1 as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \> 10 mm when measured by CT, magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or \> 20 mm when measured by chest x-ray. Lymph nodes must be \> 15 mm in short axis when measured by CT or MRI * Patients must have at least one "target lesion" separate from the lesion to be biopsied to be used to assess response on this protocol as defined by RECIST version 1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy * Prior therapy must have been completed at least four weeks prior to registration * Age \>= 18 * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 * Hemoglobin (Hgb) \>= 9.5 g/dL with no blood transfusion in the past 28 days (within 14 days prior to registration) * Platelets \>= 100,000/mcl (within 14 days prior to registration) * Absolute neutrophil count (ANC) \>= 1,500/mcl (within 14 days prior to registration) * Patients must have creatinine clearance estimated of \>= 50 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test (within 14 days prior to registration) * Total bilirubin level =\< 1.5 x institutional upper limit of normal (ULN) or =\< 3 x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) (within 14 days prior to registration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (within 14 days prior to registration) * Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of selumetinib or olaparib * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Women of childbearing potential (WOCBP) must agree to use two forms of birth control (hormonal or barrier method of birth control; abstinence) during the study and for 12 weeks after completing treatment * Non-sterilized male partners of WOCBP (including males sterilized by a method other than bilateral orchidectomy e.g., vasectomy) who intend to be sexually active with a female partner must be using an acceptable method of contraception such as male condom plus spermicide (condom alone in countries where spermicides are not approved) from the time of screening throughout the total duration of the study and the drug washout period (at least 16 weeks after the last dose of study intervention) to prevent pregnancy in a partner. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Vasectomized (i.e., sterile) males are considered fertile and should still use a male condom plus spermicide as indicated above during the clinical study * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial * Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression * Extra caution should be taken with olaparib, as it crosses the blood brain barrier and can cause edema in brain metastases * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria:
* Patients who have received any MEK inhibitors * Patients who have progressed while receiving a PARP inhibitor * Patients who have received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia * Patients with uncontrolled intercurrent illness * Patients with \>= grade 2 neuropathy within 14 days of registration * Patients with severe (Child-Pugh C) liver dysfunction * Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and selumetinib or any excipients thereof * Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents * Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to study enrollment even if less than 100% of the daily recommended dosing for vitamin E * Vitamin E must not be taken in the 7 days prior to initiation of treatment with selumetinib * Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or known moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, Fluconazole, verapamil). The required washout period prior to starting olaparib is at least 14 days or 5 half-lives (whichever is longer) before the first dose of study medication * Concomitant use of strong CYP2C19 inhibitors (e.g., ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole). The required washout period prior to starting selumetinib is at least 14 days or 5 half-lives (whichever is longer) before the first dose of study medication * Have received or are receiving an investigational medicinal product (IMP) or other systemic anti-cancer treatment (including chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumor embolization, or monoclonal antibodies) within 4 weeks prior to registration, or within a period during which the IMP or systemic target treatment has not been cleared from the body (e.g., a period of 5 'half-lives'), whichever is longer * Known myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) * Patients who have had previous organ transplant, allogenic bone marrow transplant or double umbilical cord blood transplantation * Patients who have had whole blood transfusion within 28 days prior to registration * Patients with ophthalmological conditions as follows: * Current or past history of retinal pigment epithelial detachment/central serous retinopathy or retinal vein occlusion. * Intraocular pressure \>21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma (irrespective of intraocular pressure \[IOP\]). Subjects with known glaucoma and increased IOP who do not have meaningful vision (light perception only or no light perception) and are not experiencing pain related to the glaucoma, may be eligible after discussion with the study chair * Patients with any other significant abnormality on ophthalmic examination should be discussed with the study chair for potential eligibility * Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor or strabismus) or longstanding orbito-temporal plexiform neurofibroma (PN) (such as visual loss, strabismus) will NOT be considered a significant abnormality for the purposes of the study * Patients with severe, active co-morbidity defined as any of the following: * History and/or confirmed pneumonitis * Uncontrolled hypertension (blood pressure \[BP\] \>= 150/90 mmHg despite medical therapy) * Acute coronary syndrome within 6 months prior to registration * Uncontrolled atrial fibrillation * Known family history of long QT syndrome * Women who are pregnant or unwilling to discontinue nursing
PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration and Biopsy, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, PROCEDURE: Multigated Acquisition Scan, DRUG: Olaparib, DRUG: Selumetinib Sulfate
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
I'm interested
Share via email
Show 282 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Adena Regional Medical Center Chillicothe, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Alaska Women's Cancer Care Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Aultman Health Foundation Canton, Ohio Site Public Contact - (ClinicalReserachDept@aultman.com)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Baystate Medical Center Springfield, Massachusetts Site Public Contact - (tamara.wrenn@baystatehealth.org)
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bryn Mawr Hospital Bryn Mawr, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
CTCA at Western Regional Medical Center Goodyear, Arizona
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Carilion Roanoke Memorial Hospital Roanoke, Virginia
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Centralia Oncology Clinic Centralia, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Centro Comprensivo de Cancer de UPR San Juan, Site Public Contact - (Roster@nrgoncology.org)
Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Dearborn Hospital Dearborn, Michigan
Corewell Health Farmington Hills Hospital Farmington Hills, Michigan
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dayton Physician LLC - Englewood Dayton, Ohio
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dublin Methodist Hospital Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Edwards Comprehensive Cancer Center Huntington, West Virginia Site Public Contact - (Christina.Cole@chhi.org)
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairfield Medical Center Lancaster, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fox Chase Cancer Center Philadelphia, Pennsylvania
Genesee Hematology Oncology PC Flint, Michigan
Genesis Healthcare System Cancer Care Center Zanesville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Good Samaritan Hospital - Cincinnati Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
Harold Alfond Center for Cancer Care Augusta, Maine
Henrico Doctor's Hospital Richmond, Virginia
Henry Ford Saint John Hospital - Macomb Medical Macomb, Michigan Site Public Contact - (kforman1@hfhs.org)
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Huron Gastroenterology PC Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Jersey City Medical Center Jersey City, New Jersey Site Public Contact - (Roster@nrgoncology.org)
John H Stroger Jr Hospital of Cook County Chicago, Illinois
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Kettering Medical Center Kettering, Ohio
Kingman Regional Medical Center Kingman, Arizona Site Public Contact - (research@sncrf.org)
Knox Community Hospital Mount Vernon, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lafayette Family Cancer Center-EMMC Brewer, Maine
Lankenau Medical Center Wynnewood, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Licking Memorial Hospital Newark, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Lyndon Baines Johnson General Hospital Houston, Texas
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson League City League City, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson West Houston Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in Sugar Land Sugar Land, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in The Woodlands Conroe, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MaineHealth Maine Medical Center- Scarborough Scarborough, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Marietta Memorial Hospital Marietta, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Memorial Hospital Marysville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Westchester Harrison, New York
Mercy Health - Perrysburg Hospital Perrysburg, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Health - Saint Anne Hospital Toledo, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Medical Center - Des Moines Des Moines, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Monmouth Medical Center Southern Campus Lakewood, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Mount Carmel East Hospital Columbus, Ohio Site Public Contact - (Jeffh@columbusccop.org)
National Institutes of Health Clinical Center Bethesda, Maryland
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington Site Public Contact - (Memorial-ClinicalTrials@yvmh.org)
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Ochsner Baptist Medical Center New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
OhioHealth Mansfield Hospital Mansfield, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Pickerington Methodist Hospital Pickerington, Ohio
OhioHealth Westerville Medical Campus/Westerville Cancer Center Westerville, Ohio
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
PCR Oncology Arroyo Grande, California Site Public Contact - (research@sncrf.org)
Paoli Memorial Hospital Paoli, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Pennsylvania Hospital Philadelphia, Pennsylvania Site Public Contact - (PennCancerTrials@careboxhealth.com)
Pocono Medical Center East Stroudsburg, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Presbyterian Intercommunity Hospital Whittier, California
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Regional Cancer System-Lacey Lacey, Washington Site Public Contact - (deidre.dillon@providence.org)
Providence Saint Mary Regional Cancer Center Walla Walla, Washington Site Public Contact - (Cheryl.Dodd@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Puerto Rico Hematology Oncology Group Bayamón,
Queen's Cancer Cenrer - POB I Honolulu, Hawaii
Queen's Cancer Center - Kuakini Honolulu, Hawaii
Queen's Medical Center Honolulu, Hawaii
Rapid City Regional Hospital Rapid City, South Dakota
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Riddle Memorial Hospital Media, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Riverside Methodist Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Ann's Hospital Westerville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint Joseph Hospital - Orange Orange, California
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Southern Illinois University School of Medicine Springfield, Illinois
Southern Ohio Medical Center Portsmouth, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Springfield Regional Cancer Center Springfield, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Springfield Regional Medical Center Springfield, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Stanford Cancer Institute Palo Alto Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
State University of New York Upstate Medical University Syracuse, New York
Strecker Cancer Center-Belpre Belpre, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Mark H Zangmeister Center Columbus, Ohio Site Public Contact - (Jeffh@columbusccop.org)
The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii Site Public Contact - (rohta@queens.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Tufts Medical Center Boston, Massachusetts Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UChicago Medicine Northwest Indiana Crown Point, Indiana Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at Saint John Medical Center Westlake, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UPMC Altoona Altoona, Pennsylvania Site Public Contact - (Roster@nrgoncology.org)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Western Maryland Cumberland, Maryland
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (tmyrick@uab.edu)
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Hawaii Cancer Center Honolulu, Hawaii
University of Illinois Chicago, Illinois
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Site Public Contact - (slusserb@med.umich.edu)
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of South Alabama Mitchell Cancer Institute Mobile, Alabama
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
Upper Valley Medical Center Troy, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
VCU Community Memorial Health Center South Hill, Virginia Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Medical Center Renton, Washington Site Public Contact - (research@valleymed.org)
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Virginia Cancer Institute Richmond, Virginia Site Public Contact - (smoore@vacancer.com)
Walter Reed National Military Medical Center Bethesda, Maryland
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
West Virginia University Healthcare Morgantown, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Women and Infants Hospital Providence, Rhode Island

Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension (TREAT-EXT)

Ruby Langeslay, MPH - Ruby.Langeslay@vcuhealth.org

NCT06747884
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria (Congenital Myotonic Dystrophy Group): * Age 5-17 years, 11 months at enrollment. Lower age limit not applicable for participants who have completed ASPIRE-DM1 protocol. Upper age limit not applicable for participants who previously participated in TREAT-01-001 (TREAT-CDM) study * A diagnosis of CDM, defined as: children having symptoms of myotonic dystrophy in the newborn period (\<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500). * Written, voluntary informed consent must be obtained before any study related procedures are conducted. Inclusion Criteria (Childhood Myotonic Dystrophy Group): * Age 3-17 years, 11 months at enrollment. Upper age limit not applicable for participants who previously participated in TREAT-01-001 (TREAT-CDM) study. * A diagnosis of ChDM, defined as: children having cognitive deficits, muscle weakness, myotonia that developed after age 1 and prior to age 10 and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4\>1,500). * Written, voluntary informed consent must be obtained before any study related procedures are conducted.
Exclusion Criteria:
* Any other non-DM1 illness that would interfere with the ability to undergo safe testing or would affect the interpretation of the results, in the opinion of the site investigator * Significant trauma within the past month * Internal metal or devices (exclusion for DEXA component) * Use of anticoagulants, such as warfarin or a direct oral anticoagulant (e.g., dabigatran) due to the increased risk of bleeding with biopsy * Platelet count \<50,000 * History of a bleeding disorder * Participation in a clinical trial involving an investigational product * History of adverse reaction to lidocaine (if participating in muscle biopsy)
Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, Myotonic Dystrophy
DM1, Childhood Myotonic Dystrophy, Congenital Myotonic Dystrophy, Myotonic Dystrophy, Myotonia, Dystrophy Myotonic, DMCRN, TREAT-EXT, TREAT CDM
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Shantel Kyles - (shantel.brown@vcuhealth.org) Levi Headrick - (levi.headrick@vcuhealth.org)

Improving Traumatic Brain Injury Rehab Care With Comm Health Services: a Research Project Within the TBI Model System

Katherine Abbasi - katherine.walker@vcuhealth.org

EARLY_PHASE1
NCT06188364
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants must be adults (age 18 or older). * Must be primary person responsible for supervision/care needs of person with TBI post-IRF discharge. * The person with TBI must have been admitted to the Brain Injury Service Unit at SAI. * If the care partner does not live in the same residence as the person with TBI, they must provide multiple daily check-ins on day-to-day care. * Must agree to use mHealth (texts, calls) and possess or be eligible to acquire a smart phone.
Exclusion Criteria:
* Any severe cognitive impairment that precludes the ability to provide informed consent or safely function as the care partner for a vulnerable adult with TBI.
OTHER: Standard of Care, OTHER: Experimental
Traumatic Brain Injury
Community Health Services, Rehabilitation Care Transitions, Caregiver Supports
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Katherine Abbasi - (katherine.walker@vcuhealth.org) Daniel Klyce - (daniel.klyce@vcuhealth.org)

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Patient Advocacy - Duchenne@regenxbio.com

PHASE2
NCT05693142
Show full eligibility criteria
Hide eligibility criteria
Part 1 - Key
Inclusion Criteria:
* The participant's legal guardian(s) is (are) willing and able to provide written, signed informed consent prior to any study-related procedures; and, where applicable, the minor participant has provided written or verbal assent according to local requirements. * Is a male at least 4 years of age and less than 12 years of age at consent or 1 to \<4 years of age at the time of dosing and ≥ 10 kg at the time of screening. * Must meet any of the following criteria: * DMD gene mutation in exons 18 and above, and a clinical picture consistent with typical DMD with the exception of a participant (Cohort 1b) with DMD gene mutation in exons 12-17. * Participant is able to walk 100 meters independently without assistive devices. Cohort 2c participant must be able to walk 10 meters independently without assistive devices. Cohort 1b participant must be able to walk with or without assistive devices. * Participant is able to complete the TTSTAND per protocol-specific criteria. * Participant has been on a stable dose of systemic glucocorticoids according to the standard of care for at least 12 weeks. Cohort 2c participants must be consistently on or off a stable dose of systemic glucocorticoids according to the standard of care for at least 12 weeks. * Clinical laboratory test results, including hepatic and renal function, are within the normal range during screening, or if abnormal, are not clinically significant, in the opinion of the investigator. * Documentation is provided at screening visit for participant's adherence to the local country's vaccination schedule. The parent(s) or legal guardian(s) must be willing to have their child receive a meningococcal vaccine, if not already vaccinated. * Participant and parent(s)/legal guardian(s) are willing and able to comply with scheduled visits, study intervention administration plan, and study procedures. Part 2 and 3
Inclusion Criteria:
* The participant's legal guardian(s) is (are) willing and able to provide written, signed informed consent prior to any study-related procedures; and, where applicable, the minor participant has provided written or verbal assent according to local requirements. * DMD gene mutation with any mutation except for those with deletions or point mutations in exons 8, 9 and/or 10. * Participant is able to complete the TTSTAND per protocol-specific criteria. * Clinical laboratory test results, including hepatic and renal function, are within the normal range during screening, or if abnormal, are not clinically significant, in the opinion of the investigator. * Documentation is provided at screening visit for participant's adherence to the local country's vaccination schedule. The parent(s) or legal guardian(s) must be willing to have their child receive a meningococcal vaccine, if not already vaccinated. * Participant and parent(s)/legal guardian(s) are willing and able to comply with scheduled visits, study intervention administration plan, and study procedures. * Is a male at least 1 year of age and ≥ 10 kg at the time of screening. * Participants 1 to \<4 years of age must meet the following criteria: * is able to walk 10 meters independently without assistive devices. * must be consistently on or off a stable dose of systemic glucocorticoids according to the standard of care for at least 12 weeks. * Participants 4 years and older must meet the following criteria: * are able to walk 100 meters independently without assistive devices. * have been on a stable dose of systemic glucocorticoids according to the standard of care for at least 12 weeks. * have a NSAA total score ≥16. Part 1
Exclusion Criteria:
* Participant has any condition that would contraindicate treatment with immunosuppression. * Participant has received ataluren (a protein restoration therapy) or an exon-skipping therapy for the treatment of DMD within 6 months of study entry or is unable to refrain from taking ataluren or exon-skipping therapy for a duration of 5 years from the time of RGX-202 administration. * Participant has received any investigational or commercial gene therapy product over his lifetime. * Participant is currently taking any other investigational intervention (other than corticosteroids) or has taken any other investigational intervention (other than corticosteroids) within 3 months prior to the scheduled Day 1 intervention. If your corticosteroid is vamorolone, the participant will be asked to temporarily convert his daily dosing to prednisolone/prednisone during a short period of time around RGX-202 administration. He will be allowed to revert back to his baseline vamorolone regimen at the original per kilogram dose at which he entered the study and should remain on this for 24 months unless the investigator determines that this is not clinically indicated or possible. * Participant has impaired cardiac function defined as a left ventricular ejection fraction of \< 55% on screening cardiac assessments (echocardiogram or MRI). * Participant is not a good candidate for the study, in the opinion of the investigator. Part 2 and 3
Exclusion Criteria:
* Participant has any condition that would contraindicate treatment with immunosuppression. * Participant has received givinostat within 3 months of study entry or has received ataluren (a protein restoration therapy) or an exon-skipping therapy for the treatment of DMD within 6 months of study entry or is unable to refrain from taking ataluren or exon-skipping therapy for a duration of 5 years from the time of RGX-202 administration. * Participant has received any investigational or commercial gene therapy product over his lifetime. * Participant is currently taking any other investigational intervention (other than corticosteroids) or has taken any other investigational intervention (other than corticosteroids) within 3 months prior to the scheduled Day 1 intervention. If your corticosteroid is vamorolone, the participant will be asked to temporarily convert his daily dosing to prednisolone/prednisone during a short period of time around RGX-202 administration. He will be allowed to revert back to his baseline vamorolone regimen at the original per kilogram dose at which he entered the study and should remain on this for 24 months unless the investigator determines that this is not clinically indicated or possible. * Participant has detectable AAV8 total binding antibodies in serum. * Participant has impaired cardiac function defined as a left ventricular ejection fraction of \< 55% on screening cardiac assessments echocardiogram or MRI). * Participant is not a good candidate for the study, in the opinion of the investigator.
GENETIC: RGX-202
Duchenne Muscular Dystrophy
Gene therapy, DMD, Duchenne Muscular Dystrophy, Duchenne
I'm interested
Share via email
Show 16 locations

Study Locations

Hide all locations
Location Contacts
Alberta Children's Hospital Calgary, Alberta Israt Yasmeen, MBT - (Israt.Yasmeen@ahs.ca)
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois Nicole Geanous - (ngeanous@luriechildrens.org)
Arkansas Children's Hospital Little Rock, Arkansas Amber Evans - (evansa17@archildrens.org)
BC Children's Hospital Vancouver, British Columbia Nela Martic - (NMartic3@cw.bc.ca)
Children's Hospital Colorado Aurora, Colorado Michele Yang - (Michele.Yang@childrenscolorado.org) Hannah Kleiner - (Hannah.Kleiner@childrenscolorado.org)
Children's Hospital London Health Science Centre London, Ontario Rhiannon Hicks - (rhiannon.hicks@lhsc.on.ca)
Children's Hospital Of Eastern Ontario Ottawa, Ontario Laura Thompson - (lathompson@cheo.on.ca)
Children's Hospital of Richmond at Virginia Commonwealth University Richmond, Virginia Falgun Patel - (Falgun.Patel@vcuhealth.org)
Children's Hospital of the King's Daughters Norfolk, Virginia Erika Paradiso - (proud.research@chkd.org)
Cincinnati Children's Cincinnati, Ohio Angela Edmondson - (Angela.Edmondson@cchmc.org)
Oregon Health & Science University Portland, Oregon Beata Dyar - (dyar@ohsu.edu)
Rare Disease Research Atlanta, Georgia Lily Goggans - (lily.goggans@rarediseaseresearch.com) Maureen Ikpeoha - (maureen.ikpeoha@rarediseaseresearch.com)
Stanford School of Medicine /Division of Neuromuscular Medicine Palo Alto, California - (neuromuscularresearch@stanford.edu)
The University of Texas Southwestern Medical Center Dallas, Texas Elaine Most - (elaine.most@utsouthwestern.edu)
University of Iowa Iowa City, Iowa Laura Knosp - (laura-knosp@uiowa.edu)
University of Massachusetts Chan Medical School Worcester, Massachusetts Tyler Mola - (tyler.mola@umassmed.edu)

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Clinical Trial Disclosure & Transparency - ClinicalTrialDisclosure@JazzPharma.com

PHASE3
NCT06282575
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria
• Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC).
• Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation, or ablative therapies.
• Received no more than 2 cycles of systemic therapy which is limited to Cisplatin and Gemcitabine (CisGem) with or without a PD-1/L1 inhibitor (physician's choice of durvalumab or pembrolizumab, where approved under local regulations) for advanced unresectable or metastatic disease.
• HER2-positive disease (defined as IHC 3+; or IHC 2+/ ISH+) by IHC and in situ Hybridization (ISH) assay (in participants with IHC 2+ tumors) at a central laboratory on new biopsy tissue or archival tissue from the most recent biopsy.
• Assessable (measurable or non-measurable) disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), per investigator assessment.
• Male or female ≥ 18 years or age (or the legal age of adulthood per country-specific regulations).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ function
• Females of childbearing potential must have a negative pregnancy test result.
• Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control. Exclusion Criteria
• Prior treatment with a HER2-targeted agent
• Prior treatment with checkpoint inhibitors, other than durvalumab or pembrolizumab
• The following BTC histologic subtypes are excluded: small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology, and mucinous cystic neoplasms detected in the biliary tract region.
• Use of systemic corticosteroids.
• Brain metastases
• Severe chronic or active infections
• History of allogeneic organ transplantation.
• Active or prior autoimmune inflammatory conditions
• History of interstitial lung disease or non-infectious pneumonitis.
• Participation in another clinical trial with an investigational medicinal product within the last 3 months.
• Females who are breastfeeding
• Any other medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures.
• Use of phenytoin
DRUG: Zanidatamab, DRUG: Cisplatin, DRUG: Gemcitabine, DRUG: Pembrolizumab, DRUG: Durvalumab
Biliary Tract Cancer
JZP598, ZW25, HER-2 positive BIliary Tract cancer, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma (ICC), Extrahepatic Cholangiocarcinoma (ECC), Zanidatamab, HER-2 overexpression, HER-2 amplification
I'm interested
Share via email
Show 178 locations

Study Locations

Hide all locations
Location Contacts
AIG Hospitals (A Unit of Asian Institute of Gastroenterology) Hyderabad, Telangana
AOU dell'Universit~ degli Studi della Campania Luigi Vanvitelli Napoli,
AdventHealth Hematology and Oncology Orlando, Florida
Aichi Cancer Center Nagoya, Aichi-ken
Akdeniz University Medical Faculty Hospital Antalya,
Asan Medical Center Seoul,
Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona - Onkologie und Palliativmedizin mit Sektionen Hamatologie und Rheumatologie Hamburg,
Atlantic Health System/Morristown Medical Center Morristown, New Jersey
Azienda Ospedaliera Universitaria Integrata Verona Verona,
Azienda Ospedaliero - Universitaria Pisana Pisa,
Azienda Ospedaliero Universitaria di Cagliari Presidio Ospedaliero Duilio Casula Monserrato, Cagliari
Azienda Sanitaria Universitaria Friuli Centrale - P.O. S. Maria della Misericordia Udine,
Biocinetic Ltda Santiago, Santiago Metropolitan
CAIPO Centro para la Atención Integral del Paciente Oncológico San Miguel de Tucumán, Tucumán Province
CHA Bundang Medical Center, CHA University Seongnam-si,
CHU Besancon Besançon, Cedex
CHU Brest Hôpital de la Cavale Blanche Brest,
CHU Estaing Clermont-Ferrand,
CHU Montepellier - Hôpital Saint Eloi Montpellier,
CHU Poitiers Poitiers,
CHU de Bordeaux - Hopital Haut Leveque Pessac, Cedex
CHU de Toulouse- (Toulouse University Hospital Center) Toulouse, Cedex 9
Cancerstudieenheten Huddinge, Karolinska Universitetssjukhuset Huddinge Huddinge,
Centro Médico Privado CEMAIC Córdoba,
Centro Médico en Oncología Clínica EXELSUS S.R.L San Miguel de Tucumán, Tucumán Province
Centro de Investigacion y Especialidades Medicas (CDIEM) Santiago, Santiago Metropolitan
Centro de Investigaciónes Clínicas - Clínica Viedma Viedma, Río Negro Province
Centrul De Oncologie "SF. Nectarie" S.R.L. Craiova, Dolj
Centrul de Oncologie Euroclinic SRL Iași,
Champalimaud Clinical Center Lisbon,
Chang Gung Memorial Hospital Kaohsiung Branch of the Chang Gung Medical Foundation Kaohsiung City,
Chang Gung Memorial Hospital Linkou Branch of the Chang Gung Medical Foundation Taoyuan District,
Charité - Universitätsmedizin Berlin - Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hamatologie und Tumorimmunologie Berlin,
Chiba Cancer Center Chiba, Chiba
Chopda Medicare & Research Centre Pvt. Ltd - Magnum Heart Institute Nashik, Maharashtra
Clinica Universidad de Navarra Pamplona, Navarre
Clínica Puerto Montt Port Montt,
Complejo Hospitalario Universitario de Santiago -Hospital Clinico Universitario de Santiago Santiago de Compostela, A Coruna
Comprehensive Cancer Center, Helsinki University Hospital Helsinki,
Docrates Cancer Center Helsinki,
Fakultni nemocnice Hradec Kralove, Klinika onkologie a radioterapie Hradec Králové,
Fakultni nemocnice v Motole, Onkologicka klinika Prague,
Fakultní nemocnice Brno, Interní hematologická a onkologická klinika Brno,
Fondazione IRCCS Istituto Nazionale per lo studio e la cura dei Tumori Milan,
Fondazione Policlinico Universitario Gemelli-IRCCS Roma,
Fundacao Pio Xii Hospital de Amor de Barretos Barretos,
Fundacion Arturo Lopez Perez (FALP) Santiago, Santiago Metropolitan
Fundación Ars Medica San Salvador de Jujuy, Jujuy Province
Fundação Doutor Amaral Carvalho - Hospital Amaral Carvalho Jaú, São Paulo
Fundação Faculdade Regional de Medicina de São José do Rio Preto (FUNFARME) São José do Rio Preto, São Paulo
Gustave Roussy Villejuif,
Hacettepe University Cancer Institute Ankara, Sihhiye
Hanyang University Seoul Hospital Seoul,
Henry Ford Health System Detroit, Michigan
Hokkaido University Hospital Sapporo, Hokkaido
Hopital Henri Mondor Paris,
Hospital Beaujon University Clichy,
Hospital Clinico Universidad de Chile Santiago, Santiago Metropolitan
Hospital Nossa Senhora Da Conceição/Centro Integrado de Pesquisa em Oncologia CIPO-GHC Porto Alegre,
Hospital Oncologico, Puerto Rico Medical Center Rio Piedras,
Hospital Provincial del Centenario Rosario,
Hospital Regional Universitario de Malaga Málaga, Andalusia
Hospital Universitario 12 de Octubre Madrid,
Hospital Universitario Fundacion Jimenez Diaz Madrid,
Hospital Universitario La Paz Madrid,
Hospital Universitario Miguel Servet Zaragoza,
Hospital Universitario Reina Sofia Córdoba,
Hospital Universitario Virgen Macarena Seville, Andalusia
Hospital Universitario y Politécnico La Fe Valencia,
Hospital de Clinicas de Porto Alegre - HCPA Porto Alegre, Rio Grande do Sul
Hunan Provincial People's Hospital Changsha, Hunan
IRCCS Ospedale Policlinico San Martino Genova, Genoa
Imelda VZW Bonheiden, Antwerpen
Instituo di Candiolo, Fondazione del Piemonte per l'Oncologia (IRCCS) Candiolo, Torino
Institut de Cancerologie de l'Ouest Saint-Herblain,
Instituto Medico de la Fundacion Estudios Clinicos Rosario,
Instituto Nacional de Cancer - INCA Rio de Janeiro,
Instituto Português de Oncologia do Porto Francisco Gentil, EPE Porto,
Institutul Clinic Fundeni Bucharest,
Irmandade Da Santa Casa de Misericordia de Porto Alegre - ISCMPA Porto Alegrev, Rio Grande do Sul
Istanbul University Cerrahpasa Medical Faculty Hospital/Clinical Research Center Istanbul, Fatih
Istituto Clinico Humanitas Rozzano,
James Lind Centro de Investigación Del Cáncer Temuco, Región de la Araucanía
Jilin Cancer Hospital Changchun, Jilin
KLES Dr Prabhakar Kore Hospital and Medical Research Centre Belagavi, Karnataka
Kagoshima University Hospital Kagoshima, Kagoshima-ken
Kanagawa Cancer Center Yokohama,
Kanazawa University Hospital Kanazawa,
Kaohsiung Medical University - Chung-Ho Memorial Hospital Kaohsiung City,
Korea University Anam Hospital Seoul,
Korea University Guro Hospital Seoul,
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IFK) Frankfurt am Main, Hesse
Kuopio University Hospital Kuopio,
Kyorin University Hospital Mitaka-shi, Tokyo-to
Kyoto University Hospital Kyoto,
LMU Universitätsklinikum München, Campus Großhadern, Medizinische Klinik und Poliklinik III - Hämatologie und Onkologie München, Bavaria
Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center New York, New York
Liga Norte Riograndense Contra O Cancer Natal, Rio Grande do Norte
London Health Sciences Centre London, Ontario
Mahamana Pandit Madan Mohan Malviya Cancer Centre Varanasi, Uttar Pradesh
Max Super Speciality Hospital - Saket (a unit of Devki Devi foundation) New Delhi,
Medizinische Hochschule Hannover - Klinik Fur Gastroenterologie, Hepatologie, Infektiologie und Endokrinologie Hanover, Nieder-Sachsen
Memorial Sloan Kettering Cancer Centers New York, New York
Mie University Hospital Tsu, Mie-ken
Military Medical Academy, Clinic for Gastroenterology and Hepatology Belgrade,
Minnesota Oncology Hematology, P.A. Maple Grove, Minnesota
Mount Vernon Cancer Centre Northwood, Middlesex
NHS Foundation Trust Royal Marsden Hospital London, England
National Cancer Center Goyang-si Gyeonggi-do,
National Cancer Center Hospital Tokyo,
National Cancer Center Hospital East Kashiwa-shi, Chiba
National Cheng Kung University Hospital Tainan City,
National Hospital Organization Kyushu Cancer Center Fukuoka,
National Hospital Organization Shikoku Cancer Center Matsuyama, Ehime
National Taiwan University Cancer Center Taipei,
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg Heidelberg, Baden-Wurttemberg
Niigata University Medical and Dental Hospital Niigata, Niigata
Norton Cancer Institute - Audubon Louisville, Kentucky
Ochsner Clinic Foundation New Orleans, Louisiana
Oncology Institute of Vojvodina, Internal Oncology Clinic Kamenitz,
Oncovida Providencia,
Onkologiska mottagningen, Sahlgrenska Universitetssjukhuset Gothenburg,
Onkologiska mottagningen, Skånes Universitetssjukhus Malmö Malmo,
Osaka Prefectural Hospital Organization Osaka International Cancer Institute Osaka, Osaka
Osaka University Hospital Suita,
Pi Health Cancer Hospital Hyderabad, Telangana
Princess Margaret Cancer Centre - University Health Network Toronto, Ontario
Pusan National University Hospital Busan,
Rabin Medical Center, Bellinson Hospital Petah Tikva,
Rajiv Gandhi Cancer Institute And Research Centre New Delhi, National Capital Territory of Delhi
Rambam Health Care Campus Haifa, Haifa District
Rocky Mountain Cancer Centers, LLP Lone Tree, Colorado
Royal Marsden Hospital NHS Foundation Trust Surrey, England
SCRI Oncology Partners Nashville, Tennessee
Saint Francis Cancer Center Greenville, South Carolina
Samsung Medical Center Seoul,
Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do,
Seoul National University Hospital Seoul,
Servicios Médicos URUMED SpA Rancagua, Libertador Gen Bernardo O Higgins
Severance Hospital, Yonsei University Health System Seoul,
Shandong Provincial Third Hospital Jinan, Shandong
Sichuan Cancer Hospital Chengdu,
Spital Clinic Judetean de Urgenta Bihor Oradea, Bihor County
Tata Memorial Hospital Mumbai, Maharashtra
Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus Dresden, Saxony
Tel Aviv Sourasky Medical Center (Ichilov) Tel Aviv,
Texas Oncology - DFW Irving, Texas
The Cancer Institute Hospital of Japanese Foundation For Cancer Research Koto-ku, Tokyo
The Chaim Sheba Medical Center, Tel Hashomer Ramat Gan, HaMerkaz,
The Christie NHS Foundation Trust Manchester,
The First Affiliated Hospital of USTC(Anhui Provincial Hospital) Hefei, Anhui
The First Hospital of Lanzhou University Lanzhou, Gansu
The Hadassah University Medical Center, Ein Kerem Hospital Jerusalem,
The Univerrsity of Texas MD Anderson Cancer Center Houston, Texas
The University of Kansas Cancer Center - Westwood Westwood, Kansas
The University of Tokyo Hospital Bunkyo-ku, Tokyo
Tohoku University Hospital Miyagi,
Trakya University Faculty of Medicine Edirne,
Tufts Medical Center Boston, Massachusetts
UZ Antwerpen Antwerp,
UZ Leuven Leuven,
Unidade Local de Saude de Almada-Seixal, E.P.E. - Hospital Garcia de Orta Almada,
Unidade Local de Saude de Coimbra, EPE - Hospitais da Universidade de Coimbra Coimbra,
Unidade Local de Saúde de São José - Hospital de Santo António dos Capuchos Lisbon,
University Clinical Center of Serbia, Clinic for Gastroenterohepatology Belgrade,
University of Michigan Hospital Ann Arbor, Michigan
University of Texas Southwestern Medical Center Dallas, Texas
Universitätsklinikum Freiburg - Klinik für Innere Medizin II, Freiburg im Breisgau, Baden-Wurttemberg
Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Medizinische Klinik I (MKI) Lübeck, Schleswig-Holstein
Universitätsklinikum Tübingen - Medizinische Universitätsklinik, Innere Medizin I Tübingen, Baden-Wuttemberg
Vall d'Hebron Institute of Oncology/Hospital Universitari de Vall d'Hebron Barcelona,
Veneto Institute of Oncology IOV - I.R.C.C.S. Padua,
Virginia Commonwealth University, VCU Health Richmond, Virginia
West China Hospital Sichuan University Chengdu, Sichuan
Western General Hospital, Edinburgh Cancer Centre Edinburgh, Scotland
Winship Cancer Institute Atlanta, Georgia
Yamaguchi University Hospital Ube,
hospital Italiano de Buenos Aires CABA,

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Wendy Parulekar - wparulekar@ctg.queensu.ca

PHASE2
NCT05640999
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery. * Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed. * Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients' age must be ≥ 18 years. * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. * Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language * Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre * Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy
Exclusion Criteria:
* Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis. * Prior pelvic radiation. * Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years. * Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan) * Patients with a documented positive surgical margin. * Patients with a documented positive peritoneal washings, if performed.
RADIATION: Vaginal brachytherapy, RADIATION: Adjuvant radiotherapy (EBRT +/- brachytherapy), OTHER: Observation
Endometrial Cancer
I'm interested
Share via email
Show 85 locations

Study Locations

Hide all locations
Location Contacts
Alaska Womens Cancer Care Anchorage, Alaska
Arthur J.E. Child Comprehensive Cancer Centre Calgary, Alberta
Ascension Saint Vincent Indianapolis Hospital Indianapolis, Indiana
Asplundh Cancer Pavilion Willow Grove, Pennsylvania
Auckland City Hospital Grafton, Auckland
BCCA - Kelowna Kelowna, British Columbia
BCCA - Prince George Prince George, British Columbia
BCCA - Vancouver Vancouver, British Columbia
BCCA - Victoria Victoria, British Columbia
CHUM-Centre Hospitalier de l'Universite de Montreal Montreal, Quebec
CIUSSS de l'Estrie - Centre hospitalier Sherbrooke, Quebec
Calvary Mater Newcastle Hospital Waratah, New South Wales
Canberra Hospital Garran, Australian Capital Territory
Case Western Reserve University Cleveland, Ohio
Catharina Ziekenhuis Eindhoven, North Brabant
Cedars-Sinai Medical Center Los Angeles, California
Christchurch Hospital Christchurch,
Cross Cancer Institute Edmonton, Alberta
Duke University Medical Center Durham, North Carolina
Duke Womens Cancer Care Raleigh Raleigh, North Carolina
Emory Decatur Hospital Decatur, Georgia
Emory Saint Josephs Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital Winship Cancer Institute Atlanta, Georgia
Erasmus Medical Center (EMC) Rotterdam,
European Institute of Oncology Milan,
Farmington Health Centre Farmington, Utah
First Physicians Group-Sarasota Sarasota, Florida
Florida Cancer Specialists - Sarasota Downtown Sarasota, Florida
Florida Cancer Specialists - Venice Pinebrook Venice, Florida
Frankston Hospital Frankston, Victoria
Grady Health System Atlanta, Georgia
Huntington Memorial Hospital Pasadena, California
Huntsman Cancer Institute University of Utah Salt Lake City, Utah
Institut Gustave-Roussy Villejuif, FR
Institut Universitaire du Cancer de Toulouse - IUCT Toulouse, Occitanie
Leiden University Medical Center (LUMC) Leiden,
London Health Sciences Centre Research Inc. London, Ontario
M.D. Anderson Cancer Center Houston, Texas
MC Haaglanden The Hague, South Holland
Maastro clinic (Maastricht UMC) Maastricht, Limburg
Mater Research Institute South Brisbane South Brisbane, Queensland
Medical College of Wisconsin Milwaukee, Wisconsin
Monash Medical Centre Clayton, Victoria
Mount Sinai Chelsea New York, New York
Mount Sinai Hospital New York, New York
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois
Northwestern University Chicago, Illinois
Odette Cancer Centre Toronto, Ontario
Ohio State University Comprehensive Columbus, Ohio
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania
Piedmont Hospital Atlanta, Georgia
Providence Portland Medical Centre Portland, Oregon
Radiotherapiegroep Arnhem, Gelderland
Royal Brisbane and Womens Hospital Herston,
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin
Sarasota Memorial Health Care Centre Sarasota, Florida
Sarasota Memorial Hospital Sarasota, Florida
Sarasota Memorial Hospital - Venice N. Venice, Florida
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey
South Western Sydney Local Health District Liverpool, New South Wales
State University Of New York Syracuse, New York
Sutter Medical Center Sacramento Sacramento, California
Swedish Medical Center First Hill Seattle, Washington
The Jewish General Hospital Montreal, Quebec
The Royal Women's Hospital Parkville, Victoria
Thomas Jefferson University Philadelphia, Pennsylvania
Trillium Health Partners - Credit Valley Hospital Mississauga, Ontario
UCHealth University of Colorado Hospital Aurora, Colorado
UMass Memorial Medical Centre Worcester, Massachusetts
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
University Health Network Toronto, Ontario
University Medical Center New Orleans New Orleans, Louisiana
University of Arizona Cancer Center Tucson, Arizona
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma
University of Utah Sugarhouse Health Centre Salt Lake City, Utah
University of Virginia Cancer Center Charlottesville, Virginia
Upstate Cancer Center Radiation Oncology at Oswego Oswego, New York
Upstate Cancer Center at Hill Radiation Oncology Syracuse, New York
Upstate Cancer Center at Verona Verona, New York
Virginia Commonwealth University Richmond, Virginia
Washington University School of Medicine St Louis, Missouri
Westmead Hospital Sydney, New South Wales
Women and Infants Hospital Providence, Rhode Island
Womens Cancer Center of Nevada Las Vegas, Nevada

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

ctrrecruit@vcu.edu

PHASE2
NCT06064097
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must be ≤ 21 years of age at the time of study enrollment * Newly diagnosed American Joint Committee on Cancer (AJCC) stage II-IV nasopharyngeal carcinoma (NPC) * Patients must have had histologic verification of the malignancy at original diagnosis * Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended * Patients must have had histologic verification of the malignancy at original diagnosis * Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended * Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients \> 16 years of age) performance status score of ≥ 60% * Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy) * Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy) * Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m\^2 or (within 7 days prior to start of protocol therapy) * A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL) 1 month to \< 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to \< 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female) 1 to \< 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female) 2 to \< 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female) 6 to \< 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to \<13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to \< 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) ≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy) * Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) ≤ 135 U/L\* (within 7 days prior to start of protocol therapy) * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L * Shortening fraction of ≥ 27% by echocardiogram, or * Ejection fraction of ≥ 50% by radionuclide angiogram * No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% if there is clinical indication for determination * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
* Patients who received prior radiotherapy to the head or neck * Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission * Patients with a diagnosis of immunodeficiency * Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded * Patients with a condition requiring systemic treatment with either corticosteroids (\> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses \> 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease * Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis * Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis * Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time * Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer * Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer * Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, PROCEDURE: Chest Radiography, DRUG: Cisplatin, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, OTHER: Electronic Health Record Review, OTHER: Fluciclovine F18, DRUG: Gemcitabine, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Multigated Acquisition Scan, BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, OTHER: Quality-of-Life Assessment, OTHER: Questionnaire Administration, RADIATION: Radiation Therapy, PROCEDURE: X-Ray Imaging
Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
I'm interested
Share via email
Show 66 locations

Study Locations

Hide all locations
Location Contacts
Albany Medical Center Albany, New York
Alfred I duPont Hospital for Children Wilmington, Delaware Site Public Contact - (Allison.bruce@nemours.org)
Arkansas Children's Hospital Little Rock, Arkansas
Arnold Palmer Hospital for Children Orlando, Florida Site Public Contact - (Jennifer.spinelli@orlandohealth.com)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia Site Public Contact - (Olivia.Floyd@choa.org)
Children's Hospital Colorado Aurora, Colorado Site Public Contact - (josh.b.gordon@nsmtp.kp.org)
Children's Hospital New Orleans New Orleans, Louisiana
Children's Hospital and Medical Center of Omaha Omaha, Nebraska
Children's Hospital of Alabama Birmingham, Alabama Site Public Contact - (oncologyresearch@peds.uab.edu)
Children's Hospital of Philadelphia Philadelphia, Pennsylvania Site Public Contact - (CancerTrials@email.chop.edu)
Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania Site Public Contact - (jean.tersak@chp.edu)
Children's Hospital of San Antonio San Antonio, Texas Site Public Contact - (bridget.medina@christushealth.org)
Children's Hospital of the King's Daughters Norfolk, Virginia Site Public Contact - (CCBDCresearch@chkd.org)
Children's Mercy Hospitals and Clinics Kansas City, Missouri Site Public Contact - (rryan@cmh.edu)
Children's National Medical Center Washington D.C., District of Columbia Site Public Contact - (OncCRC_OnCall@childrensnational.org)
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio Site Public Contact - (cancer@cchmc.org)
Connecticut Children's Medical Center Hartford, Connecticut
Cook Children's Medical Center Fort Worth, Texas Site Public Contact - (CookChildrensResearch@cookchildrens.org)
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Dell Children's Medical Center of Central Texas Austin, Texas Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org)
East Carolina University Greenville, North Carolina Site Public Contact - (eubankss@ecu.edu)
Hackensack University Medical Center Hackensack, New Jersey
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Kaiser Permanente Downey Medical Center Downey, California
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Loma Linda University Medical Center Loma Linda, California
Lurie Children's Hospital-Chicago Chicago, Illinois
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
Mary Bridge Children's Hospital and Health Center Tacoma, Washington Site Public Contact - (research@multicare.org)
Mayo Clinic in Rochester Rochester, Minnesota
Nationwide Children's Hospital Columbus, Ohio Site Public Contact - (Melinda.Triplet@nationwidechildrens.org)
Nemours Children's Clinic-Jacksonville Jacksonville, Florida Site Public Contact - (Allison.bruce@nemours.org)
Nemours Children's Hospital Orlando, Florida Site Public Contact - (Allison.bruce@nemours.org)
Newark Beth Israel Medical Center Newark, New Jersey Site Public Contact - (Christine.Kosmides@rwjbh.org)
Nicklaus Children's Hospital Miami, Florida
Penn State Children's Hospital Hershey, Pennsylvania
Phoenix Childrens Hospital Phoenix, Arizona
Prisma Health Richland Hospital Columbia, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Rady Children's Hospital - San Diego San Diego, California
Rainbow Babies and Childrens Hospital Cleveland, Ohio
Riley Hospital for Children Indianapolis, Indiana
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida Site Public Contact - (jennifer.manns@baycare.org)
Saint Jude Children's Research Hospital Memphis, Tennessee Site Public Contact - (referralinfo@stjude.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Seattle Children's Hospital Seattle, Washington
Starship Children's Hospital Grafton, Auckland
The Children's Hospital at TriStar Centennial Nashville, Tennessee
UCSF Benioff Children's Hospital Oakland Oakland, California Site Public Contact - (cogbchoak@ucsf.edu)
UCSF Medical Center-Mission Bay San Francisco, California Site Public Contact - (cancertrials@ucsf.edu)
UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas Site Public Contact - (canceranswerline@UTSouthwestern.edu)
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Florida Health Science Center - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Mississippi Medical Center Jackson, Mississippi
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Children's Hospital Madera, California Site Public Contact - (Research@valleychildrens.org)
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

ctrrecruit@vcu.edu

PHASE3
NCT06058377
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines * NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible * STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer * NOTE: Participants with inflammatory breast cancer are eligible * NOTE: Participants with occult (i.e. undetectable) primary breast cancer with axillary nodal involvement are not eligible, as MammaPrint testing has not been validated on tissue obtained from an axillary lymph node * STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines * STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer * STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease in the same breast or synchronous bilateral primary tumors are eligible, however, all tumors that are biopsied must be hormone receptor positive and HER2 negative per ASCO CAP guidelines and at least one of the tumors must be MammaPrint High-2. MammaPrint can be performed sequentially on biopsies as it is sufficient to have MammaPrint High 2 status on at least one of the lesions * NOTE: Biopsy of multiple lesions in the same breast is not required if the clinical presentation is consistent with a single disease process that is multifocal in nature. However, if there is clinical suspicion of two distinct primary breast malignancies, additional biopsies should be pursued * STEP 1: REGISTRATION (SCREENING): Participants must have either adequate tissue available to submit on-study or a prior known MammaPrint Index Score that is MP2 status * Submitting tissue for on-study MammaPrint testing: * Participants must have a minimum of ten, unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) available from initial tumor biopsy for MammaPrint assessment * NOTE: Participants must agree to have this tissue submitted to Agendia for MammaPrint Index Scoring and to have subsequent results disclosed to Southwest Oncology Group (SWOG) Cancer Research Network OR * Submitting prior known MammaPrint Index Score: * If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy * NOTE: Participants must agree to have their commercial MammaPrint Index Score disclosed to SWOG Cancer Research Network * NOTE: Participants with prior known MammaPrint result that is not MP2 status should not be enrolled to either step of this study * NOTE: Participants enrolling with known MP2 status (i.e. MP already obtained as routine care) must only sign the treatment informed consent form. Screening consent is not required when MP2 status is known prior to study enrollment * STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy * STEP 1: REGISTRATION (SCREENING): Participants must be \>= 18 years old at the time of registration * STEP 1: REGISTRATION (SCREENING): Participants must have body weight \> 30 kg * STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status of 0-2 * STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * STEP 1: REGISTRATION (SCREENING): Participant must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed * STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines * For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations * STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step 1 Registration * STEP 2: RANDOMIZATION: Participants must have MammaPrint High Risk 2 result * For participants submitting tissue for on-study MammaPrint testing: * Participants must be registered to Step 2: Randomization within 84 calendar days (12 weeks) after receiving an MP2 status from the MammaPrint Index score. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) from initial tumor biopsy OR * Submitting commercial MammaPrint Index Score: * If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 1.0 and negative 0.57) tested from initial tumor biopsy * NOTE: Participants without a MammaPrint High-Risk 2 score must not be registered to Step 2 Randomization * STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28 days prior to study Step 2: Randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed * STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study * STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2 * STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within two years prior to Step 2: Randomization * STEP 2: RANDOMIZATION: Participants must not have active autoimmune disease that has required systemic treatment in the past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) prior to Step 2: Randomization. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed * STEP 2: RANDOMIZATION: Participant must have a complete medical history and physical exam within 28 days prior to Step 2: Randomization * STEP 2: RANDOMIZATION: Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to Step 2: Randomization) * STEP 2: RANDOMIZATION: Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to Step 2: Randomization) * STEP 2: RANDOMIZATION: Platelets \>= 100 x 10\^3/uL (within 28 days prior to Step 2: Randomization) * STEP 2: RANDOMIZATION: Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to Step 2: Randomization) * STEP 2: RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 3 × institutional ULN (within 28 days prior to Step 2: Randomization) * STEP 2: RANDOMIZATION: Participants must have a calculated creatinine clearance \>= 50 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to Step 2: Randomization * STEP 2: RANDOMIZATION: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better * STEP 2: RANDOMIZATION: Participants must not have uncontrolled diabetes defined as hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization * STEP 2: RANDOMIZATION: Participants with history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have an undetectable viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization * STEP 2: RANDOMIZATION: Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained while on suppressive therapy within 6 months prior to Step 2: Randomization, if indicated * STEP 2: RANDOMIZATION: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization, if indicated * STEP 2: RANDOMIZATION: Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process and must have a negative pregnancy test at screening. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy * STEP 2: RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System * STEP 2: RANDOMIZATION: Participants who can complete questionnaires in English, or Spanish must be offered the opportunity to participate in the Quality of Life study * STEP 2: RANDOMIZATION: NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * STEP 2: RANDOMIZATION: Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
PROCEDURE: Biospecimen Collection, DRUG: Cyclophosphamide, DRUG: Doxorubicin, BIOLOGICAL: Durvalumab, OTHER: Genetic Testing, PROCEDURE: Mammography, DRUG: Paclitaxel, OTHER: Quality-of-Life Assessment
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
I'm interested
Share via email
Show 507 locations

Study Locations

Hide all locations
Location Contacts
AIS Cancer Center at San Joaquin Community Hospital Bakersfield, California
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Addison Gilbert Hospital Gloucester, Massachusetts
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Allegheny General Hospital Pittsburgh, Pennsylvania
Allegiance Health Jackson, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Alta Bates Summit Medical Center-Herrick Campus Berkeley, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Arnold Palmer Cancer Center Medical Oncology Norwin N. Huntingdon, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Baptist Cancer Center-Grenada Grenada, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Health Corbin Corbin, Kentucky
Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Beebe Health Campus Rehoboth Beach, Delaware Site Public Contact - (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware Site Public Contact - (research@beebehealthcare.org)
Bellin Memorial Hospital Green Bay, Wisconsin
Ben Taub General Hospital Houston, Texas
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Beverly Hospital Beverly, Massachusetts
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bon Secours Memorial Regional Medical Center Mechanicsville, Virginia Site Public Contact - (anne_carmellat@bshsi.org)
Bon Secours Saint Francis Hospital Charleston, South Carolina Site Public Contact - (Julia.Johnson@rsfh.com)
Bon Secours Saint Francis Medical Center Midlothian, Virginia Site Public Contact - (anne_carmellat@bshsi.org)
Bon Secours Saint Mary's Hospital Richmond, Virginia Site Public Contact - (anne_carmellat@bshsi.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Broadlawns Medical Center Des Moines, Iowa
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bryn Mawr Hospital Bryn Mawr, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
California Pacific Medical Center-Pacific Campus San Francisco, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (protocols@swog.org)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Caro Cancer Center Caro, Michigan
Cedars Sinai Medical Center Los Angeles, California
Cedars-Sinai Cancer - Tarzana Tarzana, California
Centro Comprensivo de Cancer de UPR San Juan, Site Public Contact - (ctsucontact@westat.com)
Charleston Oncology - Roper Charleston, South Carolina Site Public Contact - (Julia.Johnson@rsfh.com)
Charleston Oncology - Saint Francis Charleston, South Carolina Site Public Contact - (Julia.Johnson@rsfh.com)
Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
City of Hope Antelope Valley Lancaster, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Comprehensive Cancer Center Duarte, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Newport Beach Newport Beach, California
City of Hope South Bay Torrance, California
City of Hope South Pasadena South Pasadena, California Site Public Contact - (becomingapatient@coh.org)
City of Hope Upland Upland, California Site Public Contact - (becomingapatient@coh.org)
City of Hope at Irvine Lennar Irvine, California
City of Hope at Long Beach Elm Long Beach, California
Columbus Oncology and Hematology Associates Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Columbus Oncology and Hematology Associates Inc Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (HemonCCTrials@geisinger.edu)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Dearborn Hospital Dearborn, Michigan
Corewell Health Farmington Hills Hospital Farmington Hills, Michigan
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
CoxHealth South Hospital Springfield, Missouri
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Delaware Health Center-Grady Cancer Center Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Desert Regional Medical Center Palm Springs, California
Dickstein Cancer Treatment Center White Plains, New York Site Public Contact - (mcortese@wphospital.org)
Divine Providence Hospital Williamsport, Pennsylvania Site Public Contact - (protocols@swog.org)
Doctors Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Drexel Town Square Health Center Oak Creek, Wisconsin
Dublin Methodist Hospital Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Emory Decatur Hospital Decatur, Georgia Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org)
Emory Johns Creek Hospital Johns Creek, Georgia Site Public Contact - (m.lisa.hwang@emory.edu)
Emory Saint Joseph's Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Forbes Hospital Monroeville, Pennsylvania
Froedtert Menomonee Falls Hospital Menomonee Falls, Wisconsin
Froedtert West Bend Hospital/Kraemer Cancer Center West Bend, Wisconsin
Geisinger Cancer Center Dickson City Dickson City, Pennsylvania Site Public Contact - (hemoncctrials@geisinger.edu)
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Genesee Hematology Oncology PC Flint, Michigan
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Glens Falls Hospital Glens Falls, New York
Grady Health System Atlanta, Georgia
Grady Memorial Hospital Atlanta, Georgia Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Grant Medical Center Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
HaysMed Hays, Kansas
Helen F Graham Cancer Center Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Hematology Oncology Associates of Fredericksburg Inc Fredericksburg, Virginia Site Public Contact - (cvaughn@hoafredericksburg.com)
Hennepin County Medical Center Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Henry Ford Health Providence Novi Hospital Novi, Michigan Site Public Contact - (kfife3@hfhs.org)
Henry Ford Health Providence Southfield Hospital Southfield, Michigan Site Public Contact - (kfife3@hfhs.org)
Henry Ford Health Saint John Hospital Detroit, Michigan Site Public Contact - (Kkeenan1@hfhs.org)
Henry Ford Health Warren Hospital Warren, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Hospital Detroit, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford River District Hospital East China Township, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Macomb Medical Macomb, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Van Elslander Grosse Pointe Woods, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Warren Hospital - GLCMS Warren, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Huntington Memorial Hospital Pasadena, California
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Huron Gastroenterology PC Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
IRMC Cancer Center Indiana, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Iowa Methodist Medical Center Des Moines, Iowa
Jefferson Hospital Jefferson Hills, Pennsylvania Site Public Contact - (ddefazio@wpahs.org)
Jersey City Medical Center Jersey City, New Jersey Site Public Contact - (ctsucontact@westat.com)
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Jupiter Medical Center Jupiter, Florida Site Public Contact - (clinicaltrials@jupitermed.com)
Kadlec Clinic Hematology and Oncology Kennewick, Washington Site Public Contact - (research@kadlecmed.org)
Karmanos Cancer Institute at McLaren Greater Lansing Lansing, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Katmai Oncology Group Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
LSU Health Sciences Center at Shreveport Shreveport, Louisiana Site Public Contact - (LPost@lsuhsc.edu)
Lahey Hospital and Medical Center Burlington, Massachusetts Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lahey Medical Center-Peabody Peabody, Massachusetts Site Public Contact - (lhmc-cancer-clinical-trials@lahey.org)
Lankenau Medical Center Wynnewood, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Lawrence Memorial Hospital Lawrence, Kansas Site Public Contact - (Stephanie.Norris@LMH.ORG)
Legacy Cancer Institute Medical Oncology and Day Treatment Vancouver, Washington Site Public Contact - (oncologyresearch@lhs.org)
Legacy Good Samaritan Hospital and Medical Center Portland, Oregon Site Public Contact - (cancer@lhs.org)
Legacy Meridian Park Hospital Tualatin, Oregon
Legacy Mount Hood Medical Center Gresham, Oregon
Legacy Salmon Creek Hospital Vancouver, Washington
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lenox Hill Hospital New York, New York
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Savannah, Georgia Site Public Contact - (underberga@sjchs.org)
Loma Linda University Medical Center Loma Linda, California
Loyola University Medical Center Maywood, Illinois
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MU Health - University Hospital/Ellis Fischel Cancer Center Columbia, Missouri
MU Health Care Goldschmidt Cancer Center Jefferson City, Missouri
Manhattan Eye Ear and Throat Hospital New York, New York
Marshfield Medical Center - Minocqua Minocqua, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mease Countryside Hospital Safety Harbor, Florida Site Public Contact - (research.cto@baycare.org)
Medical Center of the Rockies Loveland, Colorado
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Medical University of South Carolina Charleston, South Carolina Site Public Contact - (hcc-clinical-trials@musc.edu)
Memorial Hospital East Shiloh, Illinois Site Public Contact - (dschwab@wustl.edu)
Memorial Medical Center Modesto, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Mercy Hospital Coon Rapids, Minnesota
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Medical Center Durango, Colorado Site Public Contact - (acline@mdmercy.com)
Mercy Medical Center - Des Moines Des Moines, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri
MetroHealth Medical Center Cleveland, Ohio Site Public Contact - (ababal@metrohealth.org)
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Mills Health Center San Mateo, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Minnesota Oncology - Burnsville Burnsville, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Monmouth Medical Center Southern Campus Lakewood, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Morristown Medical Center Morristown, New Jersey
Morton Plant Hospital Clearwater, Florida
Mount Sinai Chelsea New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Hospital New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Medical Center Miami Beach, Florida Site Public Contact - (yenrique@msmc.com)
Mount Sinai West New York, New York Site Public Contact - (CCTO@mssm.edu)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas Site Public Contact - (Emily.Carvell@bmhcc.org)
NYU Langone Hospital - Brooklyn Brooklyn, New York Site Public Contact - (david.wallach@nyulangone.org)
NYU Langone Hospital - Long Island Mineola, New York Site Public Contact - (cancertrials@nyulangone.org)
Newark Beth Israel Medical Center Newark, New Jersey Site Public Contact - (Christine.Kosmides@rwjbh.org)
North Memorial Medical Health Center Robbinsdale, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Northern Westchester Hospital Mount Kisco, New York Site Public Contact - (AMellor@northwell.edu)
Northwest Cancer Center - Hobart Hobart, Indiana
Northwest Cancer Center - Main Campus Crown Point, Indiana
Northwest Cancer Center - Valparaiso Valparaiso, Indiana Site Public Contact - (CancerResearch@COMHS.org)
Northwest Medical Specialties PLLC Tacoma, Washington Site Public Contact - (research@southsoundcare.org)
Northwest Oncology LLC Dyer, Indiana
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan Site Public Contact - (WI_research_admin@hshs.org)
Ochsner LSU Health - Cancer Treatment Center Shreveport, Louisiana
Ochsner LSU Health Monroe Medical Center Monroe, Louisiana Site Public Contact - (LPost@lsuhsc.edu)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
OhioHealth Mansfield Hospital Mansfield, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Marion General Hospital Marion, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Pickerington Methodist Hospital Pickerington, Ohio
OhioHealth Westerville Medical Campus/Westerville Cancer Center Westerville, Ohio
Oklahoma Cancer Specialists and Research Institute-Tulsa Tulsa, Oklahoma
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Overlook Hospital Summit, New Jersey
PROncology San Juan, Site Public Contact - (info@PRoncology.com)
Palo Alto Medical Foundation Health Care Palo Alto, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Fremont Fremont, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Santa Cruz Santa Cruz, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Sunnyvale Sunnyvale, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Paoli Memorial Hospital Paoli, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Phelps Memorial Hospital Center Sleepy Hollow, New York
Pocono Medical Center East Stroudsburg, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Poudre Valley Hospital Fort Collins, Colorado
Premier Blood and Cancer Center Dayton, Ohio
Prisma Health Cancer Institute - Butternut Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Easley Easley, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Faris Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Greer Greer, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Seneca Seneca, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Greenville Memorial Hospital Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
ProMedica Flower Hospital Sylvania, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
Providence Hood River Memorial Hospital Hood River, Oregon Site Public Contact - (canrsrchstudies@provdience.org)
Providence Medical Foundation - Santa Rosa Santa Rosa, California
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Regional Cancer System-Lacey Lacey, Washington Site Public Contact - (deidre.dillon@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Santa Rosa Memorial Hospital Santa Rosa, California
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Regional Cancer Center-Lee Memorial Health System Fort Myers, Florida Site Public Contact - (protocols@swog.org)
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Renown Regional Medical Center Reno, Nevada
Rex Hematology Oncology Associates-Cary Cary, North Carolina Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
Rex Hematology Oncology Associates-Garner Garner, North Carolina Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
Riddle Memorial Hospital Media, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Ridgeview Medical Center Waconia, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Riverside Methodist Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Robert Wood Johnson University Hospital Somerset Somerville, New Jersey Site Public Contact - (Siby.Varughese@rwjbh.org)
Roper Hospital Charleston, South Carolina Site Public Contact - (Julia.Johnson@rsfh.com)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Rutgers New Jersey Medical School Newark, New Jersey
SSM Health Good Samaritan Mount Vernon, Illinois
SUNY Upstate Medical Center-Community Campus Syracuse, New York
SWOG Portland, Oregon Erin F. Cobain - (ecobain@med.umich.edu)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Anthony Regional Hospital Carroll, Iowa Site Public Contact - (sbenson@iora.org)
Saint Catherine Hospital Indianapolis, Indiana Site Public Contact - (protocols@swog.org)
Saint Charles Health System Bend, Oregon Site Public Contact - (nosall@stcharleshealthcare.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint Francis Regional Medical Center Shakopee, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital East Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida Site Public Contact - (jennifer.manns@baycare.org)
Saint Joseph's/Candler - Bluffton Campus Bluffton, South Carolina Site Public Contact - (underberga@sjchs.org)
Saint Luke's Cancer Center - Allentown Allentown, Pennsylvania
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Hospital - Monroe Campus Stroudsburg, Pennsylvania Site Public Contact - (ctsucontact@westat.com)
Saint Luke's Hospital - Upper Bucks Campus Quakertown, Pennsylvania
Saint Luke's Hospital of Duluth Duluth, Minnesota Site Public Contact - (kdean@slhduluth.com)
Saint Luke's Hospital-Anderson Campus Easton, Pennsylvania Site Public Contact - (ctsucontact@westat.com)
Saint Luke's University Hospital-Bethlehem Campus Bethlehem, Pennsylvania
Saint Mary Medical Center Hobart, Indiana Site Public Contact - (CancerResearch@COMHS.org)
Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan
Saint Vincent Hospital Erie, Pennsylvania
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Salina Regional Health Center Salina, Kansas Site Public Contact - (mleepers@srhc.com)
Schulze Family Foundation Cancer Clinic - Bonita Health Center Bonita Springs, Florida Site Public Contact - (RCCR@leehealth.org)
Shaw Cancer Center Edwards, Colorado
Sibley Memorial Hospital Washington D.C., District of Columbia Site Public Contact - (jquiver1@jhmi.edu)
Sinai Hospital of Baltimore Baltimore, Maryland
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Long Ridge Stamford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Derby Care Center Derby, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut Site Public Contact - (canceranswers@yale.edu)
Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut Site Public Contact - (canceranswers@yale.edu)
South Carolina Cancer Specialists PC Hilton Head Island, South Carolina Site Public Contact - (underberga@sjchs.org)
Southeastern Medical Oncology Center-Clinton Clinton, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Goldsboro Goldsboro, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Jacksonville Jacksonville, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
State University of New York Upstate Medical University Syracuse, New York
Staten Island University Hospital Staten Island, New York
Stony Brook University Medical Center Stony Brook, New York
Sutter Auburn Faith Hospital Auburn, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Medical Center Sacramento Sacramento, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Pacific Medical Foundation Santa Rosa, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Roseville Medical Center Roseville, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Solano Medical Center/Cancer Center Vallejo, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Cancer Institute of New Jersey Hamilton Hamilton, New Jersey
The Community Hospital Munster, Indiana
The Philips Family Cancer Center Southampton, New York
The University of Kansas Cancer Center - Olathe Olathe, Kansas Site Public Contact - (OlatheCCResearch@kumc.edu)
ThedaCare Regional Cancer Center Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Medical Center - Neenah Neenah, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
Thompson Cancer Survival Center Knoxville, Tennessee
Thompson Cancer Survival Center - West Knoxville, Tennessee
Thompson Oncology Group-Oak Ridge Oak Ridge, Tennessee
Tidelands Georgetown Memorial Hospital Georgetown, South Carolina Site Public Contact - (broe@tidelandshealth.org)
Torrance Memorial Physician Network - Cancer Care Torrance, California Site Public Contact - (courtney.steeneken@tmphysicians.com)
Tower Cancer Research Foundation Beverly Hills, California Site Public Contact - (towercancerresearch@toweroncology.com)
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus Elizabeth, New Jersey
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Medical Center Moline, Illinois
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California Site Public Contact - (ucstudy@uci.edu)
UCHealth - Cherry Creek Denver, Colorado Site Public Contact - (protocols@swog.org)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (protocols@swog.org)
UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado
UCHealth Lone Tree Health Center Lone Tree, Colorado Site Public Contact - (protocols@swog.org)
UCHealth University of Colorado Hospital Aurora, Colorado
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California Site Public Contact - (ucstudy@uci.edu)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UI Healthcare Mission Cancer and Blood - Fort Dodge Fort Dodge, Iowa Site Public Contact - (trials@missioncancer.com)
UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie, Maryland
UM Upper Chesapeake Hematology and Oncology - Aberdeen Aberdeen, Maryland Site Public Contact - (nfadrwoski@umm.edu)
UM Upper Chesapeake Medical Center Bel Air, Maryland
UNC REX Cancer Center of Wakefield Raleigh, North Carolina Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
UNC Rex Healthcare Raleigh, North Carolina Site Public Contact - (CancCtrOncologyClinicalResearch@unchealth.unc.edu)
UPMC Cancer Center at UPMC Northwest Seneca, Pennsylvania
UPMC Cancer Center-Washington Washington, Pennsylvania Site Public Contact - (protocols@swog.org)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center - Passavant - Cranberry Cranberry Township, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Butler Health System Butler, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center in Coraopolis Moon Township, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Memorial York, Pennsylvania
UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania Site Public Contact - (klitchfield@PINNACLEHEALTH.org)
UPMC West Mifflin-Cancer Center Jefferson West Mifflin, Pennsylvania
UPMC Western Maryland Cumberland, Maryland
UPMC-Heritage Valley Health System Beaver Beaver, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC-Johnstown/John P. Murtha Regional Cancer Center Johnstown, Pennsylvania
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania
UPMC-Saint Margaret Pittsburgh, Pennsylvania
UW Health Carbone Cancer Center Rockford Rockford, Illinois Site Public Contact - (lkline@uwhealth.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Health Truman Medical Center Kansas City, Missouri
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (tmyrick@uab.edu)
University of Arizona Cancer Center-North Campus Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
University of Illinois Chicago, Illinois
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center at North Kansas City Hospital North Kansas City, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Site Public Contact - (slusserb@med.umich.edu)
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Texas Health Science Center at San Antonio San Antonio, Texas Site Public Contact - (phoresearchoffice@uthscsa.edu)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
Upper Valley Medical Center Troy, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Upstate Cancer Center at Oswego Oswego, New York Site Public Contact - (McDowelE@upstate.edu)
Upstate Cancer Center at Verona Verona, New York Site Public Contact - (McDowelE@upstate.edu)
VCU Community Memorial Health Center South Hill, Virginia Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Virginia Cancer Institute Richmond, Virginia Site Public Contact - (smoore@vacancer.com)
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Wayne State University/Karmanos Cancer Institute Detroit, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Weisberg Cancer Treatment Center Farmington Hills, Michigan Site Public Contact - (ctoadmin@karmanos.org)
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
West Virginia University Charleston Division Charleston, West Virginia
West Virginia University Healthcare Morgantown, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Wexford Health and Wellness Pavilion Wexford, Pennsylvania Site Public Contact - (Dawnmarie.DeFazio@ahn.org)
William E Kahlert Regional Cancer Center/Sinai Hospital Westminster, Maryland
Winter Haven Hospital Winter Haven, Florida Site Public Contact - (Research.CTO@baycare.org)
Women and Infants Hospital Providence, Rhode Island
Women's Diagnostic Center - Munster Munster, Indiana Site Public Contact - (mnicholson@comhs.org)
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)
Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)
Yolanda G Barco Oncology Institute Meadville, Pennsylvania Site Public Contact - (ctsucontact@westat.com)
Zuckerberg San Francisco General Hospital San Francisco, California

The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Boehringer Ingelheim - clintriage.rdg@boehringer-ingelheim.com

PHASE3
NCT06872892
Show full eligibility criteria
Hide eligibility criteria
Inclusion criteria: * Male or female participants. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1 % per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the participant information. * Signed and dated written informed consent prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation. * Age of participants when signing the informed consent ≥18 (at least the legal age of consent in countries where it is greater than 18 years) years. * Clinical history consistent with bronchiectasis (e.g. cough, chronic sputum production, recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by Computed Tomography (CT) scan. Participants whose past CT scan image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than five years. * Participants should be able to produce sputum for screening. * History of documented pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, participants must have had either: * at least 2 exacerbations, or * at least 1 exacerbation and an St. George's Respiratory Questionnaire (SGRQ) Symptoms score of \>40 at screening Visit 1 For participants on stable oral or inhaled antibiotics as chronic treatment for bronchiectasis and participants on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT), at least one exacerbation must have occurred since initiation of stable antibiotics or CFTR-MT. Exclusion criteria: * Any new or newly diagnosed condition of primary or secondary immunodeficiency within 1 year before randomisation. * Allergic bronchopulmonary aspergillosis being treated or requiring treatment. * Tuberculosis or non-tuberculosis mycobacterial infection being treated or requiring treatment * Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the participant at risk by participating in the trial. * Any clinically relevant (at the discretion of the investigator) acute respiratory infection or ongoing pulmonary exacerbation at screening visit or during the screening unless recovered in the opinion of the investigator prior to Visit 2. * Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study. * Major surgery (major according to the investigator's assessment) performed within 6 weeks prior to randomisation or scheduled during trial period. * Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated in situ non-melanoma skin cancers or in situ carcinoma of uterine cervix. * Evidence or medical history of moderate or severe liver disease (Child-Pugh score B or C hepatic impairment). * estimated Glomerular Filtration Rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \<30 mL/min at Visit 1. * Previous treatment with a dipeptidyl peptidase-1 (DPP1) (Cathepsin C (CatC)) inhibitor. (Note: Participants that were randomised and only received placebo in studies with DPP1 (CatC) inhibitor are allowed.) Further exclusion criteria apply.
DRUG: BI 1291583, DRUG: Placebo matching BI 1291583
Bronchiectasis
I'm interested
Share via email
Show 511 locations

Study Locations

Hide all locations
Location Contacts
A.O. dei Colli Napoli, Boehringer Ingelheim - (italia@bitrialsupport.com)
A.O.U.Policlinico G.Martino Messina, Boehringer Ingelheim - (italia@bitrialsupport.com)
AOU Policlinico G. Rodolico San Marco Catania, Boehringer Ingelheim - (italia@bitrialsupport.com)
AOU San Luigi Gonzaga Orbassano (TO), Boehringer Ingelheim - (italia@bitrialsupport.com)
APRILLUS-Asistencia e Investigacion Ciudad Autonoma Buenos Aires, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Aalborg Sygehus Syd Aalborg, Boehringer Ingelheim - (danmark@bitrialsupport.com)
Aarhus University Hospital Aarhus, Boehringer Ingelheim - (danmark@bitrialsupport.com)
Addington Hospital Durban, Boehringer Ingelheim - (southafrica@bitrialsupport.com)
Adnan Menderes Üniversitesi Aydin, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Affiliated Hospital of Nantong University Nantong, Boehringer Ingelheim - (china@bitrialsupport.com)
Affiliated Hospital, Xuzhou Medical college Xuzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
Ain Shams University Clinical Research Center (MASRI) Cairo, Boehringer Ingelheim - (support@bitrialsupport.com)
Air Force Specialized Hospital Cairo, Boehringer Ingelheim - (support@bitrialsupport.com)
Akdeniz Universitesi Tip Fakultesi Antalya, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Akron Children's Hospital Akron, Ohio Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Alfred Hospital Melbourne, Victoria Boehringer Ingelheim - (australia@bitrialsupport.com)
Altamed Specjalistyczna Praktyka Lekarska Pawel Sliwinski Warsaw, Boehringer Ingelheim - (polska@bitrialsupport.com)
Amsterdam UMC Locatie VUMC Amsterdam, Boehringer Ingelheim - (nederland@bitrialsupport.com)
Ankara University Medical Faculty Ankara, Altindag Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Arke SMO S.A. de C.V. Veracruz de Ignacio de La Llave, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Asan Medical Center Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Asklepios Fachkliniken München-Gauting Gauting, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Aso Co.,Ltd Iizuka Hospital Fukuoka, Iizuka, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Asociación Mexicana para la Investigacion Clínica, A.C(AMIC) Pachuca, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Athens Naval Hospital Athens, Boehringer Ingelheim - (hellas@bitrialsupport.com)
Augusta University Augusta, Georgia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Augustiner Krankenhäuser GmbH Cologne, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Azienda Ospedaliera San Martino Genova, Boehringer Ingelheim - (italia@bitrialsupport.com)
Azienda Ospedaliera Universitaria Integrata Verona Verona, Boehringer Ingelheim - (italia@bitrialsupport.com)
Azienda Ospedaliera Universitaria di Padova Padua, Boehringer Ingelheim - (italia@bitrialsupport.com)
Azienda Ospedaliero Universitaria delle Marche Ancona, AN Boehringer Ingelheim - (italia@bitrialsupport.com)
Azienda Socio Sanitaria Territoriale Di Monza Monza (MB), Boehringer Ingelheim - (italia@bitrialsupport.com)
B. P. Poddar Hospital and Medical Research Limited Kolkata, Boehringer Ingelheim - (india@bitrialsupport.com)
BAG Wiesbaden Wiesbaden, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
BLC Clinical Research Burlington, Ontario Boehringer Ingelheim - (canada@bitrialsupport.com)
Belfast City Hospital Belfast, Northern Ireland Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Blackpool Victoria Hospital Blackpool, Lancashire Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Bradford Royal Infirmary Bradford, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
CAPRISA Offices on the King DinuZulu Hospital Complex Springfield, Boehringer Ingelheim - (southafrica@bitrialsupport.com)
CEDIC - Centro de Investigacion Clinica CABA, Boehringer Ingelheim - (argentina@bitrialsupport.com)
CIMS Studienzentrum Bamberg GmbH Bamberg, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
CRC-Alexandria University Alexandria, Boehringer Ingelheim - (support@bitrialsupport.com)
CTC Clinical Trial Consultants AB Uppsala, Boehringer Ingelheim - (sverige@bitrialsupport.com)
Canberra Hospital Garran, Australian Capital Territory Boehringer Ingelheim - (australia@bitrialsupport.com)
Cardio 1 Medical Clinic Winnipeg, Manitoba Boehringer Ingelheim - (canada@bitrialsupport.com)
Caritas-Krankenhaus St. Maria gGmbH Donaustauf, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Central Florida Pulmonary Group Orlando, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Centre Hospitalier de L'Universite de Montreal (CHUM) Montreal, Quebec Boehringer Ingelheim - (canada@bitrialsupport.com)
Centro Dr. Lazaro Langer S.R.L Alberdi Sur, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Centro Respiratorio de Quilmes Quilmes, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Centro de Enfermedades Cardiovasculares (CEC) Bahía Blanca, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Centro de Estudios Clínicos CEC Santiago, Boehringer Ingelheim - (chile@bitrialsupport.com)
Centro de Investigacion Farmacologica del Bajío, S.C. León, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Centro de Investigacion Integral MEDIVEST S.C Chihuahua City, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Centro de Investigación Clinica Belgrano CABA, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Centro de Investigación del Maule Talca, Maule Region Boehringer Ingelheim - (chile@bitrialsupport.com)
Chang Gung Memorial Hospital(Linkou) Taoyuan District, Boehringer Ingelheim - (taiwan@bitrialsupport.com)
Changi General Hospital Singapore, Boehringer Ingelheim - (singapore@bitrialsupport.com)
Charite Universitätsmedizin Berlin KöR Berlin, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Charite Universitätsmedizin Berlin KöR Berlin, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Charlotte Maxeke Hospital Johannesburg, Boehringer Ingelheim - (southafrica@bitrialsupport.com)
Chest Hospital of Athens "Sotiria" Athens, Boehringer Ingelheim - (hellas@bitrialsupport.com)
Chiba University Hospital Chiba, Chiba Boehringer Ingelheim - (nippon@bitrialsupport.com)
China-Japan Friendship Hospital Beijing, Boehringer Ingelheim - (china@bitrialsupport.com)
Cho Ray Hospital Ho Chi Minh City, Boehringer Ingelheim - (vietnam@bitrialsupport.com)
Christchurch Hospital Christchurch, Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Chronos Pesquisa Clinica Brasília, Boehringer Ingelheim - (brasil@bitrialsupport.com)
Chungbuk National University Hospital Cheongju Chungbuk, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Cleveland Clinic Florida Palm Beach Gardens, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Clinical Hospital Centar Sestre Milosrdnice Zagreb, Boehringer Ingelheim - (hrvatska@bitrialsupport.com)
Clinical Hospital Centre Zagreb Zagreb, Boehringer Ingelheim - (hrvatska@bitrialsupport.com)
Clinical Hospital Of Infectious Diseases And Pneumophysiology Dr.Victor Babes Timisoara Timișoara, Boehringer Ingelheim - (romania@bitrialsupport.com)
Clinical Hospital of Pneumophysiology Leon Daniello Cluj-Napoca, Boehringer Ingelheim - (romania@bitrialsupport.com)
Clinical Research Associates of Central PA DuBois, Pennsylvania Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Clinical Research Institute S.C. Tlalnepantla, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Clinical Research of Rock Hill Rock Hill, South Carolina Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Cliniques Universitaires Saint-Luc Brussels, Boehringer Ingelheim - (belgique@bitrialsupport.com)
Columbia University Medical Center-New York Presbyterian Hospital New York, New York Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Complejo Hospitalario de Navarra Pamplona, Boehringer Ingelheim - (espana@bitrialsupport.com)
Complexo Hospitalario Universitario De Santiago Santiago de Compostela, Boehringer Ingelheim - (espana@bitrialsupport.com)
Concord Repatriation General Hospital Concord, Boehringer Ingelheim - (australia@bitrialsupport.com)
Connolly Hospital Blanchardstown Dublin, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Copenhagen University Hospital, Rigshospitalet København Ø, Boehringer Ingelheim - (danmark@bitrialsupport.com)
Cork University Hospital Cork, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Craigavon Area Hospital Portadown, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Da Vinci Private Clinic Pécs, Boehringer Ingelheim - (magyarorszag@bitrialsupport.com)
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Daugavpils Regional Hospital LTD Centre Outpatient Clinic Daugavpils, Boehringer Ingelheim - (latvia@bitrialsupport.com)
Diagnostics And Consultation Center Convex Ltd. Sofia, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Diex Recherche (Sherbrooke) Sherbrooke, Quebec Boehringer Ingelheim - (canada@bitrialsupport.com)
Diex Recherche (Trois-Rivieres) Trois-Rivières, Quebec Boehringer Ingelheim - (canada@bitrialsupport.com)
Dignity Health, St. Joseph's Hospital and Medical Center Phoenix, Arizona Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Dr Ismail Abdullah Cape Town, Boehringer Ingelheim - (southafrica@bitrialsupport.com)
EMED, Center of Medical Services,Private Prac,Rzeszow Rzeszów, Boehringer Ingelheim - (polska@bitrialsupport.com)
Eastern Health-Box Hill Hospital Box Hill, Victoria Boehringer Ingelheim - (australia@bitrialsupport.com)
El Paso Pulmonary Association El Paso, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Element Research Group San Antonio, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Emory University Atlanta, Georgia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Enhancing Care Foundation NPC Mount Edgecombe, Boehringer Ingelheim - (southafrica@bitrialsupport.com)
Equipo Ciencia CABA, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Erasmus Medisch Centrum-ROTTERDAM-50697 Rotterdam, Boehringer Ingelheim - (nederland@bitrialsupport.com)
Essence MD Research Naples, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Evangelische Lungenklinik Berlin Berlin, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Faculdade de Medicina de Botucatu - UNESP Botucatu, Boehringer Ingelheim - (brasil@bitrialsupport.com)
First Affiliated Hospital of Guangzhou Medical University Guangzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
First Affiliated Hospital of Xi'an JiaoTong University Xi'an, Boehringer Ingelheim - (china@bitrialsupport.com)
Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico Milan, Boehringer Ingelheim - (italia@bitrialsupport.com)
Fondazione IRCCS Policlinico S. Matteo Pavia, Boehringer Ingelheim - (italia@bitrialsupport.com)
Freeman Hospital Newcastle upon Tyne, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Froedtert and The Medical College of Wisconsin Milwaukee, Wisconsin Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Fukujuji Hospital Tokyo, Kiyose, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Fukuoka University Hospital Fukuoka, Fukuoka, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Gelre Ziekenhuis Zutphen Zutphen, Boehringer Ingelheim - (nederland@bitrialsupport.com)
General Hospital of Thessaloniki "G. Papanikolaou" Thessaloniki, Boehringer Ingelheim - (hellas@bitrialsupport.com)
Georgetown University Washington D.C., District of Columbia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Government Hospital for Chest and Communicable Diseases (GHCCD) Visakhapatnam, Boehringer Ingelheim - (india@bitrialsupport.com)
Greenslopes Private Hospital Greenslopes, Queensland Boehringer Ingelheim - (australia@bitrialsupport.com)
Guangdong Provincial People's Hospital Guangzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
Guizhou People's Hospital Guiyang, Boehringer Ingelheim - (china@bitrialsupport.com)
HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás Goiânia, Boehringer Ingelheim - (brasil@bitrialsupport.com)
HOP Amiens-Picardie Sud Amiens, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Arnaud de Villeneuve Montpellier, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Cochin Paris, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Croix-Rousse Lyon, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Haut-Lévêque Pessac, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Intercommunal Créteil, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Larrey Tououse, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Nord Laennec Saint-Herblain, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Pasteur Nice, Boehringer Ingelheim - (france@bitrialsupport.com)
HOP Pontchaillou Rennes, Boehringer Ingelheim - (france@bitrialsupport.com)
Hadassah Medical Center, Ein-Karem Jerusalem, Boehringer Ingelheim - (israel@bitrialsupport.com)
Hadassah Medical Center, Ein-Karem Jerusalem, Boehringer Ingelheim - (israel@bitrialsupport.com)
Haga Ziekenhuis The Hague, Boehringer Ingelheim - (nederland@bitrialsupport.com)
Hallym University Kangnam Sacred Heart Hospital Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Hallym University Sacred Heart Hospital Anyang-si, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Hamamatsu University Hospital Hamamatsu-shi, Shizuoka, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Hangzhou First People's Hospital Hangzhou, ZJ Boehringer Ingelheim - (china@bitrialsupport.com)
Hanyang University Medical Center Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Health Center Uzice Užice, Boehringer Ingelheim - (srbija@bitrialsupport.com)
Health Cube Medical Clinics Mandaluyong, Boehringer Ingelheim - (pilipinas@bitrialsupport.com)
Health Partners Specialty Saint Paul, Minnesota Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Heart of Australia Research Institute Chelmer, Queensland Boehringer Ingelheim - (australia@bitrialsupport.com)
Heartlands Hospital Birmingham, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Helios Hanseklinikum Stralsund Stralsund, Mecklenburg-Vorpommern Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Helsinki University Hospital Helsinki, Boehringer Ingelheim - (suomi@bitrialsupport.com)
Hirosaki University Hospital Aomori, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Hokkaido University Hospital Sapporo, Hokkaido Boehringer Ingelheim - (nippon@bitrialsupport.com)
Horizon Clinical Research Group Cypress, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Hospital A Coruña A Coruña, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Aleman Buenos Aires, Buenos Aires F.D. Boehringer Ingelheim - (argentina@bitrialsupport.com)
Hospital Central de Asturias Oviedo, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Clinic de Barcelona Barcelona, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Germans Trias I Pujol Badalona, Barcelona Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Hietzing Vienna, Boehringer Ingelheim - (oesterreich@bitrialsupport.com)
Hospital Infanta Elena Huelva, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Jerez de la Frontera Jerez de la Frontera, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital La Paz Madrid, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Politècnic La Fe Valencia, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Quirónsalud Madrid Pozuelo de Alarcón, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Raja Perempuan Zainab II, Kota Bharu Kelantan, Boehringer Ingelheim - (malaysia@bitrialsupport.com)
Hospital Son Espases Palma de Mallorca, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Sultan Idris Shah Serdang Kajang, Boehringer Ingelheim - (malaysia@bitrialsupport.com)
Hospital Sultanah Bahiyah Alor Star, Kedah Boehringer Ingelheim - (malaysia@bitrialsupport.com)
Hospital Universitari de Girona Doctor Josep Trueta Girona, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Universitario Dr Jose Eleuterio Gonzalez Nuevo León, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Hospital Universitario Dr Jose Eleuterio Gonzalez Nuevo León, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Hospital Universitario Marqués de Valdecilla Santander, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Universitario Puerto Real Puerto Real, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Universitario Virgen de la Arrixaca EL Palmar (EL Palmar), Murcia Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Universitário Lauro Wanderley João Pessoa, Boehringer Ingelheim - (brasil@bitrialsupport.com)
Hospital Vall d'Hebron Barcelona, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Virgen Macarena Seville, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital Virgen del Rocio Seville, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital de Bellvitge L'Hospitalet de Llobregat, Barcelona Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital de Mérida Mérida, Boehringer Ingelheim - (espana@bitrialsupport.com)
Hospital of Lithuanian University of Health Sciences Kauno Klinikos Kaunas, Boehringer Ingelheim - (lithuania@bitrialsupport.com)
Huadong Hospital Affiliated to Fudan University Shanghai, Shanghai Municipality Boehringer Ingelheim - (china@bitrialsupport.com)
Huzhou Central Hospital Huzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
Hvidovre Hospital Hvidovre, Boehringer Ingelheim - (danmark@bitrialsupport.com)
IKF Pneumologie GmbH & Co. KG Frankfurt, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
INCOR e Hospital das Clínicas da Universidade de São Paulo São Paulo, Boehringer Ingelheim - (brasil@bitrialsupport.com)
INS Coeur Poumon Lille, Boehringer Ingelheim - (france@bitrialsupport.com)
IUCPQ (Laval University) Québec, Boehringer Ingelheim - (canada@bitrialsupport.com)
Iatros International Bloemfontein, Free State Boehringer Ingelheim - (southafrica@bitrialsupport.com)
Ibamedica Santa Fe, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Icahn School of Medicine at Mount Sinai New York, New York Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Iloilo Doctors Hospital Iloilo City, Boehringer Ingelheim - (pilipinas@bitrialsupport.com)
Indiana University Indianapolis, Indiana Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Inmedica Vilnius, Boehringer Ingelheim - (lithuania@bitrialsupport.com)
Inova Fairfax Medical Campus Falls Church, Virginia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Institut Perubatan Respiratori Kuala Lumpur, Boehringer Ingelheim - (malaysia@bitrialsupport.com)
Institute for Pulmonary Diseases of Vojvodina Kamenitz, Boehringer Ingelheim - (srbija@bitrialsupport.com)
Institute for Respiratory Health Nedlands, Western Australia Boehringer Ingelheim - (australia@bitrialsupport.com)
Institute of Science Tokyo Hospital Bunkyo-Ku, Tokyo Boehringer Ingelheim - (nippon@bitrialsupport.com)
Instituto Ave Pulmo Mar del Plata, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Instituto de Especialidades de la Salud Rosario Rosario, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Intermountain Healthcare Salt Lake City, Utah Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Irmandade da Santa Casa de Misericordia de Porto Alegre Porto Alegre, Rio Grande do Sul Boehringer Ingelheim - (brasil@bitrialsupport.com)
Istanbul University Medical Faculty Capa Hospital Istanbul, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Istituto Clinico Humanitas Rozzano, Boehringer Ingelheim - (italia@bitrialsupport.com)
Istituto G. Gaslini Genova, Boehringer Ingelheim - (italia@bitrialsupport.com)
Jawahar Lal Nehru Medical College Ajmer, Boehringer Ingelheim - (india@bitrialsupport.com)
Jefferson Health Honickman Center Philadelphia, Pennsylvania Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Jeonbuk National University Hospital Jeonju, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Jiangmen Central Hospital Jiangmen, Guangdong Boehringer Ingelheim - (china@bitrialsupport.com)
Johns Hopkins University Baltimore, Maryland Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Kagoshima University Hospital Kagoshima, Kagoshima-ken Boehringer Ingelheim - (nippon@bitrialsupport.com)
Kameda Clinic Chiba, Kamogawa, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Kanagawa Cardiovascular and Respiratory Center Yokohama, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Kangdong Sacred Heart Hospital Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Kaohsiung Chang Gung Memorial Hospital Kaohsiung City, Boehringer Ingelheim - (taiwan@bitrialsupport.com)
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Boehringer Ingelheim - (taiwan@bitrialsupport.com)
Karolinska University Hospital Stockholm, Boehringer Ingelheim - (sverige@bitrialsupport.com)
Kasr Al Aini, Cairo University Cairo, Boehringer Ingelheim - (support@bitrialsupport.com)
Katholisches Klinikum Bochum gGmbH Bochum, North Rhine-Westphalia Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Keio University Hospital Shinjuku-ku, Tokyo Boehringer Ingelheim - (nippon@bitrialsupport.com)
King Chulalongkorn Memorial Hospital Bangkok, Boehringer Ingelheim - (thai@bitrialsupport.com)
King's College Hospital London, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Klinikum Dortmund gGmbH Dortmund, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Klinikum Wels - Grieskirchen GmbH Wels, Boehringer Ingelheim - (oesterreich@bitrialsupport.com)
Klinikum Westbrandenburg GmbH Potsdam, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Klinikum der Universität München AÖR München, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Konkuk University Medical Center Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Koranyi National Institute For Pulmonolgy Budapest, Boehringer Ingelheim - (magyarorszag@bitrialsupport.com)
Korea University Guro Hospital Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Krankenhaus Martha-Maria Halle-Dölau gGmbH Halle, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Kurashiki Central Hospital Okayama, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Kyoto University Hospital Kyoto, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Kyushu University Hospital Fukuoka, Boehringer Ingelheim - (nippon@bitrialsupport.com)
LUMPII Doctors practice Riga, Boehringer Ingelheim - (latvia@bitrialsupport.com)
Lady Davis Carmel Medical Center Haifa, Boehringer Ingelheim - (israel@bitrialsupport.com)
Liverpool Heart & Chest Hospital Liverpool, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Lung Research Queensland Chermside, Queensland Boehringer Ingelheim - (australia@bitrialsupport.com)
Lungenfachklinik Immenhausen Immenhausen, Hesse Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Lungenheilkunde München-Pasing München, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
M. S. Ramaiah Institute of Health Science Bengaluru, Boehringer Ingelheim - (india@bitrialsupport.com)
M2M Med Sp. z o.o. sp. j. Chorzów, Boehringer Ingelheim - (polska@bitrialsupport.com)
MHAT Rahila Angelova AD Pernik, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Macquarie University North Ryde, New South Wales Boehringer Ingelheim - (australia@bitrialsupport.com)
Malcom Randall VA Medical Center Gainesville, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Manisa Celal Bayar Üniversitesi Tıp Fakültesi Manisa, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Marius Nasta Institute of Pneumophthisiology Bucharest, Boehringer Ingelheim - (romania@bitrialsupport.com)
Marmara University Pendik Training and Research Hospital Istanbul, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Martin-Luther-Universität Halle-Wittenberg Halle, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Massachusetts General Hospital Boston, Massachusetts Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Mater Hospital Brisbane South Brisbane, Queensland Boehringer Ingelheim - (australia@bitrialsupport.com)
Matsue Medical Center Shimane, Matsue, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Matsusaka City Hospital Mie, Matsusaka, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Mautalen- Salud e Investigacion CABA, Boehringer Ingelheim - (argentina@bitrialsupport.com)
Mayo Clinic - Florida Jacksonville, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Mayo Clinic, Rochester Rochester, Minnesota Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Med.Center OLVI Health Center Assotiation,Private Practice Daugavpils, Boehringer Ingelheim - (latvia@bitrialsupport.com)
MediTrial s.r.o. Jindřichův Hradec, Boehringer Ingelheim - (cesko@bitrialsupport.com)
Mediadvance Clinical S.A.P.I de C.V. Chihuahua City, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Medical Center "Pulmovision" Sofia, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Medical Center "Sveti Ivan Rilski" Vidin, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Medical Center K2J2 Wołomin, Boehringer Ingelheim - (polska@bitrialsupport.com)
Medical Center Tara Veliko Tarnovo, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Medical Center Unimed Plovdiv, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Medical University of Graz State Hospital - University Hospital Graz Graz, Boehringer Ingelheim - (oesterreich@bitrialsupport.com)
Medical University of Innsbruck Innsbruck, Boehringer Ingelheim - (oesterreich@bitrialsupport.com)
Medical University of South Carolina Charleston, South Carolina Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Medizinische Hochschule hannover Hanover, Lower Saxony Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Meris Clinical Research-Tampa-70333 Tampa, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Mersin University Research and Training Hospital Chest Diseases Department Yenişehir, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Methodist Heart and Lung Institute San Antonio, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Metroplex Pulmonary & Sleep Center McKinney, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Middlemore Clinical Trials Papatoetoe, Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Midland Healthcare & Research Center Lucknow, Boehringer Ingelheim - (india@bitrialsupport.com)
Minami Kyoto Hospital Kyoto, Joyo, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Momentum Clinical Research Mount Cook, Wellington Region Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Momentum Clinical Research Dunedin Dunedin, Otago Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Momentum clinical Research Tauranga Tauranga, Bay of Plenty Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Motol University Hospital Prague, Boehringer Ingelheim - (cesko@bitrialsupport.com)
Multidisciplinary City Hospital №1 of the Akimat of Astana Astana, Boehringer Ingelheim - (kazakhstan@bitrialsupport.com)
NYU Langone Health Brooklyn, New York Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
NZ Respiratory and Sleep Institute Greenlane East, Auckland Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Nagasaki University Hospital Nagasaki, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Nagoya University Hospital Showa-Ku Nagoya, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Nanjing Drum Tower Hospital Nanjing, Jiangsu Boehringer Ingelheim - (china@bitrialsupport.com)
Nanjing First Hospital Nanjing, Boehringer Ingelheim - (china@bitrialsupport.com)
Narayana Health - Mazumdar Shaw Medical Center Bengaluru, Boehringer Ingelheim - (india@bitrialsupport.com)
National Hospital Organization Kinki-Chuo Chest Medical Center Sakai, Boehringer Ingelheim - (nippon@bitrialsupport.com)
National Jewish Health Denver, Colorado Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
National Lung Hospital Hanoi, Boehringer Ingelheim - (vietnam@bitrialsupport.com)
National Taiwan University Hospital Taipei, Boehringer Ingelheim - (taiwan@bitrialsupport.com)
National Taiwan University Hospital Yun-Lin Branch Douliu Shi, YUN Boehringer Ingelheim - (taiwan@bitrialsupport.com)
National University Hospital-Singapore-42005 Singapore, Boehringer Ingelheim - (singapore@bitrialsupport.com)
Netspiro Clinica Medica Ltda - Respsono São Bernardo do Campo, Boehringer Ingelheim - (brasil@bitrialsupport.com)
New York Medical College - Hawthorne Hawthorne, New York Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
NewYork-Presbyterian/Weill Cornell Medical Center New York, New York Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Newport Native MD, Inc Newport Beach, California Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Nhan Dan Gia Dinh Hospital Ho Chi Minh City, Boehringer Ingelheim - (vietnam@bitrialsupport.com)
Nihon University Itabashi Hospital Tokyo, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Niigata University Medical and Dental Hospital Niigata, Niigata Boehringer Ingelheim - (nippon@bitrialsupport.com)
Ninewells Hospital & Medical School Dundee, Scotland, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Ningbo Medical Center Lihuili Hospital Ningbo, Boehringer Ingelheim - (china@bitrialsupport.com)
Noordwest Ziekenhuisgroep Alkmaar, Boehringer Ingelheim - (nederland@bitrialsupport.com)
Northern General Hospital Sheffield, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Northern Jiangsu People's Hospital Yangzhou, Jiangsu Boehringer Ingelheim - (china@bitrialsupport.com)
Northwell Health Manhasset, New York Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Northwestern University Chicago, Illinois Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Oaxaca Site Management Organization, S.C. Oaxaca City, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Odense University Hospital Odense C, Boehringer Ingelheim - (danmark@bitrialsupport.com)
Office of Ricardo Fernandez-Gonzalez, MD San Juan, Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Oita University Hospital Oita, Yufu, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Oregon Health and Sciences University Portland, Oregon Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Osaka Toneyama Medical Center Osaka, Toyonaka, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Osp. Pediatrico Bambin Gesù Roma, Boehringer Ingelheim - (italia@bitrialsupport.com)
Oulun yliopistollinen keskussairaala Oulu, Boehringer Ingelheim - (suomi@bitrialsupport.com)
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak, Boehringer Ingelheim - (india@bitrialsupport.com)
Paradigm Clinical Research - Redding Redding, California Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Pauls Stradins Clinical University Hospital Riga, Boehringer Ingelheim - (latvia@bitrialsupport.com)
Peking Union Medical College Hospital Beijing, Boehringer Ingelheim - (china@bitrialsupport.com)
Peking University People's Hospital Beijing, Boehringer Ingelheim - (china@bitrialsupport.com)
Peking University Third Hospital Beijing, Boehringer Ingelheim - (china@bitrialsupport.com)
Peninsula Health Frankston, Victoria Boehringer Ingelheim - (australia@bitrialsupport.com)
People's Hospital of Sichuan Province Chengdu, Boehringer Ingelheim - (china@bitrialsupport.com)
Philippine General Hospital Taft, Manila, Boehringer Ingelheim - (pilipinas@bitrialsupport.com)
Pinehurst Medical Clinic, Inc. - East Pinehurst, North Carolina Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
PingXiang People's Hospital Pingxiang, Boehringer Ingelheim - (china@bitrialsupport.com)
Plucna ambulancia Hrebenar s.r.o. Spišská Nová Ves, Boehringer Ingelheim - (slovensko@bitrialsupport.com)
Policlinico "Paolo Giaccone" Palermo, Boehringer Ingelheim - (italia@bitrialsupport.com)
Policlinico S. Orsola-Malpighi Bologna, Boehringer Ingelheim - (italia@bitrialsupport.com)
Premier Medical Associates The Villages, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Prince of Wales Hospital-Hong Kong-20715 Hong Kong, Boehringer Ingelheim - (hongkong@bitrialsupport.com)
ProMedica Physicians Pulmonary and Sleep Medicine - Toledo Toledo, Ohio Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Providence Medical Group Alaska Anchorage, Alaska Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Providence Medical Research Center Spokane, Washington Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
QEII Health Sciences Centre Halifax, Nova Scotia Boehringer Ingelheim - (canada@bitrialsupport.com)
QingDao Municipal Hospital Qingdao, Boehringer Ingelheim - (china@bitrialsupport.com)
Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University Shanghai, Boehringer Ingelheim - (china@bitrialsupport.com)
Queen Mary Hospital Hong Kong, Boehringer Ingelheim - (hongkong@bitrialsupport.com)
Queensland Children's Hospital South Brisbane, Queensland Boehringer Ingelheim - (australia@bitrialsupport.com)
Quirino Memorial Medical Center Quezon City, Boehringer Ingelheim - (pilipinas@bitrialsupport.com)
Rabin Medical Center Beilinson Petah Tikva, Boehringer Ingelheim - (israel@bitrialsupport.com)
Radboud Universitair Medisch Centrum Nijmegen, Boehringer Ingelheim - (nederland@bitrialsupport.com)
Ramathibodi Hospital Bangkok, Bangkok Boehringer Ingelheim - (thai@bitrialsupport.com)
Republic Klaipeda Hospital Klaipėda, Boehringer Ingelheim - (lithuania@bitrialsupport.com)
Respiratory Medicine Centre, private prac., Bialystok Bialystok, Boehringer Ingelheim - (polska@bitrialsupport.com)
Riga 1st Hospital Riga, Boehringer Ingelheim - (latvia@bitrialsupport.com)
Riga East University Hospital Riga, Boehringer Ingelheim - (latvia@bitrialsupport.com)
Royal Brompton Hospital London, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Royal Infirmary of Edinburgh Edinburgh, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Royal Lancaster Infirmary Lancaster, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Royal Papworth Hospital Cambridge, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Royal Prince Alfred Hospital Camperdown, New South Wales Boehringer Ingelheim - (australia@bitrialsupport.com)
Royal Stoke University Hospital Stoke-on-Trent, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Royal University Hospital (Saskatoon) Saskatoon, Saskatchewan Boehringer Ingelheim - (canada@bitrialsupport.com)
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH Essen, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Boehringer Ingelheim - (china@bitrialsupport.com)
Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
SC Medlife S.A Cluj-Napoca, Boehringer Ingelheim - (romania@bitrialsupport.com)
SHATPPD "Dr. Dimitar Gramatikov" Rousse, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
SMG-SNU Boramae Medical Center Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Saga University Hospital Saga, Saga, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Saitama Cardiovascular and Respiratory Center Saitama, Kumagaya, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Samsung Medical Center Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
San Juan Bautista School of Medicine Caguas, Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Sarawak General Hospital Kuching, Sarawak Boehringer Ingelheim - (malaysia@bitrialsupport.com)
Sağlık Bilimleri Üniversitesi Gülhane Eğitim ve Araştırma Hastanesi Ankara, Boehringer Ingelheim - (turkiye@bitrialsupport.com)
Sbalpfz-Vratsa Vratsa, Boehringer Ingelheim - (balgariya@bitrialsupport.com)
Screenmed Sp. z o.o. Piaseczno, Boehringer Ingelheim - (polska@bitrialsupport.com)
Serviços Medicos Respirar Sul Fluminense Barra Mansa, Boehringer Ingelheim - (brasil@bitrialsupport.com)
Severance Hospital Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Shanghai Fifth People's Hospital affiliated to Fudan University Shanghai, Boehringer Ingelheim - (china@bitrialsupport.com)
Shanghai General Hospital Shanghai, Boehringer Ingelheim - (china@bitrialsupport.com)
Shanghai Pulmonary Hospital Shanghai, Shanghai Municipality Boehringer Ingelheim - (china@bitrialsupport.com)
Shengjing Hospital of China Medical University Shengyang, Boehringer Ingelheim - (china@bitrialsupport.com)
Shenzhen People's Hospital Shenzhen, Boehringer Ingelheim - (china@bitrialsupport.com)
Shiga University of Medical Science Hospital Shiga, Otsu, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Siddhi Hospital, C/o Dr. Mutha Hospital Nashik, Boehringer Ingelheim - (india@bitrialsupport.com)
Singapore General Hospital Singapore, Boehringer Ingelheim - (singapore@bitrialsupport.com)
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine Hangzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
Siriraj Hospital Bangkok, Boehringer Ingelheim - (thai@bitrialsupport.com)
Soluciones terapeuticas medico quirurgicas S de RL de CV Mexico City, Boehringer Ingelheim - (mexico@bitrialsupport.com)
Songklanagarind Hospital Songkhla, Boehringer Ingelheim - (thai@bitrialsupport.com)
Southampton General Hospital Southampton, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Specialty Hospital Medico Rijeka, Boehringer Ingelheim - (hrvatska@bitrialsupport.com)
Srinagarind Hospital Khon Kaen, Boehringer Ingelheim - (thai@bitrialsupport.com)
St James's University Hospital Leeds, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
St. Francis Medical Institute Clearwater, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
St. Paul's Hospital (Vancouver) Vancouver, British Columbia Boehringer Ingelheim - (canada@bitrialsupport.com)
St. Vincent's University Hospital Dublin, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Stern Research Partners, LLC Huntersville, North Carolina Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Suining Central Hospital Suining, Boehringer Ingelheim - (china@bitrialsupport.com)
Summit Health Bend, Oregon Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Taichung Veterans General Hospital Taichung, China Boehringer Ingelheim - (taiwan@bitrialsupport.com)
Tampere University Hospital Tampere, Boehringer Ingelheim - (suomi@bitrialsupport.com)
Tan Tock Seng Hospital Singapore, Boehringer Ingelheim - (singapore@bitrialsupport.com)
Technische Universitat Dresden Dresden, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Tenryu Hospital Shizuoka, Hamamatsu, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Terada Clinic, Respiratory Medicine & General practice Hyogo, Himeji, Boehringer Ingelheim - (nippon@bitrialsupport.com)
The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
The Catholic University of Korea, Incheon St. Mary's Hospital Bupyeong-gu, Boehringer Ingelheim - (namhan@bitrialsupport.com)
The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Boehringer Ingelheim - (namhan@bitrialsupport.com)
The First Affiliated Hospital of Anhui Medical University Hefei, Anhui Boehringer Ingelheim - (china@bitrialsupport.com)
The First Affiliated Hospital of NanChang University Nanchang, Jiangxi Boehringer Ingelheim - (china@bitrialsupport.com)
The First Affiliated Hospital of Ningbo University Ningbo, Zhejiang Boehringer Ingelheim - (china@bitrialsupport.com)
The First Affiliated Hospital of Shandong First Medical University Jinan, Boehringer Ingelheim - (china@bitrialsupport.com)
The First Affiliated Hospital of Soochow University Suzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang Boehringer Ingelheim - (china@bitrialsupport.com)
The First Affiliated Hospital, Zhejiang University Hangzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
The First Pulmonary Private Practice Prague, Boehringer Ingelheim - (cesko@bitrialsupport.com)
The Lung Research Center, LLC Chesterfield, Missouri Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
The Prince Charles Hospital Brisbane, Queensland Boehringer Ingelheim - (australia@bitrialsupport.com)
The Royal Children's Hospital Parkville, Victoria Boehringer Ingelheim - (australia@bitrialsupport.com)
The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou, Zhejiang Boehringer Ingelheim - (china@bitrialsupport.com)
The Second Affiliated Hospital of Fujian Medical University Quanzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
The Second Affiliated Hospital to Nanchang University Nanchang, Boehringer Ingelheim - (china@bitrialsupport.com)
The Second Hospital of Jilin University Changchun, Boehringer Ingelheim - (china@bitrialsupport.com)
The Second Xiangya Hospital of Central South University Changsha, Boehringer Ingelheim - (china@bitrialsupport.com)
The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg Heidelberg, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Tianjin Medical University General Hospital Tianjin, Boehringer Ingelheim - (china@bitrialsupport.com)
Tohoku University Hospital Miyagi, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Tokushima University Hospital Tokushima, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Tokyo Women's Medical University Hospital Shinjuku-ku, Tokyo, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Tongji Hospital, Tongji University Shanghai, Boehringer Ingelheim - (china@bitrialsupport.com)
Toranomon Hospital Minato-ku, Tokyo Boehringer Ingelheim - (nippon@bitrialsupport.com)
Torbay Hospital Torquay, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Trialswest Spearwood, Western Australia Boehringer Ingelheim - (australia@bitrialsupport.com)
Turku University Hospital / TYKS Turku, Boehringer Ingelheim - (suomi@bitrialsupport.com)
ULS Braga Braga, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS da Região de Aveiro Aveiro, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS da Região de Leiria, E.P.E. Leiria, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS de Coimbra, E.P.E. Coimbra, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS de Gaia/Espinho, EPE Vila Nova de Gaia, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS de Santa Maria, E.P.E Lisbon, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS de São João Porto, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULS do Alto Ave Guimarães, Boehringer Ingelheim - (portugal@bitrialsupport.com)
ULSAM - Hospital de Santa Luzia Viana do Castelo, Boehringer Ingelheim - (portugal@bitrialsupport.com)
UMC Utrecht Utrecht, Boehringer Ingelheim - (nederland@bitrialsupport.com)
UMass Memorial Medical Center Worcester, Massachusetts Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
UNIV UZ Gent Ghent, Boehringer Ingelheim - (belgique@bitrialsupport.com)
UT Health San Antonio San Antonio, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
UZ Leuven Leuven, Boehringer Ingelheim - (belgique@bitrialsupport.com)
Ulsan University Hospital Ulsan, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Univ. Gen. Hosp. of Patras Pátrai, Boehringer Ingelheim - (hellas@bitrialsupport.com)
Univ. Hospital Martin Martin, Boehringer Ingelheim - (slovensko@bitrialsupport.com)
Universitatsklinikum Freiburg Freiburg im Breisgau, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitatsklinikum Jena Jena, Thuringia Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitatsklinikum Schleswig-Holstein, Campus Kiel Kiel, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitetssjukhuset, Örebro Örebro, Boehringer Ingelheim - (sverige@bitrialsupport.com)
University Clinical Center Nis Niš, Boehringer Ingelheim - (srbija@bitrialsupport.com)
University Clinical Center of Kragujevac Kragujevac, Boehringer Ingelheim - (srbija@bitrialsupport.com)
University Clinical Center of Serbia Belgrade, Boehringer Ingelheim - (srbija@bitrialsupport.com)
University General Hospital of Heraklion Heraklion, Boehringer Ingelheim - (hellas@bitrialsupport.com)
University Hospital Hairmyres East Kilbride, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
University Hospital Llandough Cardiff, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
University Hospital of Lausanne Lausanne, Boehringer Ingelheim - (suisse@bitrialsupport.com)
University Hospitals of Cleveland Cleveland, Ohio Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University Medical Center HCMC Ho Chi Minh City, Boehringer Ingelheim - (vietnam@bitrialsupport.com)
University of Alabama at Birmingham Birmingham, Alabama Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Arizona Tucson, Arizona Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Calgary Calgary, Boehringer Ingelheim - (canada@bitrialsupport.com)
University of California Davis Sacramento, California Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Cincinnati Cincinnati, Ohio Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Florida College of Medicine Jacksonville, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Iowa Hospitals and Clinics Iowa City, Iowa Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Kansas Medical Center Kansas City, Kansas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Malaya Medical Centre Kuala Lumpur, Boehringer Ingelheim - (malaysia@bitrialsupport.com)
University of Maryland St. Joseph Medical Group Pulmonary Care and Sleep Medicine Towson, Maryland Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Miami Miami, Florida Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Michigan Health System Ann Arbor, Michigan Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Mississippi Medical Center Jackson, Mississippi Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Nebraska Medical Center Omaha, Nebraska Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Pennsylvania Philadelphia, Pennsylvania Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Texas Health Science Center at Tyler Tyler, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Texas Medical Branch at Galveston Galveston, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Texas Southwestern Medical Center Dallas, Texas Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Tsukuba Hospital Tsukuba, Boehringer Ingelheim - (nippon@bitrialsupport.com)
University of Vermont Burlington, Vermont Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Washington Seattle, Washington Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
University of Wisconsin Madison, Wisconsin Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Universitätsklinikum Aachen, AöR Aachen, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitätsklinikum Bonn AöR Bonn, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitätsklinikum Frankfurt Frankfurt, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitätsklinikum Köln (AöR) Cologne, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitätsklinikum Münster Münster, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Universitätsspital Basel Basel, Canton of Basel-City Boehringer Ingelheim - (suisse@bitrialsupport.com)
VA Caribbean Healthcare System San Juan, Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
VCA Dubultu Medical center Jūrmala, Boehringer Ingelheim - (latvia@bitrialsupport.com)
Vejle University Hospital Vejle, Boehringer Ingelheim - (danmark@bitrialsupport.com)
Velocity Clinical Research Germany GmbH, Ahrensburg Ahrensburg, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Velocity Clinical Research Germany GmbH, Lübeck Lübeck, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Velocity Clinical Research, Bristol Bristol, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Ventura County Medical Center Ventura, California Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Vilnius University Hospital, Santariskiu Vilnius, Boehringer Ingelheim - (lithuania@bitrialsupport.com)
Virginia Commonwealth University Health Systems Richmond, Virginia Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Vitaz - Campus Sint-Niklaas Sint-Niklaas, Boehringer Ingelheim - (belgique@bitrialsupport.com)
Vivantes Netzwerk für Gesundheit GmbH Berlin, Boehringer Ingelheim - (deutschland@bitrialsupport.com)
Waikato Hospital Hamilton, Boehringer Ingelheim - (newzealand@bitrialsupport.com)
Washington University School of Medicine St Louis, Missouri Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Wenzhou People's Hospital Wenzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
West China Hospital of Sichuan University Chengdu, Sichuan Boehringer Ingelheim - (china@bitrialsupport.com)
West Visayas State University Medical Center Iloilo City, Boehringer Ingelheim - (pilipinas@bitrialsupport.com)
Western General Hospital Edinburgh, Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com)
Westmead Hospital Sydney, New South Wales Boehringer Ingelheim - (australia@bitrialsupport.com)
Wuhan Union Hospital Wuhan, Boehringer Ingelheim - (china@bitrialsupport.com)
Wuxi People's Hospital Wuxi, Boehringer Ingelheim - (china@bitrialsupport.com)
Yale University School of Medicine New Haven, Connecticut Boehringer Ingelheim - (unitedstates@bitrialsupport.com)
Yamaguchi University Hospital Ube, Boehringer Ingelheim - (nippon@bitrialsupport.com)
Yeongnam University Hospital Daegu, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Yixing People'S Hospital Yixing, Boehringer Ingelheim - (china@bitrialsupport.com)
Yonsei University Wonju Severance Christian Hospital Wŏnju, Boehringer Ingelheim - (namhan@bitrialsupport.com)
Zeleznicna Hospital Kosice Košice, Boehringer Ingelheim - (slovensko@bitrialsupport.com)
Zhejiang Hospital Hangzhou, Boehringer Ingelheim - (china@bitrialsupport.com)
Zhongshan Hospital Affiliated to Fudan University Shanghai, Boehringer Ingelheim - (china@bitrialsupport.com)
the First Hospital of Jilin University Changchun, Boehringer Ingelheim - (china@bitrialsupport.com)

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Clinical Trials Administrator - clinicaltrials@regeneron.com

PHASE3
NCT06246916
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:

• Participants with histologically confirmed unresectable stage III and stage IV (metastatic) melanoma per American Joint Committee on Cancer (AJCC), eighth revised edition.
• Participants must not have received prior systemic therapy for unresectable or metastatic melanoma as described in the protocol.
• Measurable disease per RECIST version 1.1.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1
• Adequate bone marrow, hepatic, and kidney function
• Known B-Rapidly Accelerated Fibrosarcoma protein (BRAF) V600 mutation status or submitted sample for BRAF V600 mutation assessment as described in the protocol Key
Exclusion Criteria:
Medical Conditions:
• Uveal, acral or mucosal melanoma.
• Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents as described in the protocol.
• Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection. Mild cancer-related immunodeficiency (such as immunodeficiency treated with gamma globulin and without chronic or recurrent infection) is allowed. Prior/Concomitant Therapy:
• Prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1 as described in the protocol
• Systemic immune suppression as described in the protocol. Other Comorbidities:
• Participants with a history of myocarditis.
• Troponin T (TnT) or troponin I (TnI) \>2x institutional upper limit of normal (ULN).
• Active or untreated brain metastases or spinal cord compression as described in the protocol. Note: Other protocol-defined Inclusion/ Exclusion Criteria apply.
DRUG: fianlimab, DRUG: cemiplimab, DRUG: relatlimab+nivolumab
Melanoma
Unresectable Melanoma, Metastatic Melanoma, Advanced Melanoma, Stage III, Stage IV
I'm interested
Share via email
Show 101 locations

Study Locations

Hide all locations
Location Contacts
Advocate Lutheran General Hospital Park Ridge, Illinois
Allina Health Cancer Institute Minneapolis, Minnesota
Arizona Oncology Associates Tucson, Arizona
Banner MD Anderson Cancer Center Gilbert, Arizona
Beacon Clinic Coeur d'Alene, Idaho
Boca Raton Clinical Research (BRCR) Global Tamarac, Florida
Cancer Specialist of North Florida Jacksonville, Florida
Cancer and Blood Specialty Clinic Los Alamitos, California
Center For Disease And Blood Disorder Fort Worth, Texas
Centre Hospitalier Universitaire de Quebec (CHUQ) - Centre Hospitalier de l'Universite Laval (CHUL) Québec,
Clermont Oncology Center Clermont, Florida
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada
Duke Health System Durham, North Carolina
Eisenhower Medical Center Rancho Mirage, California
Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana
Fox Chase Cancer Center Philadelphia, Pennsylvania
H. Lee Moffitt Cancer Center Tampa, Florida
Hope and Healing Cancer Services Hinsdale, Illinois
Illinois CancerCare Peoria, Illinois
Ironwood Cancer & Research Centers Chandler, Arizona
Joe Arrington Cancer Research & Treatment Center Lubbock, Texas
John B. Amos Cancer Center Columbus, Georgia
John Theurer Cancer Center Hackensack, New Jersey
Kaiser Foundation Hospitals Portland, Oregon
Karmanos Cancer Institute Detroit, Michigan
Levine Cancer Institute Charlotte, North Carolina
Lifespan Cancer Institute Providence, Rhode Island
London Regional Cancer Centre London, Ontario
Markey Cancer Center Clinical Research Organization Lexington, Kentucky
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana
Maryland Oncology Hematology, P.A. Columbia, Maryland
Mayo Clinic Florida Jacksonville, Florida
Mercy South St Louis, Missouri
Messino Cancer Center Asheville, North Carolina
Minnesota Oncology Hematology, P.A Saint Paul, Minnesota
New York Oncology Hematology Albany, New York
Novant Health Cancer Institute Charlotte, North Carolina
Novant Health Weisiger Cancer Institute - Charlotte Charlotte, North Carolina
Novant Health Zimmer Cancer Institute - Wilmington Wilmington, North Carolina
Oklahoma Cancer Specialists and Research Institute, LLC Tulsa, Oklahoma
Oncology & Hematology Associates of Southwest Virginia, Inc. Roanoke, Virginia
Oncology Associates of Oregon PC Eugene, Oregon
Oncology Hematology Care Clinical Trials Cincinnati, Ohio
Oncology Hematology West P.C. dba Nebraska Cancer Specialists Omaha, Nebraska
Oregon Health and Science University Portland, Oregon
Princess Margaret Cancer Centre Toronto, Ontario
Providence Medical Foundation Santa Rosa, California
Rocky Mountain Regional VA Medical Center Aurora, Colorado
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Saint Francis Cancer Center Greenville, South Carolina
Sansum Clinic Santa Barbara, California
Sarah Cannon Research Institute (SCRI) Oncology Partners Nashville, Tennessee
Seidman Cancer Center Cleveland, Ohio
St John's Cancer Institute Santa Monica, California
St. Joseph Hospital Orange Orange, California
St. Luke's University Health Network Allentown, Pennsylvania
St. Vincent Healthcare Billings, Montana
Sunnybrook Health Sciences Centre Toronto, Ontario
Sutter Health Sacramento, California
Swedish Cancer Institute Seattle, Washington
Swedish Cancer Institute - Edmonds Campus Edmonds, Washington
Swedish Cancer Institute - Issaquah Campus Issaquah, Washington
Tennessee Oncology Nashville, Tennessee
Tennessee Oncology - Chattanooga Chattanooga, Tennessee
Texas Oncology Dallas, Texas
Texas Oncology - Austin Central, Central Austin Cancer Center Austin, Texas
Texas Oncology - Austin Midtown, Midtown Medical Center I Austin, Texas
Texas Oncology - Bedford Bedford, Texas
Texas Oncology - Fort Worth Fort Worth, Texas
Texas Oncology - Grapevine Grapevine, Texas
Texas Oncology - Harlingen, Medical Arts Pavillion Harlingen, Texas
Texas Oncology - Longview Longview, Texas
Texas Oncology - McAllen McAllen, Texas
Texas Oncology - Medical City Dallas, Texas
Texas Oncology - Weslaco, Knapp Medical Plaza Weslaco, Texas
Texas Oncology-Palestine Cancer Center Palestine, Texas
Texas Oncology-Tyler, Northeast Texas Cancer Institute Tyler, Texas
The Melanoma and Skin Cancer Institute Englewood, Colorado
The University of Kansas Cancer Center Westwood, Kansas
The University of Texas Health Science Center at Tyler D/B/A UT Health East Texas HOPE Cancer Center Tyler, Texas
The University of Texas MD Anderson Cancer Center Houston, Texas
The Valley Hospital Inc. Paramus, New Jersey
UCHealth Fort Collins, Colorado
University Cancer & Blood Center Athens, Georgia
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of California Los Angeles Los Angeles, California
University of California San Francisco (UCSF) San Francisco, California
University of Colorado Cancer Center Aurora, Colorado
University of Michigan Ann Arbor, Michigan
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center Pittsburgh, Pennsylvania
University of Tennessee Medical Center Knoxville, Tennessee
University of Utah Huntsman Cancer Institute Salt Lake City, Utah
University of Virginia Charlottesville, Virginia
University of Wisconsin Carbone Cancer Center Madison, Wisconsin
VA St. Louis Healthcare System St Louis, Missouri
Virginia Cancer Specialists, PC Fairfax, Virginia
Virginia Commonwealth University Massey Cancer Center Richmond, Virginia
Virginia Oncology Associates Newport News, Virginia
Washington University St Louis, Missouri
West Virginia University Morgantown, West Virginia
Yale Cancer Center New Haven, Connecticut

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

Katharina Staufer, MD - clinical@versantis.com

PHASE2
NCT05900050
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Patients with ACLF Grade 1, 2, or 3a according to European Association for the Study of the Liver (EASL)-CLIF criteria;
• Onset of ACLF not more than 14 days before Baseline (BL);
• Presence of ascites requiring diagnostic or therapeutic paracentesis;
• Patients with dry body weight ≥40 and \<140 kg;
• Written informed consent obtained prior to the start of any study-related procedures.
Exclusion Criteria:

• Presence of any of the following organ failure(s) as per the EASL-CLIF criteria and/or adapted from CLIF-C Organ Failure (CLIF-C OF)/CLIF- Sequential Organ Failure Assessment (CLIF-SOFA) scores:
• Respiratory failure necessitating invasive mechanical ventilation;
• Coagulation failure (INR \> 3.2 or platelet count ≤20 x 109/L);
• Severe cardiovascular failure requiring the use of high dose vasopressors;
• ACLF grade 3b: Presence of four or more organ failures as per EASL CLIF criteria;
• Presence of spontaneous or secondary bacterial peritonitis;
• Presence of uncontrolled severe infection(with hemodynamic instability or shock);
• Poorly controlled seizure disorder;
• Patients with history of upper gastro-intestinal bleeding over the past 7 days prior to BL, acute bleeding or bleeding upon paracentesis at screening (SCR) or BL;
• Contraindication for paracentesis;
• Coagulation disorders such as disseminated intravascular coagulation or hemophilia;
• Potential or known hypersensitivity to liposomes;
• Potential or known risk factors for allergic/anaphylactoid like reactions (e.g., mastocytosis/elevated basal tryptase) or multiple hypersensitivities;
• Patients after organ transplantation receiving immunosuppressive medication;
• Any severe disease considered to be potentially detrimental at the discretion of the Principal Investigator. This includes but is not limited to hepatocellular carcinoma outside Milan criteria, cholangiocarcinoma, extrahepatic cancer over the past 2 years or people who inject drugs;
• Need for Renal Replacement Therapy or any extracorporeal liver support device (e.g., MARS®, Prometheus®, plasmapheresis);
• Alfapump® in place to manage ascites;
• Pregnancy and lactation;
• Women of child-bearing potential who are not willing to use adequate contraception;
• Patients who participate in another clinical trial at the time of SCR or within 4 weeks prior to SCR.
DRUG: VS-01 on top of SOC, OTHER: SOC (Control Group)
Acute-On-Chronic Liver Failure, Ascites
Chronic liver diseases, Hepatic Dysfunction, Extrahepatic Organ Dysfunction, Liver Failure, Renal Disease, Hepatic Impairment, Renal Impairment, Hepatic Decompensation, Cirrhosis
I'm interested
Share via email
Show 37 locations

Study Locations

Hide all locations
Location Contacts
ASST Grande Ospedale Metropolitano Niguarda Milan,
Azienda Ospedaliero-Universitaria Policlinico Umberto I Roma,
Baylor Clinic Houston, Texas
Cedars Sinai Medical Center Los Angeles, California
Centre Hospitalier Régional Universitaire de Tours Tours, Centre-Val de Loire
Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz Besançon, Franche-Comte
Charité Universitätsmedizin Berlin Berlin,
Chu Rennes - Hopital Pontchaillou Rennes, Ille Et Vilaine
Cleveland Clinic Cleveland, Ohio
Columbia University Medical Center/ New York Presbyterian Hospital New York, New York
Debreceni Egyetem Klinikai Kozpont Debrecen, Hajdú-Bihar
Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet Eger, Heves County
Hopital de la Croix Rousse Lyon,
Hospital Clinic de Barcelona Barcelona,
Hospital General Universitario Gregorio Marañon Madrid,
Hospital Universitari y Politècnic La Fe Valencia,
Hospital Universitario Puerta de Hierro- Majadahonda Madrid,
Hospital Universitario Ramon y Cajal Madrid,
Hospital University Of Vall d'Hebron-Vall d'Hebron Research Institute (VHIR) Barcelona,
Hôpital Universitaire Pitié Salpêtrière Paris, Île-de-France Region
Mayo Clinic Rochester, Minnesota
Mayo Clinic Hospital Jacksonville, Florida
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical University of South Carolina Charleston, South Carolina
Medizinische Hochschule hannover Hanover, Lower Saxony
Piedmont Atlanta Hospital Atlanta, Georgia
Richmond VA Medical Center Richmond, Virginia
Tampa General Hospital Tampa, Florida
The Liver Institute At Methodist Dallas Dallas, Texas
Universitair Ziekenhuis Antwerpen Edegem, Brussels Capital
Universitair Ziekenhuis Gent Ghent,
Universitair Ziekenhuis Leuven Leuven, Flemish Brabant
Universitatsklinikum Jena Jena, Thuringia
University of California Davis Medical Center Sacramento, California
University of Missouri Health Care Columbia, Missouri
Universitätsklinikum Münster Münster,
Virginia Commonwealth University Richmond, Virginia

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

ctrrecruit@vcu.edu

PHASE2
NCT05564377
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient must have measurable disease * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of \>= 50% or Karnofsky performance status of \>= 50% * Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider * All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL) * Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria: * Patients must have progressed on at least one line of standard systemic therapy OR * Patients whose disease has no standard treatment that has been shown to prolong overall survival * Patient must meet one of the following requirements: * Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR * Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria: * Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial * Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response \[CR\] or partial response \[PR\]) to any intervening therapy after collection of the tissue * Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR * Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria: * Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available * NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions. Performance of the mandatory research biopsy or submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only * NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial
DRUG: Alpelisib, DRUG: Binimetinib, PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Scan, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, DRUG: Fluorouracil, DRUG: Fulvestrant, DRUG: Ipatasertib, DRUG: Leucovorin, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Multigated Acquisition Scan, PROCEDURE: Mutation Carrier Screening, DRUG: Neratinib Maleate, DRUG: Nilotinib Hydrochloride Monohydrate, DRUG: Olaparib, DRUG: Oxaliplatin, DRUG: Paclitaxel, DRUG: Palbociclib, BIOLOGICAL: Panitumumab, PROCEDURE: Positron Emission Tomography, DRUG: Selumetinib Sulfate, DRUG: Sotorasib
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
I'm interested
Share via email
Show 458 locations

Study Locations

Hide all locations
Location Contacts
AMG Crystal Lake - Oncology Crystal Lake, Illinois Site Public Contact - (advocateresearch@advocate.com)
AMG Libertyville - Oncology Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Adena Regional Medical Center Chillicothe, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Advocate Christ Medical Center Oak Lawn, Illinois
Advocate Good Samaritan Hospital Downers Grove, Illinois Site Public Contact - (Barbara.barhamand@advocatehealth.com)
Advocate Good Shepherd Hospital Barrington, Illinois
Advocate Illinois Masonic Medical Center Chicago, Illinois
Advocate Lutheran General Hospital Park Ridge, Illinois
Advocate Sherman Hospital Elgin, Illinois
Advocate South Suburban Hospital Hazel Crest, Illinois
Alaska Women's Cancer Care Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Armes Family Cancer Center Findlay, Ohio
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Aultman Health Foundation Canton, Ohio Site Public Contact - (ClinicalReserachDept@aultman.com)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BI-LO Charities Children's Cancer Center Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Baptist Cancer Center-Grenada Grenada, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baystate Medical Center Springfield, Massachusetts Site Public Contact - (tamara.wrenn@baystatehealth.org)
Beacon Kalamazoo Kalamazoo, Michigan
Beacon Kalamazoo Cancer Center Kalamazoo, Michigan
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Beth Israel Deaconess Medical Center Boston, Massachusetts
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Broward Health Medical Center Fort Lauderdale, Florida Site Public Contact - (Allison.bruce@nemours.org)
Bryn Mawr Hospital Bryn Mawr, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
CTCA at Southeastern Regional Medical Center Newnan, Georgia
CTCA at Western Regional Medical Center Goodyear, Arizona
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (ecog.rss@jimmy.harvard.edu)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
Capital Health Medical Center-Hopewell Pennington, New Jersey
Carilion Roanoke Memorial Hospital Roanoke, Virginia
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Centralia Oncology Clinic Centralia, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Centro Comprensivo de Cancer de UPR San Juan, Site Public Contact - (ecog.rss@jimmy.harvard.edu)
Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Children's Hospital of Orange County Orange, California Site Public Contact - (oncresearch@choc.org)
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Foundation Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Columbus Oncology and Hematology Associates Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Columbus Oncology and Hematology Associates Inc Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Condell Memorial Hospital Libertyville, Illinois Site Public Contact - (advocateresearch@advocatehealth.com)
Contra Costa Regional Medical Center Martinez, California
Corewell Health Beaumont Troy Hospital Troy, Michigan
Corewell Health Children's Royal Oak, Michigan
Corewell Health Dearborn Hospital Dearborn, Michigan
Corewell Health Farmington Hills Hospital Farmington Hills, Michigan
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health William Beaumont University Hospital Royal Oak, Michigan
Covenant Medical Center-Lakeside Lubbock, Texas
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dayton Physician LLC - Englewood Dayton, Ohio
Dayton Physicians LLC-Atrium Franklin, Ohio
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Delaware Health Center-Grady Cancer Center Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Doctors Cancer Center Manatí,
Doctors Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Dublin Methodist Hospital Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
East Jefferson General Hospital Metairie, Louisiana Site Public Contact - (emede1@lsuhsc.edu)
Edwards Comprehensive Cancer Center Huntington, West Virginia Site Public Contact - (Christina.Cole@chhi.org)
Epic Care Cyberknife Center Walnut Creek, California
Epic Care-Dublin Dublin, California
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairfield Medical Center Lancaster, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fox Chase Cancer Center Philadelphia, Pennsylvania
Genesee Hematology Oncology PC Flint, Michigan
Genesis Healthcare System Cancer Care Center Zanesville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Good Samaritan Hospital - Cincinnati Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Grady Memorial Hospital Atlanta, Georgia Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Grant Medical Center Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Greater Dayton Cancer Center Kettering, Ohio
Gulfport Memorial Hospital Gulfport, Mississippi Site Public Contact - (emede1@lsuhsc.edu)
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
Guthrie Medical Group PC-Robert Packer Hospital Sayre, Pennsylvania
Harold Alfond Center for Cancer Care Augusta, Maine
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii Site Public Contact - (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii Site Public Contact - (i.webster@hawaiicancercare.com)
Heartland Regional Medical Center Saint Joseph, Missouri Site Public Contact - (Trisha.England2@mymlc.com)
Helen F Graham Cancer Center Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Hendrick Medical Center Abilene, Texas
Henry Ford Saint John Hospital - Macomb Medical Macomb, Michigan Site Public Contact - (kforman1@hfhs.org)
Hillcrest Hospital Cancer Center Mayfield Heights, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Houston Methodist Hospital Houston, Texas
Houston Methodist Saint John Hospital Nassau Bay, Texas Site Public Contact - (ctsucontact@westat.com)
Houston Methodist Sugar Land Hospital Sugar Land, Texas
Houston Methodist The Woodlands Hospital The Woodlands, Texas Site Public Contact - (hmthewoodlands@houstonmethodist.org)
Houston Methodist West Hospital Houston, Texas
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Huron Gastroenterology PC Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Ingalls Memorial Hospital Harvey, Illinois Site Public Contact - (clinicaltrials@ingalls.org)
Inova Fairfax Hospital Falls Church, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Inova Schar Cancer Institute Fairfax, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
John H Stroger Jr Hospital of Cook County Chicago, Illinois
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Kettering Medical Center Kettering, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Kingman Regional Medical Center Kingman, Arizona Site Public Contact - (research@sncrf.org)
Knox Community Hospital Mount Vernon, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lafayette Family Cancer Center-EMMC Brewer, Maine
Lankenau Medical Center Wynnewood, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Licking Memorial Hospital Newark, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Loyola University Medical Center Maywood, Illinois
Lyndon Baines Johnson General Hospital Houston, Texas
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MaineHealth Cancer Care and IV Therapy - South Portland South Portland, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Maine Medical Center- Scarborough Scarborough, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic Hospital in Arizona Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Medical Center of the Rockies Loveland, Colorado
Medical Oncology Hematology Consultants PA Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Memorial Hospital Marysville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Memorial Hospital East Shiloh, Illinois Site Public Contact - (dschwab@wustl.edu)
Memorial Hospital of South Bend South Bend, Indiana
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Westchester Harrison, New York
Mercy Cancer Center - Carmichael Carmichael, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Elk Grove Elk Grove, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Rocklin Rocklin, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Sacramento Sacramento, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Health - Paducah Cancer Center Paducah, Kentucky Site Public Contact - (BJWarner@mercy.com)
Mercy Health - Perrysburg Hospital Perrysburg, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Health - Saint Anne Hospital Toledo, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Hospital Coon Rapids, Minnesota
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Medical Center - Des Moines Des Moines, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercy San Juan Medical Center Carmichael, California Site Public Contact - (OncologyResearch@DignityHealth.org)
Mercyhealth Cancer Institute - Rockford Rockford, Illinois Site Public Contact - (oncologyclinicaltrials@mhemail.org)
Mercyhealth Hospital and Cancer Center - Janesville Janesville, Wisconsin Site Public Contact - (oncologyclinicaltrials@mhemail.org)
Methodist Willowbrook Hospital Houston, Texas Site Public Contact - (ctsucontact@westat.com)
Miami Valley Cancer Care and Infusion Greenville, Ohio
Miami Valley Hospital Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital North Dayton, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Miami Valley Hospital South Centerville, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
Michigan Healthcare Professionals Pontiac Pontiac, Michigan Site Public Contact - (Emily.Crofts@trinity-health.org)
Midwestern Regional Medical Center Zion, Illinois
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Monmouth Medical Center Southern Campus Lakewood, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Einstein Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Montefiore Medical Center-Weiler Hospital The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Mount Carmel East Hospital Columbus, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mount Sinai Hospital New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Hospital Medical Center Chicago, Illinois Site Public Contact - (suhi@sinai.org)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas Site Public Contact - (Emily.Carvell@bmhcc.org)
NYU Langone Hospital - Long Island Mineola, New York Site Public Contact - (cancertrials@nyulangone.org)
National Institutes of Health Clinical Center Bethesda, Maryland
Nebraska Medicine-Bellevue Bellevue, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington Site Public Contact - (Memorial-ClinicalTrials@yvmh.org)
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan Site Public Contact - (WI_research_admin@hshs.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
OhioHealth Mansfield Hospital Mansfield, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Marion General Hospital Marion, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
PCR Oncology Arroyo Grande, California Site Public Contact - (research@sncrf.org)
PROncology San Juan, Site Public Contact - (info@PRoncology.com)
Pali Momi Medical Center ‘Aiea, Hawaii
Paoli Memorial Hospital Paoli, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Pennsylvania Hospital Philadelphia, Pennsylvania Site Public Contact - (PennCancerTrials@careboxhealth.com)
Phelps Health Delbert Day Cancer Institute Rolla, Missouri Site Public Contact - (research@phelpshealth.org)
Pluta Cancer Center Rochester, New York Site Public Contact - (ecog.rss@jimmy.harvard.edu)
Pocono Medical Center East Stroudsburg, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Poudre Valley Hospital Fort Collins, Colorado
Premier Blood and Cancer Center Dayton, Ohio
Presbyterian Intercommunity Hospital Whittier, California
Prisma Health Cancer Institute - Butternut Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Easley Easley, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Faris Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Greer Greer, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Seneca Seneca, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Richland Hospital Columbia, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Regional Cancer System-Lacey Lacey, Washington Site Public Contact - (deidre.dillon@providence.org)
Providence Saint Mary Regional Cancer Center Walla Walla, Washington Site Public Contact - (Cheryl.Dodd@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Puerto Rico Hematology Oncology Group Bayamón,
Queen's Cancer Cenrer - POB I Honolulu, Hawaii
Queen's Cancer Center - Kuakini Honolulu, Hawaii
Queen's Medical Center Honolulu, Hawaii
Rapid City Regional Hospital Rapid City, South Dakota Site Public Contact - (research@monument.health)
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Reid Health Richmond, Indiana
Renown Regional Medical Center Reno, Nevada Site Public Contact - (research@sncrf.org)
Riddle Memorial Hospital Media, Pennsylvania Site Public Contact - (turzoe@mlhs.org)
Riverside Methodist Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Robert Wood Johnson University Hospital Somerset Somerville, New Jersey Site Public Contact - (Siby.Varughese@rwjbh.org)
Roger Williams Medical Center Providence, Rhode Island Site Public Contact - (fdallesandro@chartercare.org)
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Ann's Hospital Westerville, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Saint Barnabas Medical Center Livingston, New Jersey Site Public Contact - (joanne.loeb@rwjbh.org)
Saint Elizabeth Youngstown Hospital Youngstown, Ohio
Saint Francis Cancer Center Greenville, South Carolina Site Public Contact - (Heather_Rich@bshsi.org)
Saint Francis Hospital Greenville, South Carolina Site Public Contact - (Heather_Rich@bshsi.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint John's Cancer Institute Santa Monica, California
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital - Orange Orange, California
Saint Joseph Hospital East Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Hospital Chesterfield, Missouri
Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Sanford Bismarck Medical Center Bismarck, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Broadway Medical Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford Joe Lueken Cancer Center Bemidji, Minnesota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford Roger Maris Cancer Center Fargo, North Dakota Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Sharp Memorial Hospital San Diego, California Site Public Contact - (cathy.wood@sharp.com)
Sheboygan Physicians Group Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Southeastern Medical Oncology Center-Clinton Clinton, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Goldsboro Goldsboro, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Jacksonville Jacksonville, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southern Illinois University School of Medicine Springfield, Illinois
Southern Ohio Medical Center Portsmouth, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Springfield Regional Cancer Center Springfield, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Springfield Regional Medical Center Springfield, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Stanford Cancer Institute Palo Alto Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
State University of New York Upstate Medical University Syracuse, New York
Straub Clinic and Hospital Honolulu, Hawaii
Strecker Cancer Center-Belpre Belpre, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Summerlin Hospital Medical Center Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Angeles Clinic and Research Institute - West Los Angeles Office Los Angeles, California Site Public Contact - (ecog.rss@jimmy.harvard.edu)
The Mark H Zangmeister Center Columbus, Ohio Site Public Contact - (Jeffh@columbusccop.org)
The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii Site Public Contact - (rohta@queens.org)
ThedaCare Cancer Care - Berlin Berlin, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - New London New London, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Shawano Shawano, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Cancer Care - Waupaca Waupaca, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Cancer Center Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Medical Center - Appleton Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
ThedaCare Regional Medical Center - Neenah Neenah, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Toledo Clinic Cancer Centers-Toledo Toledo, Ohio
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Tufts Medical Center Boston, Massachusetts Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UC San Diego Health System - Encinitas Encinitas, California
UC San Diego Medical Center - Hillcrest San Diego, California Site Public Contact - (rhabbaba@health.ucsd.edu)
UC San Diego Moores Cancer Center La Jolla, California Site Public Contact - (cancercto@ucsd.edu)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (ecog.rss@jimmy.harvard.edu)
UCHealth University of Colorado Hospital Aurora, Colorado
UCSF Medical Center-Mission Bay San Francisco, California Site Public Contact - (cancertrials@ucsf.edu)
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at Southwest General Hospital Middleburg Heights, Ohio
UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida
UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida
UPMC Altoona Altoona, Pennsylvania Site Public Contact - (ecog.rss@jimmy.harvard.edu)
UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Monroeville Monroeville, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center Erie Erie, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania Site Public Contact - (haneydl@upmc.edu)
UPMC Western Maryland Cumberland, Maryland
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania
UPMC-Passavant Hospital Pittsburgh, Pennsylvania
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Medical Center New Orleans New Orleans, Louisiana Site Public Contact - (emede1@lsuhsc.edu)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (tmyrick@uab.edu)
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Florida Health Science Center - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
University of Hawaii Cancer Center Honolulu, Hawaii
University of Illinois Chicago, Illinois
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Site Public Contact - (slusserb@med.umich.edu)
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of South Alabama Mitchell Cancer Institute Mobile, Alabama Site Public Contact - (pfrancisco@usouthal.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
Upper Valley Medical Center Troy, Ohio Site Public Contact - (clinical.trials@daytonncorp.org)
VA Palo Alto Health Care System Palo Alto, California
VCU Community Memorial Health Center South Hill, Virginia Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Cancer Center at Stony Point Richmond, Virginia Site Public Contact - (ctoclinops@vcu.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Medical Center Renton, Washington Site Public Contact - (research@valleymed.org)
Vanderbilt Breast Center at One Hundred Oaks Nashville, Tennessee
Vanderbilt University/Ingram Cancer Center Nashville, Tennessee
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Virginia Cancer Institute Richmond, Virginia Site Public Contact - (smoore@vacancer.com)
Walter Reed National Military Medical Center Bethesda, Maryland
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
West Virginia University Charleston Division Charleston, West Virginia
West Virginia University Healthcare Morgantown, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Women and Infants Hospital Providence, Rhode Island
Woodland Cancer Care Center Michigan City, Indiana
Woodland Memorial Hospital Woodland, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Zangmeister Center Grove City Grove City, Ohio

Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study

Emily Federmann - Emily.Federmann@vcuhealth.org

PHASE1
NCT06874192
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* History of statin intolerance (As defined by the NLA 2023 guidelines) Patients who have experienced one or more adverse effects associated with statin therapy, which resolves or improves with dose continuation or reduction * Stable dose of lipid-lowering regimen (statin or non-statin) for at least one month * Patients able to provide informed consent. * Aged 18 to 80 will be enrolled in the study.
Exclusion Criteria:
* Known hypersensitivity to colchicine, current use of colchicine or other anti-inflammatory medications. * Renal impairment (eGFR \<45 mL/min/1.73 m2) * Transaminitis (ALT or AST \>3 times upper limit of normal) * Cirrhosis * Severe Heart Failure * Active cancer or currently on chemotherapy * Irritable Bowel Syndrome, Inflammatory Bowel Disease (Crohn's or Ulcerative Colitis) or other diarrheal related GI pathologies * Active infection * Autoimmune or inflammatory condition * Pregnancy or breastfeeding.
DRUG: Low-dose colchicine at 0.5mg daily, OTHER: Placebo
Statin Adverse Reaction
statin intolerance
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Virginia Commonwealth University Richmond, Virginia Pamela Alebna - (pamela.alebna@vcuhealth.org) Anurag Mehta - (anurag.mehta@vcuhealth.org)

De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

Idris Yakubu, PharmD - idris.yakubu@vcuhealth.org

PHASE3
NCT06001320
Show full eligibility criteria
Hide eligibility criteria
Historical Control group: Inclusion Criteria
• Kidney transplant recipients
• Male or female age ≥ 18 years old
• African American race
• CMV high risk (D+/R-)
• received valganciclovir for CMV prophylaxis Historical Control group: Exclusion
• Re-transplantation
• Panel of reactive antibody ≥80% at the time of transplant
• Positive cytotoxic cross match at the time of transplant Experimental Group Inclusion Criteria
• Kidney transplant recipients
• Male or female age ≥ 18 years old
• African American race
• CMV high risk (D+/R-)
• Ability to provide informed consent before any trial related activities Exclusion Criteria
• Re-transplantation
• Panel of reactive antibody ≥80% at the time of transplant
• Positive cytotoxic cross match at the time of transplant
• Pregnancy and Breastfeeding
• Prisoners
• Patients with hypersensitivity to acyclovir, valacyclovir or any of its components
• Patients with hypersensitivity to Letermovir or any of its components
• If Patients are taking any of these medications: pimozide, ergot alkaloids (ergotamine, dihydroergotamine), or pitavastatin/simvastatin co-administered with cyclosporine, we will work with the prescribing physician to find an appropriate replacement therapy which will not interfere with any study-related interventions. Otherwise, participants will be excluded from the study.
DRUG: Letermovir 480 mg once daily, OTHER: Historical/Control
Kidney Transplant, Complications, CMV
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
VCU Medical Center Richmond, Virginia Lauren K Wallace, MS - (cctrctgov@vcu.edu)

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

ctrrecruit@vcu.edu

PHASE1
NCT06102902
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have histologically confirmed and radiographically measurable metastatic colorectal adenocarcinoma with known BRAF V600E mutation, confirmed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory with at least one tumor measurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and for which standard curative or palliative measures do not exist or are no longer effective * Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 in combination with cetuximab and encorafenib in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Hemoglobin (Hb) ≥ 9 mg/dl * Total bilirubin ≤ 1.5 mg/dl (excluding Gilbert's disease) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 x institutional upper limit of normal (ULN) * Creatinine clearance (CrCL) glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m\^2 * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. Patients should be New York Heart Association Functional Classification of class II or better * Patients must have progressed after at least 1 prior systemic treatment for incurable advanced or metastatic disease * Patients must have received prior treatment with the combination of encorafenib and cetuximab. They must have tolerated the combination at doses planned for the study * The effects of ZEN003694 on the developing human fetus are unknown. For this reason and because BRD and BET inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 4 months following the last dose of study drug. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 72 hours prior to the start of investigational product. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
Exclusion Criteria:
* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 or other agents used in study * Patients with uncontrolled intercurrent illness including, but not limited to, active bleeding diatheses, poorly controlled infection/disorders, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy * Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or substrates of CYP1A2 with narrow therapeutic windows are ineligible. Strong inhibitors or inducers of CYP3A4 must be discontinued at least 7 days prior to the first dose of ZEN003694. As proton pump inhibitors (PPIs), H2 receptor antagonists, and antacids may alter the pharmacokinetics of ZEN003694 by reducing ZEN003694 exposure, patients receiving proton pump inhibitors are ineligible. If H2 blockers or other acid reducing agents are used concomitantly with ZEN003694, a staggered dosing schedule should be used, either dose ZEN003694 2 hours before the H2 blocker or 10-12 hours after an H2 blocker. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Pregnant women are excluded from this study because ZEN003694 is BRD and BET inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694, breastfeeding should be discontinued if the mother is treated with ZEN003694. These potential risks may also apply to other agents used in this study
DRUG: BET Bromodomain Inhibitor ZEN-3694, PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, BIOLOGICAL: Cetuximab, PROCEDURE: Computed Tomography, PROCEDURE: Echocardiography Test, DRUG: Encorafenib, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Multigated Acquisition Scan
Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
I'm interested
Share via email
Show 12 locations

Study Locations

Hide all locations
Location Contacts
Los Angeles General Medical Center Los Angeles, California Site Public Contact - (uscnorrisinfo@med.usc.edu)
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
UCHealth University of Colorado Hospital Aurora, Colorado
USC / Norris Comprehensive Cancer Center Los Angeles, California
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Clinical Research Center Fairway, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Toll Free Number - Trialsites@msd.com

PHASE3
NCT06312176
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer * Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor * Is a chemotherapy candidate * Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization * Has adequate organ function * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
Exclusion Criteria:
* Has breast cancer amenable to treatment with curative intent * Has experienced an early recurrence (\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment * Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications * Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer * Active autoimmune disease that has required systemic treatment in the past 2 years * History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease * Has an active infection requiring systemic therapy
DRUG: Sacituzumab tirumotecan, BIOLOGICAL: Pembrolizumab, DRUG: Paclitaxel, DRUG: Nab-paclitaxel, DRUG: Capecitabine, DRUG: Liposomal doxorubicin
Breast Neoplasms
Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
I'm interested
Share via email
Show 252 locations

Study Locations

Hide all locations
Location Contacts
AZ Maria Middelares-IKG ( Site 1106) Ghent, Oost-Vlaanderen
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1876) Adana,
AdventHealth Altamonte Springs ( Site 0021) Altamonte Springs, Florida
Agios Loukas Clinic ( Site 1347) Thessaloniki,
Akademiska sjukhuset ( Site 1802) Uppsala, Uppsala County
All India Institute of Medical Sciences ( Site 2051) New Delhi, National Capital Territory of Delhi
Amphia Ziekenhuis, locatie Breda Molengracht-oncologie ( Site 1523) Breda, North Brabant
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1871) Ankara,
Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032) Thomasville, Georgia
Aretaieio Hospital Oncology Unit ( Site 1345) Athens, Attica
Asan Medical Center-Department of Oncology ( Site 2352) Seoul,
Auckland City Hospital ( Site 2031) Auckland,
BC Cancer Surrey ( Site 0315) Surrey, British Columbia
Banner MD Anderson Cancer Center-Oncology ( Site 0004) Gilbert, Arizona
Bialostockie Centrum Onkologii ( Site 1585) Bialystok, Podlaskie Voivodeship
Blackpool Victoria Hospital ( Site 1941) Blackpool,
Bon Secours Cork Hospital ( Site 1422) Cork,
Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015) Midlothian, Virginia
Bradford Hill Norte ( Site 0456) Antofagasta,
Bradfordhill ( Site 0452) Santiago, Region M. de Santiago
Brust-Zentrum ( Site 1841) Zurich, Canton of Zurich
Budapesti Uzsoki Utcai Kórház-Onkoradiológiai Osztály ( Site 1373) Budapest,
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2905) Port Elizabeth, Eastern Cape
CENTRO MEDICO ZAMBRANO HELLION-Centro de Cáncer de Mama ( Site 0595) San Pedro Garza García, Nuevo León
CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0302) Québec, Quebec
CIMCA ( Site 0551) San José, Provincia de San José
CIO - Centro de Inmuno-Oncología de Occidente ( Site 0592) Guadalajara, Jalisco
CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0301) Montreal, Quebec
CRO-IRCCS ( Site 1478) Aviano, Friuli Venezia Giulia
Cancer Institute Hospital of JFCR ( Site 2464) Koto, Tokyo
Cancer and Blood Specialty Clinic ( Site 0001) Los Alamitos, California
Cancercare Rondebosch Oncology-Clinical trials ( Site 2904) Rondebosch, Western Cape
CaritasKlinikum Saarbrücken St. Theresia ( Site 1304) Saarbrücken, Saarland
Catharina Ziekenhuis ( Site 1526) Eindhoven, North Brabant
Centre François Baclesse ( Site 1250) Caen, Calvados
Centre Hospitalier Universitaire de Poitiers-Pôle régional de cancérologie ( Site 1243) Poitiers, Vienne
Centre de Cancérologie du Grand Montpellier ( Site 1244) Montpellier, Languedoc-Roussillon
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski ( Site 0308) Rimouski, Quebec
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0383) Buenos Aires,
Centrul Medical Neolife- Baneasa ( Site 1704) Bucharest,
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1582) Bydgoszcz, Kuyavian-Pomeranian Voivodeship
Chang Gung Medical Foundation-Linkou Branch-General Surgery ( Site 2414) Taoyuan District,
Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 2413) Kaohsiung City,
Changhua Christian Hospital ( Site 2410) Changhua,
City Hospital, Nottingham University Hospitals NHS Trust ( Site 1945) Nottingham,
Clinica Vallesur - AUNA ( Site 0652) Arequipa, Ariqipa
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 1103) Brussels, Bruxelles-Capitale, Region de
Clínica RedSalud Vitacura ( Site 0455) Santiago, Region M. de Santiago
Curo Oncology ( Site 2908) Pretoria, Gauteng
Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) Boston, Massachusetts
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 1375) Debrecen,
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1878) Yenimahalle, Ankara
Errikos Dunant Hospital Center ( Site 1348) Athens, Attica
European Interbalkan Medical Center ( Site 1341) Thessaloniki,
FALP-UIDO ( Site 0451) Santiago, Region M. de Santiago
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0507) Bogotá, Bogota D.C.
Fakultni nemocnice Kralovske Vinohrady-Onkologická klinika ( Site 1135) Prague,
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1132) Olomouc, Olomoucký kraj
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 1134) Ostrava-Poruba, Moravskoslezský kraj
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 1136) Prague, Praha 5
Fiona Stanley Hospital-Medical Oncology ( Site 2004) Murdoch, Western Australia
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1472) Milan, Lombardy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1477) Roma,
Frankston Hospital-Oncology and Haematology ( Site 2003) Frankston, Victoria
Fukushima Medical University Hospital ( Site 2461) Fukushima,
Fundacion Colombiana de Cancerología Clinica Vida ( Site 0506) Medellín, Antioquia
Fundacion Estudios Clinicos-Oncology ( Site 0384) Rosario, Santa Fe Province
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0387) La Rioja,
Fundación Valle del Lili ( Site 0508) Santiago de Cali, Valle del Cauca Department
Gifu University Hospital ( Site 2486) Gifu,
Greenebaum Comprehensive Cancer Center ( Site 0036) Baltimore, Maryland
Grupo Médico ASSET-Clinical Research ( Site 0596) Mexico City, Mexico City
HOSPITAL CLINICO DE VALENCIA-Oncology ( Site 1752) Valencia, Valenciana, Comunitat
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 1756) Madrid,
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1758) Pozuelo de Alarcón, Madrid
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1870) Ankara,
Hadassah Medical Center ( Site 1451) Jerusalem,
Health Pharma Professional Research S.A. de C.V: ( Site 0598) Mexico City, Mexico City
Helios Klinikum Berlin-Buch-Klinik für Gynäkologie und Geburtshilfe ( Site 1314) Berlin,
Hematology Oncology Associates of Rockland ( Site 0054) Nyack, New York
Henry Ford Health ( Site 0002) Detroit, Michigan
Hiroshima City Hiroshima Citizens Hospital ( Site 2478) Hiroshima,
Hokkaido University Hospital ( Site 2460) Sapporo, Hokkaido
Holy Cross Hospital ( Site 0073) Silver Spring, Maryland
Hopital Prive Jean Mermoz-Oncology ( Site 1246) Lyon, Rhone-Alpes
Hospital Aleman-Oncology ( Site 0386) Buenos Aires,
Hospital Beata María Ana-oncology ( Site 1755) Madrid,
Hospital Italiano de Córdoba ( Site 0385) Córdoba,
Hospital Metropolitano - Sede Lindora ( Site 0550) Santa Ana, Provincia de San José
Hospital Militar Central Luis Arias Schereiber ( Site 0651) Jesús María, Lima
Hospital Moinhos de Vento ( Site 0403) Porto Alegre, Rio Grande do Sul
Hospital Sultan Ismail ( Site 2153) Johor Bahru, Johor
Hospital Universitari Vall d'Hebron-Oncology ( Site 1750) Barcelona,
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 0590) Monterrey, Nuevo León
Hospital Universitario Reina Sofia-Oncologia Medica ( Site 1754) Córdoba,
Hospital Universitario Virgen Macarena ( Site 1757) Seville,
Hospital do Câncer Mãe de Deus ( Site 0404) Porto Alegre, Rio Grande do Sul
Hygeia Hospital ( Site 1346) Marousi, Attica
Hôpital privé du Confluent SAS-Service d'oncologie médicale ( Site 1242) Nantes, Loire-Atlantique
IBCC - Núcleo de Pesquisa e Ensino ( Site 0401) São Paulo,
ICIMED ( Site 0552) San José,
IMAT S.A.S ( Site 0502) Montería, Departamento de Córdoba
INCAN-TUMORES MAMARIOS ( Site 0597) Mexico City, Mexico City
IPOR Instituto Peruano de Oncología & Radioterapia ( Site 0653) Lima,
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1480) Meldola, Forli-Cesena
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1474) Bologna,
Inova Schar Cancer Institute ( Site 0025) Fairfax, Virginia
Institut Curie-Oncology medical Department ( Site 1240) Paris,
Institut Jules Bordet-Medicine Oncology ( Site 1104) Anderlecht, Bruxelles-Capitale, Region de
Instituto Alexander Fleming-Alexander Fleming ( Site 0382) Buenos Aires, Buenos Aires F.D.
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1662) Porto,
Instituto de Oncologia Saint Gallen ( Site 0412) Santa Cruz do Sul, Rio Grande do Sul
Instituto do Câncer Brasil - Unidade Taubaté ( Site 0408) Taubaté, São Paulo
Institutul Oncologic Cluj ( Site 1701) Cluj-Napoca,
Ironwood Cancer & Research Centers ( Site 0066) Chandler, Arizona
Isala, locatie Zwolle ( Site 1525) Zwolle, Overijssel
Istituto Clinico Humanitas ( Site 1476) Rozzano, Milano
Istituto Europeo di Oncologia IRCCS-Divisione di Senologia Medica ( Site 1475) Milan, Lombardy
Jessa Ziekenhuis-Limburgs Oncologisch Centrum ( Site 1105) Hasselt, Limburg
Jewish General Hospital ( Site 0303) Montreal, Quebec
Juntendo University Hospital ( Site 2468) Bunkyo, Tokyo
Kanagawa Cancer Center ( Site 2472) Yokohama, Kanagawa
Karolinska Universitetssjukhuset Solna ( Site 1801) Stockholm, Stockholm County
Kitasato University Hospital ( Site 2471) Sagamihara, Kanagawa
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinik für Senologie/ Brustzentrum ( Site 1300) Essen, North Rhine-Westphalia
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute-Centre for cancer ( Site 2056) Mumbai, Maharashtra
Kumamoto University Hospital ( Site 2480) Kumamoto,
Kyoto University Hospital ( Site 2475) Kyoto,
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0068) New York, New York
Levine Cancer Institute ( Site 0014) Charlotte, North Carolina
Maastricht UMC+-Medical Oncology ( Site 1522) Maastricht, Limburg
Mackay Memorial Hospital ( Site 2412) Taipei,
Macquarie University-MQ Health Clinical Trials Unit ( Site 2002) Macquarie University, New South Wales
Mary Bird Perkins Cancer Center-Breast & GYN Pavilion ( Site 0042) Baton Rouge, Louisiana
Mater Misericordiae University Hospital-Clinical Trials Research Unit ( Site 1423) Dublin,
Mazowiecki Szpital Onkologiczny ( Site 1581) Wieliszew, Masovian Voivodeship
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1584) Siedlce, Masovian Voivodeship
Meander Medisch Centrum ( Site 1521) Amersfoort, Utrecht
Medipol Mega Universite Hastanesi-oncology ( Site 1875) Stanbul, Istanbul
Memorial Ankara Hastanesi-Medical Oncology ( Site 1874) Ankara,
Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028) Baltimore, Maryland
Metro Davao Medical and Research Center ( Site 2202) Davao City, Davao Del Sur
Mie University Hospital ( Site 2483) Tsu, Mie-ken
Moores Cancer Center ( Site 0059) La Jolla, California
Mount Alvernia ICON Cancer Center ( Site 2251) Singapore, North East
Mrukmed-Mrukmed ( Site 1592) Rzeszów, Podkarpackie Voivodeship
NYU Langone Health - Brooklyn ( Site 0089) Brooklyn, New York
NYU Langone Hospital - Long Island ( Site 0090) Mineola, New York
Nagoya City University Hospital ( Site 2474) Nagoya, Aichi-ken
Narodowy Instytut Onkologii - Oddzial w Gliwicach-Centrum Diagnostyki i Leczenia Chorob Piersi ( Site 1590) Gliwice, Silesian Voivodeship
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Piersi i Chirurgii ( Site 1580) Warsaw, Masovian Voivodeship
National Center for Global Health and Medicine ( Site 2469) Shinjuku, Tokyo
National Cheng Kung University Hospital-Surgery ( Site 2411) Tainan City,
National Taiwan University Hospital-Oncology ( Site 2415) Taipei,
National University Hospital ( Site 2250) Singapore, Central Singapore
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1520) Amsterdam, North Holland
Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 1138) České Budějovice, Jihočeský kraj
Nordsjællands Hospital - Hillerød ( Site 1184) Hillerød, Capital Region
North West Cancer Centre ( Site 1944) Londonderry, Derry and Strabane
Næstved Sygehus ( Site 1182) Næstved, Region Sjælland
Odense Universitetshospital ( Site 1181) Odense C, Region Syddanmark
Okayama University Hospital ( Site 2485) Okayama,
Oncoclínica Oncologistas Associados-Clinical Research ( Site 0407) Teresina, Piauí
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8001) Roanoke, Virginia
Oncosalud ( Site 0650) Lima, Muni Metro de Lima
Oncovida ( Site 0453) Santiago, Region M. de Santiago
Orlando Health Cancer Institute ( Site 0011) Orlando, Florida
Osaka International Cancer Institute ( Site 2477) Osaka,
Ospedale San Martino ( Site 1479) Genova,
Ospedale San Raffaele-Oncologia Medica ( Site 1471) Milan,
Pantai Hospital Kuala Lumpur ( Site 2151) Kuala Lumpur,
Pitie Salpetriere University Hospital ( Site 1249) Paris, Orne
Pontificia Universidad Catolica de Chile ( Site 0454) Santiago, Region M. de Santiago
Prince of Wales Hospital ( Site 2041) Shatin,
Princess Margaret Cancer Centre ( Site 0310) Toronto, Ontario
Providence Medical Foundation-Oncology ( Site 0020) Fullerton, California
Providence Portland Medical Center ( Site 0044) Portland, Oregon
Providence St. Vincent Medical Center ( Site 0081) Portland, Oregon
Puerto Rico Medical Research Center LLC ( Site 0675) Hato Rey,
Queen Mary Hospital ( Site 2040) Hksar,
Rabin Medical Center ( Site 1453) Petah Tikva,
Rajiv Gandhi Cancer Institute And Research Centre-Department of Clinical Research ( Site 2052) New Delhi, National Capital Territory of Delhi
Rambam Health Care Campus-Oncology Division ( Site 1452) Haifa,
Rigshospitalet ( Site 1180) Copenhagen, Capital Region
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 1702) Florești, Cluj
SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1315) Gera, Thuringia
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053) Edgewood, Kentucky
Saint Luke's Cancer Institute ( Site 0027) Kansas City, Missouri
Saitama Medical University International Medical Center ( Site 2462) Hidaka, Saitama
Samsun Medical Park Hastanesi-medical oncology ( Site 1873) Samsun,
Samsung Medical Center-Division of Hematology/Oncology ( Site 2351) Seoul,
Sandton Oncology Medical Group (Pty) Ltd ( Site 2911) Sandton, Gauteng
Sarawak General Hospital ( Site 2154) Kuching, Sarawak
Semmelweis Egyetem-Belgyógyászati és Onkológiai Klinika ( Site 1381) Budapest,
Seoul National University Hospital-Internal Medicine ( Site 2353) Seoul,
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 2350) Seoul,
Sheba Medical Center ( Site 1450) Ramat Gan,
Showa Medical University Hospital ( Site 2466) Shinagawa, Tokyo
Social medical corporation Hakuaikai Sagara Hospital ( Site 2481) Kagoshima,
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0501) Valledupar, Cesar Department
Somogy Vármegyei Kaposi Mór Oktató Kórház-Oncology center ( Site 1371) Kaposvár, Somogy County
Southlake Regional Health Centre ( Site 0311) Newmarket, Ontario
Spital Thun ( Site 1840) Thun, Canton of Bern
Spitalul Clinic Filantropia ( Site 1703) Bucharest, București
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1940) London, London, City of
St. Marianna University Hospital ( Site 2465) Kawasaki, Kanagawa
St. Vincent's University Hospital-Medical Oncology Research Department ( Site 1420) Dublin,
Stamford Hospital ( Site 0049) Stamford, Connecticut
Stony Brook University-Cancer Center ( Site 0034) Stony Brook, New York
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1595) Kielce, Świętokrzyskie Voivodeship
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterápiás Klinika ( Site 1379) Szeged, Csongrád megye
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1583) Koszalin, West Pomeranian Voivodeship
Szpitale Pomorskie Sp. z o. o.-Oddział Onkologii Klinicznej ( Site 1593) Gdynia, Pomeranian Voivodeship
Södra Älvsborgs Sjukhus Borås ( Site 1803) Borås, Västra Götaland County
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1872) Istanbul,
Tata Memorial Hospital-Medical Oncology ( Site 2053) Mumbai, Maharashtra
Texas Oncology - San Antonio ( Site 8002) San Antonio, Texas
Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) Dallas, Texas
The Center for Cancer and Blood Disorders ( Site 0041) Fort Worth, Texas
The Royal Cornwall Hospital ( Site 1943) Truro, England
The University of Osaka Hospital ( Site 2476) Suita, Osaka
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0057) Tyler, Texas
Thomas Jefferson University - Clinical Research Institute ( Site 0056) Philadelphia, Pennsylvania
Tohoku University Hospital ( Site 2482) Sendai, Miyagi
Tokai University Hospital ( Site 2473) Isehara, Kanagawa
Tokyo Medical University Hospital ( Site 2467) Shinjuku, Tokyo
UCHealth Cherry Creek Medical Center ( Site 0094) Denver, Colorado
UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0677) San Juan,
UT Southwestern Medical Center ( Site 0050) Dallas, Texas
Unidade Local de Saude Amadora/Sintra - Hospital Prof Dr Fernando Fonseca ( Site 1663) Lisbon, Lisbon District
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1661) Lisbon,
Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1311) Düsseldorf, North Rhine-Westphalia
Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Geburtshilfe ( Site 1301) Erlangen, Bavaria
University College London Hospital-Cancer Clinical Trials Unit ( Site 1942) London, London, City of
University General Hospital of Larissa ( Site 1343) Larissa, Thessaly
University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 1844) Basel, Canton of Basel-City
University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040) Madison, Wisconsin
University of Chicago Medical Center ( Site 0067) Chicago, Illinois
University of Colorado Anschutz Medical Campus ( Site 0061) Aurora, Colorado
University of Colorado Health - Highlands Ranch Hospital ( Site 0095) Highlands Ranch, Colorado
University of Florida College of Medicine ( Site 0063) Gainesville, Florida
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 1107) Namur,
VCU Health Adult Outpatient Pavillion ( Site 0070) Richmond, Virginia
Vejle Sygehus ( Site 1183) Vejle, Region Syddanmark
Washington University School of Medicine ( Site 0076) St Louis, Missouri
Westmead Hospital ( Site 2000) Westmead, New South Wales
Wits Clinical Research ( Site 2903) Johannesburg, Gauteng
Yale Cancer Center ( Site 0060) New Haven, Connecticut
Zachodniopomorskie Centrum Onkologii ( Site 1588) Szczecin, West Pomeranian Voivodeship
Zala Vármegyei Szent Rafael Kórház-Onkológiai osztály ( Site 1372) Zalaegerszeg, Zala County
Zangmeister Cancer Center ( Site 7000) Columbus, Ohio
Ziekenhuis Rijnstate-Rijnstate Centrum Oncologisch Onderzoek ( Site 1524) Arnhem, Gelderland

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Toll Free Number - Trialsites@msd.com

PHASE3
NCT06456346
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Diagnosis of Essential Thrombocythemia (ET) based on World Health Organization Criteria for myeloproliferative neoplasms, and an indication for cytoreductive therapy regardless of age or risk status * Has a centrally assessed bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis * Has received no prior cytoreductive treatment for their ET * Human Immunodeficiency Virus (HIV)-infected participants have well controlled HIV on antiretroviral therapy * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable
Exclusion Criteria:
* History of any illness/impairment of gastrointestinal function that might interfere with drug absorption * History of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has an active infection requiring systemic therapy * Has had a major surgery \<4 weeks prior to first dose of study intervention or has not recovered from side effects of major surgery \>4 weeks prior to first dose
DRUG: Bomedemstat, DRUG: Hydroxyurea, DRUG: Bomedemstat placebo, DRUG: Hydroxyurea placebo
Essential Thrombocythemia
essential thrombocythemia, ET, bomedemstat, IMG-7289
I'm interested
Share via email
Show 135 locations

Study Locations

Hide all locations
Location Contacts
Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 0324) Aarhus, Central Jutland
Akademiska sjukhuset ( Site 0545) Uppsala, Uppsala County
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 0502) Ankara,
Antalya Egitim ve Arastırma Hastanesi ( Site 0508) Antalya,
Austin Health-Cancer Clinical Trials Centre ( Site 0206) Heidelberg, Victoria
Azienda Ospedaliera Universitaria Careggi ( Site 0441) Florence, Tuscany
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 0443) Alessandria, Ancona
Biocenter ( Site 0149) Concepción, Región del Biobío
Boston Pilgrim Hospital ( Site 0525) Boston, Lincolnshire
Bradfordhill-Clinical Area ( Site 0142) Santiago, Region M. de Santiago
C.I.C.E. 9 de Julio ( Site 0104) San Miguel de Tucumán, Tucumán Province
CHU Bordeaux Haut-Leveque-service de mèdecine interne et maladies infectieuses ( Site 0346) Pessac, Aquitaine
Carmel Hospital ( Site 0426) Haifa,
Centre Hospitalier Régional Universitaire de Tours - Hôpital-Hématologie et Thérapie Cellulaire ( Site 0342) Tours, Indre-et-Loire
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 0344) Limoges, Haute-Vienne
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu ( Site 0347) Nantes, Loire-Atlantique
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Hematology ( Site 0349) Nice, Alpes-Maritimes
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0037) Greenfield Park, Quebec
Centro de Investigacion Clinica de Oaxaca ( Site 0181) Oaxaca City, Oaxaca
Chang Gung Medical Foundation-Linkou Branch ( Site 0243) Taoyuan District,
Chang Gung Memorial Hospital- Chiayi ( Site 0242) Chiayi City, Chiayi
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0369) Berlin,
Clinica Universidad de Navarra-Hematology Department ( Site 0485) Madrid, Madrid, Comunidad de
Clínica Alemana de Santiago ( Site 0143) Santiago, Region M. de Santiago
Clínica Inmunocel ( Site 0147) Santiago, Region M. de Santiago
Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0105) Santa Fe,
Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0402) Debrecen,
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi-Hemotology ( Site 0510) Ankara,
Duke University Health System (DUHS) ( Site 0012) Durham, North Carolina
Ehime University Hospital ( Site 0612) Tōon, Ehime
Exempla Lutheran Medical Center ( Site 0014) Golden, Colorado
FALP-UIDO ( Site 0148) Santiago, Region M. de Santiago
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0447) Milan, Lombardy
Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0444) Pavia,
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0445) Roma,
Freeman Hospital ( Site 0532) Newcastle upon Tyne,
Fujita Health University Hospital ( Site 0613) Toyoake, Aichi-ken
Fukushima Medical University Hospital ( Site 0616) Fukushima,
Fundacion Colombiana de Cancerología Clinica Vida ( Site 0164) Medellín, Antioquia
Galilee Medical Center ( Site 0431) Nahariya,
Glan Clwyd Hospital ( Site 0528) Bodelwyddan, Denbighshire
Gloucestershire Royal Hospital ( Site 0521) Gloucester, Gloucestershire
Guy's & St Thomas' NHS Foundation Trust ( Site 0523) London, London, City of
HENRI MONDOR HOSPITAL ( Site 0348) Créteil, Val-de-Marne
HOSPITAL CLÍNIC DE BARCELONA ( Site 0481) Barcelona, Catalonia
Hacettepe Universite Hastaneleri-Department of Hematology ( Site 0505) Ankara,
Hadassah Medical Center ( Site 0424) Jerusalem,
Hammersmith Hospital ( Site 0533) London, London, City of
Higiea Oncologia ( Site 0184) Mexico City, Mexico City
Hokkaido University Hospital ( Site 0601) Sapporo, Hokkaido
Hopital Saint-Louis ( Site 0341) Paris,
Hospital Costa del Sol-Hematology Service ( Site 0493) Marbella, Malaga
Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0490) Badalona, Barcelona
Hospital Italiano de Buenos Aires ( Site 0102) ABB, Buenos Aires F.D.
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0489) Barcelona,
Hospital Universitario 12 de Octubre ( Site 0494) Madrid,
Hospital Universitario Austral ( Site 0101) Pilar, Buenos Aires
Hospital Universitario Marqués de Valdecilla-Haematology ( Site 0486) Santander, Cantabria
Hospital Universitario Ramón y Cajal-Hematology ( Site 0484) Madrid, Madrid, Comunidad de
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( Site 0488) Salamanca,
Hôpital de la Conception ( Site 0351) Marseille, Bouches-du-Rhone
IC La Serena Research ( Site 0150) La Serena, Coquimbo Region
IMAT S.A.S ( Site 0162) Montería, Departamento de Córdoba
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0446) Bologna,
Institut Català d'Oncologia - L'Hospitalet ( Site 0482) L'Hospitalet de Llobregat, Catalonia
Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 0352) Toulouse, Haute-Garonne
Juntendo University Hospital ( Site 0611) Bunkyo-ku, Tokyo
Kanazawa University Hospital ( Site 0614) Kanazawa, Ishikawa-ken
Kansai Medical University Hospital ( Site 0607) Hirakata, Osaka
Karolinska Universitetssjukhuset Huddinge ( Site 0541) Huddinge, Stockholm County
Kindai University Hospital ( Site 0600) Sayama, Osaka
Kobe City Medical Center General Hospital ( Site 0603) Kobe, Hyōgo
Kocaeli Üniversitesi-Hematology ( Site 0506) Kocaeli,
Kyushu University Hospital ( Site 0605) Fukuoka,
Levine Cancer Institute ( Site 0009) Charlotte, North Carolina
Lincoln County Hospital ( Site 0535) Lincoln, Great Britain
Los Angeles Cancer Network ( Site 0025) Glendale, California
Los Cobos Medical Center ( Site 0165) Bogotá, Bogota D.C.
Medipol Mega Universite Hastanesi ( Site 0504) Istanbul,
Medivest Centro de Investigación Integral ( Site 0183) Chihuahua City, Chihuahua
Medizinische Hochschule Hannover ( Site 0371) Hanover, Lower Saxony
Mie University Hospital ( Site 0615) Tsu, Mie-ken
Monash Health-Haematology Research ( Site 0202) Clayton, Victoria
National Cheng Kung University Hospital-Clinical Trial Center ( Site 0245) Tainan City,
National Hospital Organization Sendai Medical Center ( Site 0617) Sendai, Miyagi
National Taiwan University Hospital ( Site 0241) Taipei,
Nippon Medical School Hospital ( Site 0608) Tokyo,
Odense Universitetshospital-Department of Hematology ( Site 0325) Odense C, Region Syddanmark
Okayama University Hospital ( Site 0604) Okayama,
Ondokuz Mayıs Universitesi-hematology ( Site 0507) Samsun,
Ordensklinikum Linz GmbH Elisabethinen ( Site 0562) Linz, Upper Austria
Oregon Health & Science University ( Site 0018) Portland, Oregon
Ospedale di Circolo e Fondazione Macchi Varese ( Site 0442) Varese,
Parkview Research Center at Parkview Regional Medical Center ( Site 0006) Fort Wayne, Indiana
Petz Aladar Egyetemi Oktato Korhaz-Hematológia ( Site 0405) Győr, Győr-Moson-Sopron
Pratia Onkologia Katowice ( Site 0461) Katowice, Silesian Voivodeship
Queen Mary Hospital ( Site 0221) Hksar,
Rabin Medical Center ( Site 0425) Petah Tikva,
Rambam Health Care Campus ( Site 0429) Haifa,
Rigshospitalet-Hematology - CTU ( Site 0321) Copenhagen, Capital Region
Roskilde Sygehus-Department of Hematology ( Site 0323) Roskilde, Region Sjælland
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0203) Adelaide, South Australia
Royal Gwent Hospital ( Site 0524) Newport,
Royal Perth Hospital-Haematology ( Site 0204) Perth, Western Australia
Sahlgrenska Universitetssjukhuset-Department of hematology and coagulation ( Site 0543) Gothenburg, Västra Götaland County
Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie-Oddział Hematoonkologii, Transplantacji Szp ( Site 0463) Lublin, Lublin Voivodeship
Sheba Medical Center ( Site 0428) Ramat Gan,
Skånes Universitetssjukhus Lund-Department of Hematology ( Site 0544) Lund, Skåne County
Somogy Vármegyei Kaposi Mór Oktató Kórház-Haematológiai osztály ( Site 0406) Kaposvár, Somogy County
Soroka Medical Center ( Site 0427) Beersheba,
Sourasky Medical Center ( Site 0422) Tel Aviv,
Stanford Cancer Center ( Site 0024) Palo Alto, California
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 0466) Kielce, Świętokrzyskie Voivodeship
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 0404) Nyíregyháza, Szabolcs-Szatmár-Bereg
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 0407) Szeged, Csongrád megye
The Ohio State University Wexner Medical Center ( Site 0028) Columbus, Ohio
Trakya University Medical Faculty Hospital-Hematology ( Site 0501) Edirne,
Universitaetsklinikum Essen ( Site 0366) Essen, North Rhine-Westphalia
Universitetssjukhuset Örebro ( Site 0542) Örebro, Örebro County
University College London Hospital ( Site 0527) London, London, City of
University of Michigan ( Site 0003) Ann Arbor, Michigan
University of Miyazaki Hospital ( Site 0609) Miyazaki,
University of Texas Health Science Center at San Antonio ( Site 0021) San Antonio, Texas
University of Texas MD Anderson Cancer Center ( Site 0026) Houston, Texas
University of Virginia ( Site 0020) Charlottesville, Virginia
University of Yamanashi Hospital ( Site 0606) Chūō, Yamanashi
Universitätsklinikum Aachen ( Site 0367) Aachen, North Rhine-Westphalia
Universitätsklinikum Halle ( Site 0361) Halle, Saxony-Anhalt
Universitätsklinikum Jena-Klinik für Innere Medizin II, Abt. Hämatologie und Internistische Onkolog ( Site 0364) Jena, Thuringia
Universitätsmedizin Johannes Gutenberg Universität Mainz-3. Medizinische Klinik und Poliklinik ( Site 0365) Mainz, Rhineland-Palatinate
VCU Health Adult Outpatient Pavillion ( Site 0008) Richmond, Virginia
VK&K Studien GbR ( Site 0370) Landshut, Bavaria
Westmead Hospital ( Site 0201) Westmead, New South Wales
Yitzhak Shamir Medical Center. ( Site 0421) Ẕerifin,
centre hospitalier lyon sud ( Site 0343) Pierre-Bénite, Rhone

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Study Director - clinicaltrials@beigene.com

PHASE3
NCT06073821
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment * Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 * Measurable disease by Computer Tomography/Magnetic Resonance Imaging * Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \< 3.0 x ULN * Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute
Exclusion Criteria:
* Previous systemic treatment for CLL * Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation * Known central nervous system involvement * History of confirmed progressive multifocal leukoencephalopathy (PML) * Uncontrolled hypertension Note: Other protocol defined criteria may apply
DRUG: Sonrotoclax, DRUG: Zanubrutinib, DRUG: Venetoclax, DRUG: Obinutuzumab
CLL
CLL, Chronic Lymphocytic Leukemia
I'm interested
Share via email
Show 205 locations

Study Locations

Hide all locations
Location Contacts
Affiliated Hospital of Nantong University Nantong,
Aichi Cancer Center Hospital Clinical Oncology Nagoya, Aichi-ken
Aiiku Hospital Sapporo, Hokkaido
Alaska Oncology and Hematology, Llc Anchorage, Alaska
Albert Schweitzer Ziekenhuis Dordrecht,
Amsterdam Umc Vu Mc Amsterdam,
Ankara University Medical Faculty Ankara, Altindag
Aomori Prefectural Central Hospital Aomori,
Aou Maggiore Della Carita Novara,
Arthur Je Child Comprehensive Cancer Centre Calgary,
Asan Medical Center Seoul,
Assuta Ashdod Medical Center Ashdod,
Assuta Medical Center Tel Aviv,
Atrium Health Levine Cancer Institute (Lci) Charlotte, North Carolina
Auckland City Hospital Grafton, Auckland
Austin Health Heidelberg, Victoria
Auxilio Mutuo Cancer Center San Juan,
Azienda Ospedaliera Di Padova Padua,
Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi Bologna,
Azienda Ospedaliero Universitaria di Ferrara Ferrara,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Milan, Milan
British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia
CHU Lille Lille,
Cabrini Hospital Malvern Malvern East, Victoria
CancerCare Manitoba Winnipeg, Manitoba
Carmel Medical Center Haifa, Haifa District
Centralny Szpital Kliniczny Uck Wum Warsaw,
Centre Henri Becquerel Rouen,
Centre Hospitalier Le Mans Le Mans,
Centre Hospitalier Universitaire Nantes Hotel Dieu Nantes,
Centre Hospitalier de Luniversite de Montreal (Chum) Montreal, Quebec
Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre Greenfield Park, Quebec
Centre Leon Berard Lyon,
Centre de Lutte Contre Le Cancer Institut Bergonie Bordeaux,
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus Porto Alegre,
Centrum Fur Haematologie Und Onkologie Bethanien Frankfurt am Main,
Chao Family Comprehensive Cancer Center Orange, California
Chiba Cancer Center Chiba, Chiba
Chongqing University Cancer Hospital Chongqing, Chongqing Municipality
Chu Clermont Ferrand Therapie Cellulaire and Hematolo Clermontferrand,
Chu Nancy Hopital Brabois VandoeuvrelesNancy,
Chu Rennes Rennes Cedes,
Chu Tours Hopital Bretonneau Tours,
Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic) Québec,
Churchill Hospital Oxford University Hospital Nhs Trust Headington,
City of Hope National Medical Center Duarte, California
Ciusss de Lestrie Chus Sherbrooke, Quebec
Cleveland Clinic Foundation Cleveland, Ohio
Clinical Research Alliance, Inc Westbury, New York
Clinique Louis Pasteur Esseylesnancy,
Columbia University Medical Center New York, New York
Concord Repatriation General Hospital Concord,
Cross Cancer Institute Edmonton, Alberta
Duke University Medical Center Durham, North Carolina
Dunedin Hospital Dunedin,
Elisabeth Tweesteden Ziekenhuis Tilburg,
Erciyes University School of Medicine Kayseri,
Fakultni Nemocnice Ostrava Poruba,
Fakultni nemocnice Brno Brno,
Fakultni nemocnice Hradec Kralove Hradec Králové,
Fakultni nemocnice Olomouc Olomouc,
Fakultni nemocnice Plzen Pilsen,
Flevoziekenhuis Almere Stad,
Flinders Medical Centre Bedford Park, South Australia
Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana
Fox Chase Cancer Center Philadelphia, Pennsylvania
Franciscus Gasthuis And Vlietland Schiedam,
Fred Hutchinson Cancer Research Center Seattle, Washington
Fujian Medical University Union Hospital Fuzhou, Fujian
Gazi University Ankara, Central Anatolia
GenesisCare North Shore St Leonards, New South Wales
Gunderson Health System La Crosse, Wisconsin
Hadassah University Hospital Ein Kerem Jerusalem, Jerusalem
HagaZiekenhuis Sgravenhage,
Hanusch Krankenhaus Vienna,
Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular São Paulo,
Health New Zealand Canterbury Christchurch,
Henan Cancer Hospital Zhengzhou, Henan
Hollywood Private Hospital Nedlands, Western Australia
Hopital Prive du Confluent Nantes,
Hopital de la Pitie Salpetriere Paris,
Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp Ribeirão Preto,
Hospital Erasto Gaertner Curitiba, Paraná
Hospital La Candelaria Santa Cruz de Tenerife,
Hospital Universitario La Paz Madrid,
Hospital Universitario Ramon y Cajal Madrid,
Hospital Universitario de Burgos Burgos,
Hospital Universitario de Gran Canaria Dr Negrin Las Palmas de Gran Canaria,
Hospital Universitario de Octubre Madrid,
Huntsman Cancer Institute Salt Lake City, Utah
Hyogo Prefectural Amagasaki General Medical Center AmagasakiCity, Hyōgo
Ikazia Ziekenhuis Rotterdam,
Illinois CancerCare, PC Peoria, Illinois
Institut Catala Doncologia Hospital Duran I Reynals L'Hospitalet de Llobregat,
Institute of Hematology and Hospital of Blood Disease Tianjin,
Instytut Hematologii I Transfuzjologii Warsaw,
Istituto Europeo Di Oncologia Milan, Milan
Jiangsu Province Hospital Nanjing, Jiangsu
Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University ) Jieyang, Guangdong
Jining No Peoples Hospital West Branch Jining, Shandong
John Theurer Cancer Center Hackensack University Medical Center Hackensack, New Jersey
Kagoshima University Hospital Kagoshima, Kagoshima-ken
Kansai Medical University Hospital Hirakata-shi, Osaka
Karolinska Universitetssjukhuset Solna Stockholm,
Kent and Canterbury Hospital Canterbury,
Kindai University Hospital Osakasayama-shi, Osaka
Kings College London,
Kocaeli Universitesi Tip Fakultesi Kocaeli,
Kumamoto University Hospital Kumamoto,
Kurashiki Central Hospital Okayama,
Lakeridge Health Oshawa, Ontario
Maasstad Hospital Rotterdam,
Martini Ziekenhuis Groningen,
Md Anderson Cancer Center Madrid Spain Madrid,
Meander Medisch Centrum Amersfoort,
MedStar Georgetown University Hospital Washington D.C., District of Columbia
Medical College of Wisconsin Milwaukee, Wisconsin
Medizinische Universitatsklinik Innsbruck Innsbruck,
Mission Cancer and Blood Waukee, Iowa
Moffitt Cancer Center Tampa, Florida
Monash Health Clayton, Victoria
Mount Sinai Comprehensive Cancer Center Miami Beach, Florida
Nanfang Hospital of Southern Medical University Guangzhou, Guangdong
Nanyang Central Hospital Nanyang, Henan
National Cancer Center (Korea) IlsandongGu GoyangSi, Gyeonggi-do
National Cancer Center Hospital Tokyo,
National Hospital Organization Okayama Medical Center Okayama,
Nho Shikoku Cancer Center Matsuyama, Ehime
Niigata University Medical and Dental Hospital Niigata, Niigata
Noordwest Ziekenhuisgroep Alkmaar,
Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich,
North Shore Hospital Auckland,
Northwestern University Chicago, Illinois
Norton Cancer Institute Pavilion Louisville, Kentucky
Ochsner Clinic Foundation New Orleans, Louisiana
Oncology Associates of Oregon Willamette Valley Cancer Center Eugene, Oregon
Osaka Metropolitan University Hospital Osaka,
Ospedale Santa Maria della Misericordia Perugia,
Peking University Third Hospital Beijing,
Pindara Private Hospital Gold Coast, Queensland
Praxis Am Volkspark Berlin,
Princess Alexandra Hospital Woolloongabba,
Princess Margaret Cancer Centre Toronto, Ontario
Reinier de Graaf Gasthuis Delft,
Royal Marsden Nhs Foundation Royal Marsden Hospital Sutton,
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
SCRI Tennessee Oncology Chattanooga Chattanooga, Tennessee
Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do,
Seoul National University Hospital Seoul,
Severance Hospital Yonsei University Health System Seoul,
Shaare Zedek Medical Center Jerusalem,
Shandong Provincial Hospital Jinan, Shandong
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital Chengdu,
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein São Paulo,
Southampton General Hospital Southampton,
Southeastern Regional Medical Center Lumberton, North Carolina
St Jamess University Hospital Leeds,
St Vincents Hospital Melbourne Fitzroy, Victoria
Stanford Medicine Palo Alto, California
Sunshine Coast Hospital and Health Service Birtinya, Queensland
Tauranga Hospital Tauranga,
The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu
The Alfred Hospital Melbourne, Victoria
The Catholic University of Korea, Seoul St Marys Hospital SeochoGu, Seoul Teugbyeolsi
The Clatterbridge Cancer Centre Liverpool Liverpool,
The First Affiliated Hospital of Anhui Medical University Hefei, Anhui
The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi
The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang
The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang
The First Hospital of China Medical University Shenyang, Liaoning
The First Peoples Hospital of Changzhou Changzhou, Jiangsu
The James Cancer Hospital and Solove Research Institute At Ohio State University Columbus, Ohio
The Second Affiliated Hospital of Nanchang University Nanchang,
The Second Affiliated Hospital of Xian Jiaotong University Xi'an, Shaanxi
The University of Kansas Cancer Center Westwood, Kansas
Tohoku University Hospital Miyagi,
Tokai University Hospital Iseharashi, Kanagawa
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei
UCLA Department of Medicine Hematologyoncology Los Angeles, California
Unesp Faculdade de Medicina Da Universidade Estadual Paulista Campus Botucatu Botucatu,
Unite de Recherche Clinique Du Cisss Des Laurentides SaintJerome, Quebec
Universitaetsklinikum Schleswig Holstein Campus Luebeck Lübeck,
Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg Salzburg,
University College Hospital Ibadan,
University Hospitals Dorset Royal Bournemouth Hospital Bournemouth,
University of California San Diego (Ucsd) Moores Cancer Center La Jolla, California
University of Colorado Cancer Center Aurora, Colorado
University of Iowa Hospitals and Clinics Iowa City, Iowa
University of Minnesota Minneapolis, Minnesota
University of North Carolina at Chapel Hill Chapel Hill, North Carolina
Uniwersytecki Szpital Kliniczny Wroclaw, Lower Silesian Voivodeship
Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu Wroclaw,
Uniwersytecki Szpital Kliniczny Nr W Lublinie Lublin,
Valkyrie Clinical Trials Los Angeles, California
Vcu Health Systemmassey Comprehensive Cancer Center Richmond, Virginia
Virginia Cancer Institute Richmond, Virginia
Vseobecna Fakultni Nemocnice v Praze Prague,
Washington University School of Medicine St Louis, Missouri
Wellington Regional Hospital (Ccdhb) Wellington,
West China Hospital, Sichuan University Chengdu, Sichuan
Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi Lodz,
Yamagata University Hospital Yamagata, Yamagata
Yantai Yuhuangding Hospital Yantai,
Yichang Central Peoples Hospitaljiangnan Branch Yichang, Hubei
Yokohama Municipal Citizens Hospital Yokohama,

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

ctrrecruit@vcu.edu

PHASE1
NCT05673200
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have histologically confirmed triple-negative breast cancer (TNBC) (estrogen receptor \[ER\] and progesterone receptor \[PR\] =\< 10%, human epidermal growth factor receptor-2 \[HER2\]-negative per American Society of Clinical Oncology \[ASCO\]/College of American Pathologists \[CAP\] guidelines) that is metastatic or unresectable * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of ASTX727 in combination with pembrolizumab (MK-3475) and paclitaxel in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (or Karnofsky \>= 60%) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (within 14 days prior to registration) * Platelets \>= 100,000/mm\^3 (within 14 days prior to registration) * Hemoglobin \>= 9 g/dL or \>= 5.6 mmol/L (within 14 days prior to registration) * Criteria must be met without packed red blood cell (pRBC) transfusion within the prior 14 days of registration. Participants can be on stable dose of erythropoietin (90 days or more prior to registration) * Creatinine clearance (CrCl) \>= 30 mL/min (within 14 days prior to registration) * Glomerular filtration rate (GFR) can also be used in place of CrCl * Total bilirubin =\< 1.5 x upper limit of normal (ULN) OR direct bilirubin =\< ULN for patients with total bilirubin levels \> 1.5 × ULN (within 14 days prior to registration) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \[SGPT\]) =\< 3 x institutional ULN (within 14 days prior to registration) * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if there is evidence of measurable extracranial disease, and if follow-up brain imaging 4 weeks after central nervous system (CNS)-direct therapy shows no evidence of progression. Patients with carcinomatous meningitis are not eligible. * Patients with a prior malignancy whose natural history does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Concurrent use of other antineoplastic treatments is not allowed. * Patients should be New York Heart Association Functional Classification of class II or better. * Patients who have received live attenuated vaccines within the 30 days prior to registration are not eligible. Seasonal flu vaccines that do not contain live virus, and coronavirus disease 2019 (COVID-19) vaccinations and boosters are permitted. * Patients with prior history of peripheral neuropathy are allowed if it has recovered to grade 1 or less. * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial. * Patients who have received 0-3 prior lines of chemotherapy in the metastatic setting. Patients who have received prior PD-1/PD-L1 monoclonal antibodies in any disease setting are eligible. * For enrollment to Dose Finding Cohort: Availability and willingness to provide archival tumor tissue as required per protocol. * For enrollment to Dose Expansion Cohort: (i) Willingness to provide baseline and 3-week tumor tissue biopsy specimens. (ii) Patients must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * The effects of ASTX727 and pembrolizumab (MK-3475) on the developing human fetus are unknown. For this reason and because these agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 180 days after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Pregnant women are excluded from this study because pembrolizumab (MK-3475) is an anti PD-1 monoclonal antibody agent, ASTX727 is a hypomethylating agent, and paclitaxel is a class D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab (MK-3475), breastfeeding should be discontinued if the mother is treated with pembrolizumab (MK-3475). These potential risks may also apply to other agents used in this study. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 180 days after completion of study treatment. * Ability to understand and the willingness to sign a written informed consent document (or have legally acceptable representative sign, if applicable). * Patients who have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia. * Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Has not received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor \[G-CSF\], granulocyte macrophage colony-stimulating factor \[GM-CSF\], or recombinant erythropoietin) within 4 weeks prior to registration.
Exclusion Criteria:
* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within the 7 days prior to registration. * Has a known additional malignancy that is progressing or requires active treatment. * Has an active autoimmune disease that has required systemic treatment within 2 years prior to registration (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Current treatment with systemic steroids up to 10 mg of prednisone daily or equivalent is allowed. * Patients with uncontrolled intercurrent illness (including but not limited to interstitial lung disease or active, non-infectious pneumonitis) or a history of (non-infectious) pneumonitis that required steroids. * History of grade 3-4 immediate hypersensitivity reaction to paclitaxel or other drugs formulated in polyoxyl 35 castor oil. * Patients who are receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727, pembrolizumab (MK-3475), and/or paclitaxel. * Has a known history of active tuberculosis (TB). * Gastrointestinal disorder that may impact absorption of oral medications. * History of solid organ or bone marrow transplantation.
PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, DRUG: Decitabine and Cedazuridine, PROCEDURE: Magnetic Resonance Imaging, DRUG: Paclitaxel, BIOLOGICAL: Pembrolizumab
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
I'm interested
Share via email
Show 10 locations

Study Locations

Hide all locations
Location Contacts
Mayo Clinic Hospital in Arizona Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
UC Irvine Health Cancer Center-Newport Costa Mesa, California
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California Site Public Contact - (ucstudy@uci.edu)
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

ctrrecruit@vcu.edu

NA
NCT06611540
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Willingness and ability to provide a documented informed consent. * Is 25 years or older. * Has an intact cervix. * Has had a referral for colposcopy and/or cervical excisional procedure in which routine cervical cancer screening has included HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance \[ASC-US\] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit. * Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable.
Exclusion Criteria:
* Is pregnant when presenting for the referral visit or gave birth within the past 3 months. * Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure \[LEEP\], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit. * Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records. * Known medical conditions that, in the opinion of the investigator, preclude study participation. * Previous participation in the SHIP Trial. Participation is defined as completing the self-collection. * Is experiencing unusual bleeding or pelvic pain.
PROCEDURE: Biospecimen Collection, PROCEDURE: Cervical Biopsy, PROCEDURE: Colposcopy, OTHER: Electronic Health Record Review, PROCEDURE: Endocervical Curettage, PROCEDURE: Excision, PROCEDURE: HPV Self-Collection, PROCEDURE: Human Papillomavirus Test, OTHER: Questionnaire Administration
Cervical Carcinoma, Human Papillomavirus Infection
I'm interested
Share via email
Show 25 locations

Study Locations

Hide all locations
Location Contacts
Cleveland Clinic Foundation Cleveland, Ohio Miriam Cremer - (cremerm@ccf.org)
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia Lisa C. Flowers - (lflowe2@emory.edu)
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Deanna L. Kepka - (deanna.kepka@hci.utah.edu)
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Jenell S. Coleman - (colemanj@jhmi.edu)
Louisiana State University Health Science Center New Orleans, Louisiana Michael E. Hagensee - (mhagen@lsuhsc.edu)
M D Anderson Cancer Center Houston, Texas Elizabeth Y. Chiao - (eychiao@mdanderson.org)
Minneapolis VA Medical Center Minneapolis, Minnesota Elisheva Danan - (elizabeth.danan@va.gov)
Montefiore Medical Center-Einstein Campus The Bronx, New York Mark H. Einstein - (mark.einstein@rutgers.edu)
NYP/Weill Cornell Medical Center New York, New York Denise A. Howard - (deh3002@med.cornell.edu)
UCSF Medical Center-Parnassus San Francisco, California George Sawaya - (george.sawaya@ucsf.edu)
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Lisa Rahangdale - (lisa_rahangdale@med.unc.edu)
UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania Harold C. Wiesenfeld - (wieshc@upmc.edu)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Warner K. Huh - (whuh@uabmc.edu)
University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio Leeya F. Pinder - (pinderl@ucmail.uc.edu)
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida Erin Kobetz-Kerman - (ekobetz@med.miami.edu)
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Diane M. Harper - (harperdi@med.umich.edu)
University of Mississippi Medical Center Jackson, Mississippi Carolann Risley - (crisley@umc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico Cosette M. Wheeler - (cwheeler@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Joan L. Walker - (joan-walker@ouhsc.edu)
University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania Carmen Guerra - (carmen.guerra@pennmedicine.upenn.edu)
University of Puerto Rico Rio Piedras, Ana P. Ortiz - (ana.ortiz7@upr.edu)
University of Washington Medical Center - Northwest Seattle, Washington Rachel L. Winer - (RLW@UW.EDU)
UofL Health Medical Center Northeast Louisville, Kentucky Tanya E. Franklin - (tanya.franklin@louisville.edu)
Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia Nicole W. Karjane - (nicole.karjane@vcuhealth.org)
Yale University New Haven, Connecticut Sangini Sheth - (sangini.sheth@yale.edu)

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

ctrrecruit@vcu.edu

PHASE1
NCT04301076
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have histologically or cytologically confirmed CD2+, CD3+, or CD4+ acute, lymphoma or poor-risk chronic subtypes of ATLL including previously untreated or previously treated individuals who have received no more than 1 previous cycle of EPOCH, cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) * Patients previously treated with azidothymidine (AZT), interferon (IFN), bexarotene, or mogamulizumab are eligible. Patients with stable disease at high risk of relapse from prior non-combination chemotherapy containing treatment are eligible to participate * Documentation of HTLV infection by enzyme-linked immunosorbent assay (ELISA) in individuals with confirmation of HTLV-1 infection (by immunoblot or polymerase chain reaction \[PCR\]) or a consistent clinical picture (including two of three of: 1) CD4+ leukemia or lymphoma, 2) hypercalcemia, and/or 3) Japanese, Caribbean, or South American birthplace) is required for enrollment. Confirmation of HTLV-1 infection is required to continue the subject on protocol after the first cycle of therapy. Patients will be enrolled based on reports from local or referral labs (e.g., Mayo Clinic or LabCorp). Confirmation will be performed by Ratner Lab at Washington University, retrospectively, but this is not a Clinical Laboratory Improvement Amendments (CLIA) assay and is not reimbursed by insurance * Age ≥ 18 years * Because no dosing or adverse event (AE) data are currently available on the use of lenalidomide in combination with EPOCH in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Absolute neutrophil count \>= 1,000/mm\^3 unless decreased due to bone marrow (BM) involvement with lymphoma * Platelets \>= 100,000/mm\^3 unless decreased due to BM involvement with lymphoma * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN), if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without lenalidomide and if transaminitis and bilirubinemia improves to meet parameters, participant may be enrolled * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2 x institutional ULN, if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without lenalidomide and if transaminitis and bilirubinemia improve to meet parameters, participant may be enrolled * Creatinine =\< institutional ULN OR glomerular filtration rate (GFR) \>= 60 mL/min/1.73 m\^2 for participants with creatinine levels above institutional normal * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Patients must have a life expectancy \> 12 weeks * Patients must have no serious active infection requiring therapy at the time of study entry * Patients must not require the concurrent use of chemotherapy, interferon, zidovudine, arsenic, radiation therapy, or other specific anti-tumor therapy, during the course of this study * The effects of lenalidomide on the developing human fetus are unknown. Immunodulatory derivative (immunomodulatory imide drug \[IMiD\]) agents as well as other therapeutic agents used in this trial are known to be teratogenic. Females of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to, and again within 24 hours of starting lenalidomide, and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counselled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. FCBP must use adequate contraception for at least 28 days after discontinuation from study. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for at least 28 days after discontinuation from study * Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
* Patients that have received prior IMiDs for treatment of ATLL * Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study * Patients who have not recovered to grade 1 or better from AEs due to prior anti-cancer therapy (not including cycle 1 of EPOCH, CHOP, or CHOPE if received off protocol) within 14 days prior to enrollment, with the exception of alopecia * Patients who are receiving any other investigational agents or have received them within 14 days prior to enrollment * History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide or other agents used in study. Anaphylactic reactions including death have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur * Patients unable to take aspirin or prophylactic doses of low molecular weight heparin or direct oral anticoagulants * Patients with urinary outflow obstruction (contraindication for cyclophosphamide) * Patients with any form of demyelinating disease should not be given vincristine sulfate injection * Patients with uncontrolled intercurrent illness * Patients with psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because lenalidomide is an IMiD agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenalidomide, breastfeeding should be discontinued if the mother is treated with lenalidomide. These potential risks may also apply to other agents used in this study
PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Biopsy, PROCEDURE: Computed Tomography, DRUG: Cyclophosphamide, DRUG: Doxorubicin Hydrochloride, DRUG: Etoposide, DRUG: Lenalidomide, PROCEDURE: Positron Emission Tomography, DRUG: Prednisone, DRUG: Vincristine Sulfate
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
I'm interested
Share via email
Show 19 locations

Study Locations

Hide all locations
Location Contacts
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Nassau Uniondale, New York
Memorial Sloan Kettering Westchester Harrison, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu)
NYP/Weill Cornell Medical Center New York, New York
NYU Langone Hospital - Long Island Mineola, New York Site Public Contact - (cancertrials@nyulangone.org)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

ctrrecruit@vcu.edu

PHASE3
NCT06580314
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients with newly diagnosed, pathologically confirmed, Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer of the following types: * High grade serous * High grade endometrioid, and/or * Other epithelial ovarian cancer with BRCA1/2 deleterious alteration (germline or somatic) * Submission of pathology report is required * Ovarian cancer = ovarian, fallopian, or primary peritoneal cancer * Patients must have: * Documented variant (tumor or germline) in BRCA1 or BRCA2 that is predicted to be pathogenic or suspected pathogenic (deleterious alteration) * Submission of testing report is required. OR * BRCA 1/2 wildtype AND known HRD deficient tumor determined by any commercial or academic, Clinical Laboratory Improvement Act (CLIA)-certified laboratory (e.g., Myriad MyChoice©) * Submission of testing report is required * Patient must have undergone cytoreductive surgery (primary or interval) * Patients must have completed first line platinum-based therapy prior to registration: * Platinum based chemotherapy course must have consisted of a minimum of 4 treatment cycles and a maximum of 9, although it is strongly recommended that patients receive at least 6 cycles unless medically contraindicated * For those receiving less than 6 cycles of platinum-based therapy, the reason for this must be documented and could include hematologic toxicity or non-hematologic toxicities directly related to therapy * Intravenous, intraperitoneal, or neoadjuvant platinum-based chemotherapy is allowed; for weekly therapy, three weeks are considered one cycle * Patients must not have received an investigational agent during their first line course of chemotherapy * Patients must have, in the opinion of the investigator, no clinical evidence of disease progression following completion of this chemotherapy course (partial or complete response to platinum-based chemotherapy) * Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression following completion of this chemotherapy course (partial or complete response to platinum-based chemotherapy) * Patients must be randomized at least 3 weeks and no more than 12 weeks after their last dose of chemotherapy (last dose is the day of the last infusion of platinum agent) * No previous treatment with a PARP inhibitor, including olaparib, niraparib, and rucaparib * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Not pregnant and not nursing * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3 * Platelets ≥ 100,000 cells/mm\^3 * Hemoglobin ≥ 9 g/dl * Creatinine clearance (CrCL) of \> 30 mL/min by the Cockcroft-Gault formula * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * No active infection requiring parental antibiotic(s) * No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube * No current inability to swallow orally administered medication * No history of myelodysplastic syndrome and/or acute myeloid leukemia * No history of allogeneic bone marrow transplant * No concomitant use of strong or moderate CYP3A inducers * No known hypersensitivity to olaparib or any of the excipients of the product
BIOLOGICAL: Bevacizumab, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, PROCEDURE: Magnetic Resonance Imaging, DRUG: Olaparib
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
I'm interested
Share via email
Show 511 locations

Study Locations

Hide all locations
Location Contacts
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Alaska Breast Care and Surgery LLC Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alaska Oncology and Hematology LLC Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alaska Women's Cancer Care Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Alegent Health Bergan Mercy Medical Center Omaha, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Immanuel Medical Center Omaha, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alegent Health Lakeside Hospital Omaha, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Alta Bates Summit Medical Center-Herrick Campus Berkeley, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Anchorage Associates in Radiation Medicine Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Ascension Borgess Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Ascension Borgess Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Ascension Saint Vincent Indianapolis Hospital Indianapolis, Indiana Site Public Contact - (research@stvincent.org)
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Augusta University Medical Center Augusta, Georgia Site Public Contact - (ga_cares@augusta.edu)
Avera Cancer Institute at Pierre Pierre, South Dakota Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute at Yankton Yankton, South Dakota Site Public Contact - (OncRegulatory@avera.org)
Avera Cancer Institute-Aberdeen Aberdeen, South Dakota Site Public Contact - (oncregulatory@avera.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Baptist Health Corbin Corbin, Kentucky
Baptist Health Lexington Lexington, Kentucky
Baptist Health Louisville Louisville, Kentucky Site Public Contact - (Cbcresearch@bhsi.com)
Baptist Health Paducah Paducah, Kentucky
Bay Area Hospital Coos Bay, Oregon Site Public Contact - (cherie.cox@bayareahospital.org)
Beebe Health Campus Rehoboth Beach, Delaware Site Public Contact - (research@beebehealthcare.org)
Beebe Medical Center Lewes, Delaware Site Public Contact - (research@beebehealthcare.org)
Beebe South Coastal Health Campus Millville, Delaware Site Public Contact - (research@beebehealthcare.org)
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bethesda North Hospital Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Billings Clinic-Cody Cody, Wyoming Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Bronson Battle Creek Battle Creek, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Bronson Methodist Hospital Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
CARTI Cancer center Little Rock, Arkansas Site Public Contact - (Research@CARTI.com)
CHI Health Good Samaritan Kearney, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
CHI Health Saint Francis Grand Island, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
California Pacific Medical Center-Pacific Campus San Francisco, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Cambridge Medical Center Cambridge, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Camden Clark Medical Center Parkersburg, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care and Hematology-Fort Collins Fort Collins, Colorado Site Public Contact - (Roster@nrgoncology.org)
Cancer Center at Saint Joseph's Phoenix, Arizona Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Cancer Center of Western Wisconsin New Richmond, Wisconsin Site Public Contact - (mmcorc@healthpartners.com)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan Site Public Contact - (connie.szczepanek@crcwm.org)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Central Care Cancer Center - Bolivar Bolivar, Missouri Site Public Contact - (aroland@kccop.org)
Central Care Cancer Center - Garden City Garden City, Kansas Site Public Contact - (aroland@kccop.org)
Central Care Cancer Center - Great Bend Great Bend, Kansas Site Public Contact - (aroland@kccop.org)
Centralia Oncology Clinic Centralia, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Christiana Care - Union Hospital Elkton, Maryland Site Public Contact - (frank.crum@christianacare.org)
Christiana Care Health System-Christiana Hospital Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Christiana Care Health System-Concord Health Center Chadds Ford, Pennsylvania Site Public Contact - (lbarone@christianacare.org)
Christiana Care Health System-Wilmington Hospital Wilmington, Delaware Site Public Contact - (lbarone@christianacare.org)
Clackamas Radiation Oncology Center Clackamas, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Cleveland Clinic Foundation Cleveland, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Columbus Oncology and Hematology Associates Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Columbus Oncology and Hematology Associates Inc Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Commonwealth Cancer Center-Corbin Corbin, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Cooper Hospital University Medical Center Camden, New Jersey
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Cox Cancer Center Branson Branson, Missouri
CoxHealth South Hospital Springfield, Missouri
Creighton University Medical Center Omaha, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Danbury Hospital Danbury, Connecticut
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Delaware Health Center-Grady Cancer Center Delaware, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Doctors Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Dublin Methodist Hospital Dublin, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Eden Hospital Medical Center Castro Valley, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Edward Hospital/Cancer Center Naperville, Illinois
Edward Hospital/Cancer Center?Plainfield Plainfield, Illinois Site Public Contact - (Cancerresearch@edward.org)
Elmhurst Memorial Hospital Elmhurst, Illinois Site Public Contact - (Jrohde@emhc.org)
Essentia Health - Baxter Clinic Baxter, Minnesota
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Ely Clinic Ely, Minnesota
Essentia Health - Fosston Fosston, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - International Falls Clinic International Falls, Minnesota
Essentia Health - Jamestown Clinic Jamestown, North Dakota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Moose Lake Clinic Moose Lake, Minnesota
Essentia Health - Park Rapids Park Rapids, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's Hospital - Superior Superior, Wisconsin
Essentia Health Saint Mary's Medical Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health-Hayward Clinic Hayward, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health-Spooner Clinic Spooner, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Lakes Medical Center Wyoming, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Northland Medical Center Princeton, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Flaget Memorial Hospital Bardstown, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Freeman Health System Joplin, Missouri Site Public Contact - (LJCrockett@freemanhealth.com)
Fresno Cancer Center Fresno, California Site Public Contact - (Kpoct@kp.org)
Geauga Hospital Chardon, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Genesee Hematology Oncology PC Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Good Samaritan Hospital - Cincinnati Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Goshen Center for Cancer Care Goshen, Indiana Site Public Contact - (cccois@goshenhealth.com)
Grady Memorial Hospital Atlanta, Georgia Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Grant Medical Center Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Great Falls Clinic Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
HSHS Saint Elizabeth's Hospital O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii Site Public Contact - (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii Site Public Contact - (i.webster@hawaiicancercare.com)
Health Partners Inc Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Heartland Oncology and Hematology LLP Council Bluffs, Iowa
Heartland Regional Medical Center Saint Joseph, Missouri Site Public Contact - (Trisha.England2@mymlc.com)
Helen F Graham Cancer Center Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Hematology Oncology Consultants-Clarkston Clarkston, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Hennepin County Medical Center Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Henry Ford Health Saint John Hospital Detroit, Michigan Site Public Contact - (Kkeenan1@hfhs.org)
Henry Ford Health Warren Hospital Warren, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Madison Heights Hospital - Breast Warren, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford River District Hospital East China Township, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Academic Grosse Pointe Woods, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Breast Grosse Pointe Woods, Michigan Site Public Contact - (karen.forman@ascension.org)
Henry Ford Saint John Hospital - Macomb Medical Macomb, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Saint John Hospital - Van Elslander Grosse Pointe Woods, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Warren Hospital - Breast Macomb Macomb, Michigan Site Public Contact - (kforman1@hfhs.org)
Henry Ford Warren Hospital - GLCMS Warren, Michigan Site Public Contact - (kforman1@hfhs.org)
Hi-Line Sletten Cancer Center Havre, Montana Site Public Contact - (Roster@nrgoncology.org)
Hillcrest Hospital Cancer Center Mayfield Heights, Ohio Site Public Contact - (TaussigResearch@ccf.org)
Holy Cross Hospital Fort Lauderdale, Florida Site Public Contact - (eileen.georgi@holy-cross.com)
Hope Cancer Center Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Houston Methodist Hospital Houston, Texas
Houston Methodist Saint John Hospital Nassau Bay, Texas Site Public Contact - (Roster@nrgoncology.org)
Houston Methodist The Woodlands Hospital The Woodlands, Texas Site Public Contact - (hmthewoodlands@houstonmethodist.org)
Houston Methodist West Hospital Houston, Texas
Huntington Memorial Hospital Pasadena, California
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Huron Gastroenterology PC Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
IU Health North Hospital Carmel, Indiana Site Public Contact - (iutrials@iu.edu)
Idaho Urologic Institute-Meridian Meridian, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana Site Public Contact - (iutrials@iu.edu)
Jefferson Torresdale Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Jersey City Medical Center Jersey City, New Jersey Site Public Contact - (Roster@nrgoncology.org)
John H Stroger Jr Hospital of Cook County Chicago, Illinois
John Muir Medical Center-Walnut Creek Walnut Creek, California Site Public Contact - (clinicalresearch@johnmuirhealth.com)
Kadlec Clinic Hematology and Oncology Kennewick, Washington Site Public Contact - (research@kadlecmed.org)
Kaiser Permanente - Panorama City Panorama City, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Cancer Treatment Center South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Los Angeles Medical Center Los Angeles, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Medical Center-Vacaville Vacaville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente Oakland-Broadway Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente South Bay Harbor City, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente West Los Angeles Los Angeles, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente- Marshall Medical Offices Redwood City, California
Kaiser Permanente-Bellflower Bellflower, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Deer Valley Medical Center Antioch, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Irvine Irvine, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Rancho Cordova Cancer Center Rancho Cordova, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Richmond Richmond, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Riverside Riverside, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Roseville Roseville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Diego Zion San Diego, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Marcos San Marcos, California Site Public Contact - (clinical.trials@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Stockton Stockton, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Woodland Hills Woodland Hills, California Site Public Contact - (clinical.trials@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Katmai Oncology Group Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kuakini Medical Center Honolulu, Hawaii
LSU Health Baton Rouge-North Clinic Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Lake Regional Hospital Osage Beach, Missouri Site Public Contact - (clinicaltrials@lakeregional.com)
Lakeview Hospital Stillwater, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York Site Public Contact - (CancerTrials@nyulangone.org)
Legacy Good Samaritan Hospital and Medical Center Portland, Oregon Site Public Contact - (cancer@lhs.org)
Legacy Meridian Park Hospital Tualatin, Oregon
Legacy Salmon Creek Hospital Vancouver, Washington
Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Longmont United Hospital Longmont, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
MaineHealth Maine Medical Center- Scarborough Scarborough, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Mary Greeley Medical Center Ames, Iowa
McFarland Clinic - Ames Ames, Iowa Site Public Contact - (ksoder@mcfarlandclinic.com)
McFarland Clinic - Boone Boone, Iowa
McFarland Clinic - Jefferson Jefferson, Iowa
McFarland Clinic - Marshalltown Marshalltown, Iowa
McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa
Medical Center of the Rockies Loveland, Colorado
Medical College of Wisconsin Milwaukee, Wisconsin
Medical Oncology Hematology Consultants PA Newark, Delaware Site Public Contact - (lbarone@christianacare.org)
Memorial Hermann Texas Medical Center Houston, Texas
Memorial Hospital North Colorado Springs, Colorado
Memorial Hospital of Carbondale Carbondale, Illinois Site Public Contact - (clinical.research@sih.net)
Memorial Medical Center Modesto, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Nassau Uniondale, New York
Memorial Sloan Kettering Westchester Harrison, New York
Mercy Cancer Center Merced, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Cape Girardeau Cape Girardeau, Missouri
Mercy Cancer Center - Carmichael Carmichael, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Elk Grove Elk Grove, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Rocklin Rocklin, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Cancer Center - Sacramento Sacramento, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri
Mercy Hospital Coon Rapids, Minnesota
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Joplin Joplin, Missouri Site Public Contact - (esmeralda.carrillo@mercy.net)
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Hospital Washington Washington, Missouri
Mercy Medical Center Durango, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mercy San Juan Medical Center Carmichael, California Site Public Contact - (OncologyResearch@DignityHealth.org)
Methodist Jennie Edmundson Hospital Council Bluffs, Iowa Site Public Contact - (kathryn.bartz@nmhs.org)
Methodist Medical Center of Illinois Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Methodist Willowbrook Hospital Houston, Texas Site Public Contact - (Roster@nrgoncology.org)
Michigan Healthcare Professionals Pontiac Pontiac, Michigan Site Public Contact - (Emily.Crofts@trinity-health.org)
Miller-Dwan Hospital Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Mills Health Center San Mateo, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Mills-Peninsula Medical Center Burlingame, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Minnesota Oncology - Burnsville Burnsville, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Mission Hope Medical Oncology - Santa Maria Santa Maria, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monticello Cancer Center Monticello, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
MyMichigan Medical Center Alpena Alpena, Michigan Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Gladwin Gladwin, Michigan Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Gratiot Alma, Michigan Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Midland Midland, Michigan Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Mount Pleasant Mount Pleasant, Michigan Site Public Contact - (CVResearch@mymichigan.org)
MyMichigan Medical Center Saginaw Saginaw, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
MyMichigan Medical Center Tawas Tawas City, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
NYU Langone Hospital - Long Island Mineola, New York Site Public Contact - (cancertrials@nyulangone.org)
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC Omaha, Nebraska
Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ Council Bluffs, Iowa Site Public Contact - (Liza.brandes@nmhs.org)
Nebraska Methodist Hospital Omaha, Nebraska
New Ulm Medical Center New Ulm, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Newland Medical Associates-Clarkston Clarkston, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Newland Medical Associates-Pontiac Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
North Memorial Medical Health Center Robbinsdale, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Northside Hospital Atlanta, Georgia Site Public Contact - (ClinicalTrials@northside.com)
Northwest Wisconsin Cancer Center Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Norwalk Hospital Norwalk, Connecticut Site Public Contact - (jennifer.long@norwalkhealth.org)
OSF Saint Anthony's Health Center Alton, Illinois
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan Site Public Contact - (WI_research_admin@hshs.org)
Ochsner Baptist Medical Center New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
OhioHealth Mansfield Hospital Mansfield, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Marion General Hospital Marion, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth O'Bleness Hospital Athens, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Pickerington Methodist Hospital Pickerington, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
OhioHealth Westerville Medical Campus/Westerville Cancer Center Westerville, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Oncology Associates PC Omaha, Nebraska Site Public Contact - (info@oa-oc.com)
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
Orlando Health Cancer Institute Orlando, Florida Site Public Contact - (CancerClinicalTrials@orlandohealth.com)
Our Lady of The Lake Baton Rouge, Louisiana
Our Lady of the Lake Medical Oncology Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Our Lady of the Lake Physician Group Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Pali Momi Medical Center ‘Aiea, Hawaii
Palo Alto Medical Foundation Health Care Palo Alto, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Camino Division Mountain View, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Fremont Fremont, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Gynecologic Oncology Mountain View, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Santa Cruz Santa Cruz, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Palo Alto Medical Foundation-Sunnyvale Sunnyvale, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
PeaceHealth Saint John Medical Center Longview, Washington Site Public Contact - (kmakin-bond@peacehealth.org)
PeaceHealth Saint Joseph Medical Center Bellingham, Washington
PeaceHealth United General Medical Center Sedro-Woolley, Washington Site Public Contact - (rcrompton@peacehealth.org)
Penrose-Saint Francis Healthcare Colorado Springs, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Phelps Health Delbert Day Cancer Institute Rolla, Missouri Site Public Contact - (research@phelpshealth.org)
Pocono Medical Center East Stroudsburg, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Poudre Valley Hospital Fort Collins, Colorado
Princeton Community Hospital Princeton, West Virginia
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin
ProMedica Flower Hospital Sylvania, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio Site Public Contact - (PCIOncResearch@promedica.org)
Providence Alaska Medical Center Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Providence Medical Foundation - Santa Rosa Santa Rosa, California
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Queen of The Valley Napa, California
Providence Regional Cancer Partnership Everett, Washington Site Public Contact - (marilyn.birchman@providence.org)
Providence Regional Cancer System-Aberdeen Aberdeen, Washington Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Centralia Centralia, Washington Site Public Contact - (deidre.dillon@providence.org)
Providence Regional Cancer System-Lacey Lacey, Washington Site Public Contact - (deidre.dillon@providence.org)
Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California Site Public Contact - (Najee.Boucher@providence.org)
Providence Saint Mary Regional Cancer Center Walla Walla, Washington Site Public Contact - (Cheryl.Dodd@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Santa Rosa Memorial Hospital Santa Rosa, California
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Queen's Cancer Cenrer - POB I Honolulu, Hawaii
Queen's Cancer Center - Kuakini Honolulu, Hawaii
Queen's Cancer Center - Pearlridge ‘Aiea, Hawaii
Queen's Medical Center Honolulu, Hawaii
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Rice Memorial Hospital Willmar, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Ridgeview Medical Center Waconia, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Ridley-Tree Cancer Center Santa Barbara, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Riverside Methodist Hospital Columbus, Ohio Site Public Contact - (Jennifer.Sexton@ohiohealth.com)
Riverwood Healthcare Center Aitkin, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Rohnert Park Cancer Center Rohnert Park, California Site Public Contact - (Kpoct@kp.org)
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
SIH Cancer Institute Carterville, Illinois Site Public Contact - (clinical.research@sih.net)
SSM Health Good Samaritan Mount Vernon, Illinois Site Public Contact - (gayla.hall@ssmhealth.com)
Sacred Heart Hospital Pensacola, Florida Site Public Contact - (eebrou@ascension.org)
Saint Alphonsus Cancer Care Center-Baker City Baker City, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Anthony Hospital Lakewood, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Anthony North Hospital Westminster, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Charles Health System Bend, Oregon Site Public Contact - (nosall@stcharleshealthcare.org)
Saint Charles Health System-Redmond Redmond, Oregon
Saint Francis Cancer Center Greenville, South Carolina Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint Francis Regional Medical Center Shakopee, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Hospital East Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph London London, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Mount Sterling Mount Sterling, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph's Medical Center Stockton, California
Saint Louis Cancer and Breast Institute-Ballwin Ballwin, Missouri
Saint Louis Cancer and Breast Institute-South City St Louis, Missouri
Saint Luke's Cancer Center - Allentown Allentown, Pennsylvania
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Hospital - Monroe Campus Stroudsburg, Pennsylvania Site Public Contact - (Roster@nrgoncology.org)
Saint Luke's Hospital - Upper Bucks Campus Quakertown, Pennsylvania
Saint Luke's Hospital-Anderson Campus Easton, Pennsylvania Site Public Contact - (Roster@nrgoncology.org)
Saint Luke's University Hospital-Bethlehem Campus Bethlehem, Pennsylvania
Saint Mary Corwin Medical Center Pueblo, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Mary's Hospital Centralia, Illinois Site Public Contact - (Roster@nrgoncology.org)
Saint Michael Cancer Center Silverdale, Washington Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Patrick Hospital - Community Hospital Missoula, Montana Site Public Contact - (amy.hanneman@providence.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Santa Cruz Radiation Oncology Medical Group Santa Cruz, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sheboygan Physicians Group Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Sidney and Lois Eskenazi Hospital Indianapolis, Indiana Site Public Contact - (iutrials@iu.edu)
Skagit Regional Health Cancer Care Center Mount Vernon, Washington Site Public Contact - (rcccclinicalresearch@skagitvalleyhospital.org)
South Sacramento Cancer Center Sacramento, California Site Public Contact - (Kpoct@kp.org)
Southern Illinois University School of Medicine Springfield, Illinois
Southwest Oncology PC Durango, Colorado Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Stanford Cancer Institute Palo Alto Palo Alto, California Site Public Contact - (ccto-office@stanford.edu)
State University of New York Upstate Medical University Syracuse, New York
Straub Clinic and Hospital Honolulu, Hawaii
Sutter Auburn Faith Hospital Auburn, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Centers Radiation Oncology Services-Auburn Auburn, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Centers Radiation Oncology Services-Cameron Park Cameron Park, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Centers Radiation Oncology Services-Roseville Roseville, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Cancer Research Consortium Novato, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Davis Hospital Davis, California Site Public Contact - (NCIclinicaltrials@sutterhealth.org)
Sutter Medical Center Sacramento Sacramento, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Pacific Medical Foundation Santa Rosa, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Roseville Medical Center Roseville, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Sutter Solano Medical Center/Cancer Center Vallejo, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-Ballard Campus Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-Cherry Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The Cancer Center of Hawaii-Liliha Honolulu, Hawaii
The Cancer Center of Hawaii-Pali Momi ‘Aiea, Hawaii
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The Permanente Medical Group-Roseville Radiation Oncology Roseville, California Site Public Contact - (Kpoct@kp.org)
The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii Site Public Contact - (rohta@queens.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Torrance Memorial Physician Network - Cancer Care Torrance, California Site Public Contact - (courtney.steeneken@tmphysicians.com)
Tower Cancer Research Foundation Beverly Hills, California Site Public Contact - (towercancerresearch@toweroncology.com)
TriHealth Cancer Institute-Anderson Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
TriHealth Cancer Institute-Westside Cincinnati, Ohio Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Trinity Health Grand Rapids Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Medical Center - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Muskegon Hospital Muskegon, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UC San Diego Moores Cancer Center La Jolla, California Site Public Contact - (cancercto@ucsd.edu)
UCHealth - Cherry Creek Denver, Colorado Site Public Contact - (Roster@nrgoncology.org)
UCHealth Greeley Hospital Greeley, Colorado Site Public Contact - (Roster@nrgoncology.org)
UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado
UCHealth Memorial Hospital Central Colorado Springs, Colorado
UCHealth University of Colorado Hospital Aurora, Colorado
UChicago Medicine Northwest Indiana Crown Point, Indiana Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UH Seidman Cancer Center at Saint John Medical Center Westlake, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UHHS-Chagrin Highlands Medical Center Beachwood, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
United Hospital Center Bridgeport, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
University Medical Center New Orleans New Orleans, Louisiana Site Public Contact - (emede1@lsuhsc.edu)
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (tmyrick@uab.edu)
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Chicago Medicine-Orland Park Orland Park, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Florida Health Science Center - Gainesville Gainesville, Florida Site Public Contact - (cancer-center@ufl.edu)
University of Hawaii Cancer Center Honolulu, Hawaii
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Michigan - Brighton Center for Specialty Care Brighton, Michigan
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan Site Public Contact - (slusserb@med.umich.edu)
University of Michigan Health - Sparrow Lansing Lansing, Michigan Site Public Contact - (harsha.trivedi@umhsparrow.org)
University of Michigan Health - West Wyoming, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Rochester Rochester, New York
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
Valley Radiation Oncology Peru, Illinois
Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
WVUH-Berkely Medical Center Martinsburg, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Walter Reed National Military Medical Center Bethesda, Maryland
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
West Michigan Cancer Center Kalamazoo, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
West Virginia University Healthcare Morgantown, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Western Illinois Cancer Treatment Center Galesburg, Illinois
Wheeling Hospital/Schiffler Cancer Center Wheeling, West Virginia
Wilcox Memorial Hospital and Kauai Medical Clinic Lihue, Hawaii
Women and Infants Hospital Providence, Rhode Island
Woodland Memorial Hospital Woodland, California Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or - LillyTrials@Lilly.com

PHASE3
NCT06119581
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy. * Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label). * Must have disease with evidence of KRAS G12C mutation. * Must have known programmed death-ligand 1 (PD-L1) expression * Part A: Greater than or equal to (≥)50 percent (%). * Part B: 0% to 100%. * Must have measurable disease per RECIST v1.1. * Must have an ECOG performance status of 0 or 1. * Estimated life expectancy ≥12 weeks. * Ability to swallow capsules. * Must have adequate laboratory parameters. * Contraceptive use should be consistent with local regulations for those participating in clinical studies. * Women of childbearing potential must * Have a negative pregnancy test. * Not be breastfeeding during treatment
Exclusion Criteria:
* Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3. * Have had any of the following prior to randomization: \-- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC. \--- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated: * Have known active central nervous system metastases and/or carcinomatous meningitis. Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B) * Have predominantly squamous cell histology for NSCLC * Only for participants with mild to moderate renal insufficiency: Unable to avoid aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs) two days before (5 days for long acting NSAIDs), day of, and two days after administration of pemetrexed * Is unable or unwilling to take folic acid or vitamin B12 supplementation.
DRUG: LY3537982, DRUG: Pembrolizumab, DRUG: Placebo, DRUG: Cisplatin, DRUG: Carboplatin, DRUG: Pemetrexed
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Advanced Non-Small Cell Lung Cancer, KRAS G12 Lung Cancer, Advanced Lung Cancer, Metastatic Lung Cancer, KRAS G12C inhibitor, KRAS G12C Positive, KRAS Mutation, KRAS G12 Mutation, Lung Cancer Mutation, Olomorasib, Lung Diseases, Neoplastic Processes, Pathologic Processes, Neoplasm Metastasis, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Antineoplastic Agents, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Lung Neoplasms
I'm interested
Share via email
Show 428 locations

Study Locations

Hide all locations
Location Contacts
"Theagenio" Cancer Hospital of Thessaloniki Thessaloniki,
AZ Glorieux Ronse Ronse,
AZ Groeninge Campus Kennedylaan Kortrijk,
AZ Sint-Jan Brugge-Oostende AV Bruges,
AZ Sint-Maarten Mechelen,
Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital Ankara,
Aberdeen Royal Infirmary Aberdeen,
Actualidad Basada en la Investigación del Cáncer Guadalajara,
Adana City Hospital Adana,
Adana Medical Park Seyhan Hastanesi Adana,
Affiliated Hospital of Guangdong Medical University Zhanjiang,
Agios Savvas Regional Cancer Hospital Athens,
Aichi Cancer Center Hospital Nagoya,
Akdeniz Universitesi Hastanesi Antalya,
Akershus universitetssykehus Lørenskog,
All India Institute of Medical Sciences New Delhi, National Capital Territory of Delhi
Allina Health Cancer Institute - Abbott Northwestern Hospital Minneapolis, Minnesota
Ankara Bilkent Sehir Hastanesi Ankara,
Ankara Etlik City Hospital Ankara,
Arké SMO S.A de C.V Veracruz,
Asan Medical Center Seoul,
Asante Rogue Regional Medical Center Medford, Oregon
Ashwin Hospital Coimbatore,
Asklepios Fachkliniken München-Gauting Gauting,
Asklepios Klinik Harburg Hamburg,
Attikon General University Hospital Chaïdári, Attikí
Avix Investigacion Clinica, S.C. Monterrey,
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento Verona,
BASS Cancer Center Walnut Creek, California
BC Cancer Abbotsford Abbotsford,
BC Cancer Vancouver Vancouver,
Bacs-Kiskun Megyei Korhaz Kecskemét,
Ballarat Health Services Ballarat Central,
Banner MD Anderson Cancer Center Gilbert, Arizona
Banner University Medical Center Phoenix Phoenix, Arizona
Baptist Memorial Hospital-Memphis Memphis, Tennessee
Beijing Cancer Hospital Beijing, Beijing Municipality
Bezmialem Vakf Üniversitesi Istanbul,
Boston Medical Center Boston, Massachusetts
Brooke Army Medical Center Fort Sam Houston, Texas
Budapesti Uzsoki Utcai Korhaz Budapest,
Buddhist Dalin Tzu Chi General Hospital Chiayi City,
CEDOES Vitória,
CHI Saint Joseph Cancer Center - East Lexington, Kentucky
CHIREC - site delta Auderghem,
CHU Bordeaux Haut-Leveque Pessac,
CHU Lille - Institut Coeur Poumon Lille,
CHU de Toulouse - Hopital Larrey Toulouse,
CHUAC-Hospital Teresa Herrera A Coruña,
CHUS - Hospital Clinico Universitario Santiago de Compostela,
CHUV (centre hospitalier universitaire vaudois) Lausanne,
CIO - Centro de Inmuno-Oncología de Occidente Guadalajara,
CIUSSS- saguenay-Lac-Saint-Jean Chicoutimi,
COE Ensino e Pesquisa São José dos Campos,
Cabinet Medical Oncomed Timișoara,
Cancer Hospital Chinese Academy of Medical Science Beijing,
Cedars-Sinai Medical Center Los Angeles, California
Centre Antoine-Lacassagne Nice,
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois Vandœuvre-lès-Nancy, Lorraine
Centre Hospitalier Universitaire de Poitiers Poitiers, Vienne
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou Rennes,
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer Toulon,
Centre Leon Berard Lyon,
Centro Hospitalar E Universitário De Coimbra Coimbra,
Centro Hospitalar do Porto - Hospital de Santo António Porto,
Centro Onco-Hematológico Roma (COHR) Mexico City,
Centro Paulista de Oncologia Clínica São Paulo,
Centro de Investigacion Clinica de Oaxaca Oaxaca City, Oaxaca
Centro de Pesquisa Clínica do Instituto do Câncer do Ceará Fortaleza,
Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA Rio de Janeiro,
Centrul de Oncologie "Sfântul Nectarie" Craiova,
Champalimaud Foundation Lisbon,
Chang Gung Medical Foundation-LinKou Branch Taoyuan District,
Chang Gung Memorial Hospital at Kaohsiung Kaohsiung City,
Changhua Christian Hospital Changhua,
Charite Campus Virchow-Klinikum Berlin,
Cheltenham General Hospital Cheltenham,
Chi Mei Hospital - Liouying Branch Tainan City,
Chi Mei Medical Center Tainan City, Tainan
Chonnam National University Hwasun Hospital Hwasun-gun,
Chung Shan Medical University Hospital Taichung,
Chungbuk National University Hospital Cheongju Chungbuk,
Clearview Cancer Institute Huntsville, Alabama
Clinica Amo - Rio Vermelho Salvador,
Clinica Integral Internacional de Oncología Puebla City,
Clinical Research Alliance Westbury, New York
Clinique Saint Pierre Ottignies,
Community Cancer Center North Indianapolis, Indiana
Complejo Asistencial Universitario de León - Hospital de León León,
Complejo Hospitalario de Navarra Pamplona,
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada
Comprehensive Hematology Oncology St. Petersburg, Florida
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire
Dicle Üniversitesi Diyarbakır,
Drammen Sykehus, Vestre Viken HF Drammen,
Duke Cancer Institute Durham, North Carolina
ETZ Elisabeth Tilburg,
Ege Universitesi Hastanesi Izmir,
Emory University School of Medicine- Grady Campus Atlanta, Georgia
Erasmus Medisch Centrum Rotterdam,
Errikos Dunant Hospital Center Athens,
European Interbalkan Medical Center Thessaloniki,
Evangelische Lungenklinik Berlin Berlin,
Faculdade de Medicina do ABC Santo André,
Fakultni nemocnice Bulovka Prague,
Farkasgyepui Tudogyogyintezet Farkasgyepű,
Fondazione IRCCS Istituto Nazionale dei Tumori Milan,
Fondazione Policlinico Universitario Agostino Gemelli Roma,
Franciscan Health Indianapolis, Indiana
Franziskus-Hospital Harderberg Georgsmarienhütte,
Frisius Medisch Centrum Leeuwarden,
Fujian Cancer Hospital Fuzhou,
Fundação Faculdade Regional de Medicina de São José do Rio Preto Sao Jose Rio Preto,
Fundação Pio XII - Hospital de Câncer de Barretos Barretos, São Paulo
G. Papanikolaou General Hospital Thessaloniki,
Gangnam Severance Hospital, Yonsei University Health System Gangnam-gu,
Gold Coast University Hospital Southport,
Gosford Hospital Gosford,
Goulburn Valley Health Shepparton,
Gral Medical Diagnostic Center Bucharest,
Grant Medical Foundation - Ruby Hall Clinic Pune,
Gustave Roussy Villejuif,
H.R.U Málaga - Hospital General Málaga,
HCG Manavata Cancer Centre Nashik,
HELIOS Klinikum Erfurt Erfurt,
Hainan General Hospital Haikou,
Hanyang University Seoul Hospital Seoul,
Harbin Medical University Cancer Hospital Harbin, Heilongjiang
Haukeland Universitetssjukehus Bergen,
Health Pharma Professional Research S.A. de C.V: Mexico City, DIF
Health Pharma Querétaro Juriquilla,
HealthPartners Cancer Research Center Saint Paul, Minnesota
Helios Klinikum Emil von Behring Berlin-Zehlendorf Berlin,
Hemato Oncology Clinic Ahmedabad,
Highlands Oncology Group Springdale, Arkansas
Higiea Oncologia Mexico City,
Himeji Medical Center Himeji,
Hokkaido University Hospital Sapporo, Hokkaido
Hopital Foch Suresnes,
Hospices Civils de Lyon - Hopital Louis Pradel Bron,
Hospital BP São Paulo,
Hospital Brasilia Lago Sul, Federal District
Hospital Clinico Universitario Lozano Blesa Zaragoza, Aragon
Hospital Clinico de Valencia Valencia,
Hospital Cuf porto Porto,
Hospital Infanta Cristina Badajoz,
Hospital Insular de Gran Canaria Las Palmas de Gran Canaria,
Hospital Jerez de la Frontera Jerez de la Frontera,
Hospital Paulistano São Paulo,
Hospital Pulido Valente Lisbon,
Hospital Santa Catarina - Paulista São Paulo,
Hospital Sao Domingos Bequimão,
Hospital Sao Lucas da PUCRS Porto Alegre,
Hospital Sirio Libanes São Paulo,
Hospital Tacchini Bento Gonçalves,
Hospital Universitari Dexeus Barcelona,
Hospital Universitari Son Espases Palma de Mallorca,
Hospital Universitari Vall d'Hebron Barcelona,
Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Monterrey, Nuevo León
Hospital Universitario 12 de Octubre Madrid,
Hospital Universitario Quironsalud Madrid Pozuelo de Alarcón,
Hospital Universitario Ramon y Cajal Madrid,
Hospital Universitario Virgen del Rocio Seville,
Hospital Universitário Evangélico Mackenzie Curitiba,
Hospital da Luz Lisboa Lisbon,
Hospital de Cancer de Londrina Londrina,
Houston Methodist Hospital Houston, Texas
Hualien Tzu Chi Medical Center Hualien City,
Huddersfield Royal Infirmary Huddersfield,
Hunan Cancer Hospital Changsha, Hunan
Hunan Cancer Hospital Changsha, Hunan
Hwa Mei Hospital University of Chinese Academy of Sciences Ningbo,
Hämato-Onkologie Hamburg, Prof. Laack und Partner Hamburg,
Hôpital Robert Schuman Vantoux,
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola Bologna,
Ibaraki Prefectural Central Hospital Kasama,
Icesp - Instituto Do Câncer Do Estado de São Paulo São Paulo,
Icon Cancer Centre Wesley Auchenflower,
Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana
Institut Curie Paris,
Institut Jean Godinot Reims,
Institut de Cancerologie de l'Ouest Saint-Herblain,
Instituto Catalan de Oncologia - Hospital Duran i Reynals Hospitalet,
Instituto D'Or Pesquisa e Ensino Rio de Janeiro,
Instituto D'Or de Pesquisa e Ensino (IDOR) São Paulo,
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA Rio de Janeiro,
Instituto Português de Oncologia do Porto Francisco Gentil, EPE Porto,
Instituto Tumori Giovanni Paolo II Bari,
Instituto de Assistência Médica ao Servidor Público Estadual - IAMSPE/HSPE-FMO Conhecer Centro de Oncolog -T São Paulo,
Institutul Oncologic Cluj-Napoca,
Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli,
Istituto Nazionale Tumori Regina Elena Rome,
Istituto Oncologico Veneto IRCCS Padua,
Japanese Foundation for Cancer Research Kōtō City,
Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry,
Jeroen Bosch Hospital 's-Hertogenbosch,
Jilin Cancer Hospital Changchun, Jilin
Jinan Central Hospital Jinan, Shandong
Johns Hopkins Bayview Medical Center Baltimore, Maryland
Juntendo University Hospital Bunkyo-ku, Tokyo
KLES Dr. Prabhakar Kore Hospital & M.R.C Belagavi, Karnataka
Kadlec Clinic Hematology and Oncology Kennewick, Washington
Kaiser Permanente Interstate Medical Office Central Portland, Oregon
Kanagawa Cancer Center Yokohama,
Kanagawa Cardiovascular and Respiratory Center Yokohama,
Kanazawa University Hospital Kanazawa,
Kansai Medical University Hospital Hirakata-shi, Osaka
Kantonsspital Winterthur Winterthur,
Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City,
Karmanos Cancer Institute Detroit, Michigan
Keimyung University Dongsan Hospital Daegu,
Kindai University Hospital- Osakasayama Campus Sayama,
Klinik Floridsdorf Vienna,
Klinikum Chemnitz Chemnitz,
Klinikum Nürnberg Nord Nuremberg,
Kobe City Medical Center General Hospital Kobe,
Kocaeli Üniversitesi Kocaeli,
Kolhapur Cancer Centre Private Limited Kolhāpur,
Korea University Anam Hospital Seoul,
Korea University Guro Hospital Seoul,
Krankenhaus Martha-Maria Halle-Dölau Halle,
Krishna Institute of Medical Sciences - Karad Karad,
Kyungpook National University Chilgok Hospital Daegu,
Kyushu University Hospital Fukuoka,
Lahey Hospital & Medical Center Burlington, Massachusetts
Landeskrankenhaus Feldkirch Rankweil,
Laura and Isaac Perlmutter Cancer Center New York, New York
Leids Universitair Medisch Centrum Leiden,
Lexington Medical Center West Columbia, South Carolina
Lifepoint Multispeciality Hospital Pune,
Lifespan Cancer Institute Providence, Rhode Island
Liga Norte Riograndense Contra O Cancer Natal, Rio Grande do Norte
Linyi Cancer Hospital Linyi, Shandong
Liuzhou People's Hospital Liuzhou,
Lotus-Med Bucharest,
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Torrance, California
LungenClinic Grosshansdorf Großhansdorf,
MICS Centrum Medyczne Torun Torun,
MV-Zentrum für Onkologie und Hämatologie Cologne,
Mackay Base Hospital Mackay,
Mahatma Gandhi Cancer Hospital and Research Institute Visakhapatnam,
Maimonides Cancer Center Brooklyn, New York
Manhattan Eye, Ear and Throat Hospital New York, New York
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana
Medical University of South Carolina Charleston, South Carolina
Medisch Spectrum Twente Enschede,
Memorial Antalya Hospital Antalya,
Memorial Sloan Kettering Cancer Center New York, New York
Mercy Cancer Center Merced, California
Miami Cancer Institute at Baptist Health, Inc. Miami, Florida
Millennium Oncology Research Clinic Hollywood, Florida
Miyagi Cancer Center Natori,
Mount Vernon Hospital Northwood,
Mälarsjukhuset Eskilstuna,
Nagasaki University Hospital Nagasaki,
Nanjing First Hospital Nanjing,
Nantong Tumor Hospital Nantong,
National Cancer Center Goyang-si Gyeonggi-do,
National Cancer Center Hospital East Kashiwa-shi, Chiba
National Cheng Kung University Hospital Tainan City,
National Hospital Organization Asahikawa Medical Center Asahikawa,
National Hospital Organization Kinki-Chuo Chest Medical Center Sakai,
National Hospital Organization Kyushu Cancer Center Fukuoka,
National Hospital Organization Shikoku Cancer Center Matsuyama, Ehime
National Hospital Organization Yamaguchi Ube Medical Center Ube,
National Taiwan University Cancer Center (NTUCC) Taipei,
National Taiwan University Hospital Taipei,
National Taiwan University Hospital - Hsinchu branch Zhubei,
National Taiwan University Hospital Yun-Lin Branch Dou-Liou Region Douliu,
Nemocnice AGEL Ostrava - Vitkovice a.s. Ostrava,
New Cross Hospital Wolverhampton,
New Taipei Municipal TuCheng Hospital New Taipei City,
Niigata Cancer Center Hospital Niigata, Niigata
Ninewells Hospital and Medical School Dundee,
Nizam's Institute of Medical Sciences Hyderabad, Andhra Pradesh
North Mississippi Hematology and Oncology Associates Tupelo, Mississippi
Northwell Health/ RJ Zuckerberg Cancer Center Lake Success, New York
Nouvel Hôpital Civil (NHC) Strasbourg,
Núcleo de Pesquisa Clínica da Rede São Camilo São Paulo,
ONCOSITE - Centro de Pesquisa Clinica em Oncologia Ijuí,
OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces Barakaldo,
Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala Ocala, Florida
Okayama University Hospital Okayama, Okayama-ken
Oncare - Unidad Valle San Pedro Garza García,
Oncocentro de Minas Gerais Belo Horizonte,
Oncology Hematology Associates Springfield, Missouri
Oncominas Pouso Alegre,
Ondokuz Mayıs Universitesi Samsun,
One Day Med Szczecin,
Onkologiezentrum Donauwörth Donauwörth,
Ordensklinikum Linz GmbH Elisabethinen Linz,
Orszagos Koranyi Pulmonologiai Intezet Budapest,
Orszagos Onkologiai Intezet Budapest,
Oslo universitetssykehus, Radiumhospitalet Oslo,
Ospedale di Circolo e Fondazione Macchi Varese Varese,
Ovidius Clinical Hospital OCH Ovidiu,
Pacific Medical College & Hospital Udaipur,
PanAmerican Clinical Research - Guadalajara Guadalajara,
Parc de Salut Mar - Hospital del Mar Barcelona,
Parkview Research Center at Parkview Regional Medical Center Fort Wayne, Indiana
Perlmutter Cancer Center at NYU Langone Hospital - Long Island Mineola, New York
Policlinico "G. Rodolico" Catania,
Preparaciones Oncológicas S.C. León,
Prisma Health Cancer Institute Greenville, South Carolina
Providence Portland Medical Center Portland, Oregon
Providence St. Vincent Medical Center Portland, Oregon
Pusan National University Yangsan Hospital Yangsan, Gyeongsangnam-do
Regional Cancer Centre - Thiruvananthapuram Thiruvananthapuram,
Renati Innovation Guadalajara,
Renmin Hospital of Wuhan University Wuhan,
Roskilde University Hospital Roskilde,
Royal Adelaide Hospital Adelaide, South Australia
S C Oncocenter Oncologie Clinica S R L Timișoara,
SC Memorial Healthcare International SRL Bucharest,
SRV Hospitals Bengaluru,
SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical Madison, Wisconsin
Sahyadri Super Speciality Hospital Pune, Maharashtra
Sainte Catherine Institut du Cancer Avignon Provence Avignon,
Saitama Medical University International Medical Center Saitama,
Samsung Medical Center Seoul,
Severance Hospital, Yonsei University Health System Seoul,
Shandong Cancer Hospital Jinan, Shandong
Shanghai Chest Hospital Shanghai, Shanghai Municipality
Shizuoka Cancer Center Sunto-gun, Shizuoka
Sibley Memorial Hospital Washington D.C., District of Columbia
Sichuan Cancer Hospital Chengdu,
Sir Charles Gairdner Hospital Perth,
Sir Run Run Shaw Hospital Hangzhou,
Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul Brasília,
Sotiria Thoracic Diseases Hospital of Athens Athens,
Springfield Clinic Main Campus Springfield, Illinois
St James's University Hospital Leeds,
St Vincent'S Hospital Melbourne,
St. Antonius Ziekenhuis, locatie Utrecht Utrecht,
St. Olavs Hospital Trondheim,
Stavanger Universitetssykehus Stavanger,
Sunshine Coast University Hospital Birtinya,
Swedish Medical Center Englewood, Colorado
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej Kielce,
Sykehuset Innlandet HF Gjøvik Gjøvik,
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi Istanbul,
Taichung Veterans General Hospital Taichung, China
Taipei Veterans General Hospital Taipei,
Taizhou Hospital of Zhejiang Province Taizhou, Zhejiang
Tampa General Hospital Tampa, Florida
Tata Memorial Centre - Homi Bhabha Cancer Hospital Varanasi,
Tata Memorial Hospital Mumbai, Maharashtra
Tennessee Oncology Nashville, Tennessee
Tennessee Oncology Chattanooga Chattanooga, Tennessee
Tergooiziekenhuizen, locatie Hilversum Hilversum,
The Cancer & Hematology Centers Grand Rapids, Michigan
The Catholic University Of Korea St. Vincent's Hospital Suwon,
The Catholic University of Korea, Yeouido St. Mary's Hospital Seoul,
The Christie NHS Foundation Trust Manchester,
The First Affiliated Hospital of Guangzhou Medical University Guangzhou,
The First Affiliated Hospital of NanChang University Nanchang, Jiangxi
The First Affiliated Hospital of Xi'An Jiaotong University Xi'an, Shaanxi
The First Affiliated Hospital of Xinjiang Medical University Ürümqi,
The First Affiliated Hospital, Zhejiang University Hangzhou,
The First People's Hospital of Changzhou Changzhou, Jiangsu
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T Columbus, Ohio
The Third People's Hospital of Chengdu (CDTPH) Chengdu,
The Townsville Hospital Townsville,
The University of Arizona Cancer Center - North Campus Tucson, Arizona
The University of Kansas Cancer Center - Westwood Westwood, Kansas
The University of Vermont Medical Center Inc. Burlington, Vermont
The Valley Hospital, Inc. Ridgewood, New Jersey
Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office Philadelphia, Pennsylvania
Thoraxklinik-Heidelberg gGmbH Heidelberg,
Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin Municipality
Tochigi Cancer Center Utsunomiya,
Tokyo Metropolitan Komagome Hospital Bunkyō City,
Tongji Hospital Tongji Medical,Science & Technology Wuhan, Hubei
Tottori University Hospital Yonago,
UNC REX Cancer Center Raleigh, North Carolina
UPMC Hillman Cancer Center Pittsburgh, Pennsylvania
USO - Alliance Cancer Specialists, PC Horsham, Pennsylvania
USO - Maryland Oncology Hematology Annapolis, Maryland
USO - Northwest Cancer Specialists Vancouver, Washington
USO - Oncology Associates of Oregon Eugene, Oregon
USO - Oncology Hematology Care Cincinnati, Ohio
USO - Rocky Mountain Cancer Centers Lone Tree, Colorado
USO - Texas Oncology Webster, Texas
USO - Texas Oncology Webster, Texas
USO - US Oncology Research Network The Woodlands, Texas
USO - Virginia Cancer Specialists Fairfax, Virginia
UZ Gent Ghent,
UZ Leuven Leuven,
Uludag Universitesi Bursa,
Universitaetsklinikum Freiburg Freiburg im Breisgau,
Universitaetsklinikum Tuebingen Tübingen, Baden-Wurttemberg
Universitatsspital Zurich Zurich,
University Cancer & Blood Center, LLC Athens, Georgia
University General Hospital of Heraklion Heraklion,
University Hospital of Patras Pátrai,
University Hospital,Kyoto Prefectural University of Medicine Kyoto,
University of Chicago Hospital Chicago, Illinois
University of Florida - Jacksonville Jacksonville, Florida
University of Illinois at Chicago Chicago, Illinois
University of Kentucky Chandler Medical Center Lexington, Kentucky
University of Michigan Ann Arbor, Michigan
University of New Mexico Comprehensive Cancer Center Albuquerque, New Mexico
University of North Carolina Medical Center Chapel Hill, North Carolina
University of Tennessee Medical Center Knoxville, Tennessee
University of Texas MD Anderson Cancer Center Houston, Texas
University of Virginia Health System Charlottesville, Virginia
Universitätsklinikum Münster - Albert Schweitzer Campus Münster,
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne Yvoir,
VA Puget Sound Health Care System Seattle, Washington
VCU Health Adult Outpatient Pavillion Richmond, Virginia
Västmanlands Sjukhus Västerås Västerås,
Wakayama Medical University Hospital Wakayama, Wakayama
Wannan Medical College Yijishan Hospital Wuhu,
West China Hospital, Sichuan University Chengdu, Sichuan
Weston Park Hospital Sheffield,
William Beaumont Army Medical Center Fort Bliss, Texas
Winship Cancer Institute, Emory University Atlanta, Georgia
Wuhan Union Hospital Wuhan,
Xiangyang Central Hospital Xiangyang,
Xinjiang Medical University Cancer Hospital - Urumqi Ürümqi, Xinjiang
Yale University School of Medicine New Haven, Connecticut
Yichang Central People's Hospital Yichang,
ZNA Middelheim Antwerp,
Zhejiang Cancer Hospital Hangzhou, Zhejiang
ZhuZhou Central Hospital Zhuzhou,
Ziekenhuis St. Jansdal Harderwijk,
zmir Katip Çelebi Üniversitesi Atatürk Eitim Ve Aratrma Hastanesi Izmir,
İ.A.Ü VM Medical Park Florya Hastanesi Istanbul,

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Devon Noonan, PhD, MPH, FNP-BC - devon.noonan@duke.edu

PHASE3
NCT05008848
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Have a cancer diagnosis within the past 10 years, and can currently be receiving curative treatment * Not currently on hospice * Currently smokes \>= 5 cigarettes daily * Lives in a nonmetro/rural county (defined as having a Rural Urban Continuum Code \[RUCC\] code of 4-9) * Patient interested in participating in a smoking cessation program, and not currently participating in a smoking cessation clinical trial * Not currently using any smoking cessation pharmacotherapy (e.g. nicotine replacement therapy, bupropion or varenicline), or currently participating in any cessation program * Patient has a cell phone or smart phone device with texting ability * In order to complete the mandatory patient-completed measures, participants must be able to speak and read English * Age \>= 18 years * Participant must be willing to provide a urine sample.
Exclusion Criteria:
* Psychiatric illness which would prevent the patient from giving informed consent * Patients with impaired decision-making capacity are not eligible for this study.
BEHAVIORAL: Smoking Cessation Intervention, OTHER: Health Promotion and Education, OTHER: Informational Intervention, OTHER: Questionnaire Administration
Cigarette Smoking-Related Carcinoma
I'm interested
Share via email
Show 203 locations

Study Locations

Hide all locations
Location Contacts
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Adena Regional Medical Center Chillicothe, Ohio Site Public Contact - (Jeffh@columbusccop.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Ballad Health Cancer Care - Bristol Bristol, Virginia Site Public Contact - (charles.mays@balladhealth.org)
Ballad Health Cancer Care - Kingsport Kingsport, Tennessee Site Public Contact - (charles.mays@balladhealth.org)
Banner McKee Medical Center Loveland, Colorado
Banner North Colorado Medical Center Greeley, Colorado
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
Broadlawns Medical Center Des Moines, Iowa
CHI Health Good Samaritan Kearney, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
CHI Health Saint Francis Grand Island, Nebraska Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Camden Clark Medical Center Parkersburg, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Center of Acadiana Lafayette, Louisiana
Cancer Center of Western Wisconsin New Richmond, Wisconsin Site Public Contact - (mmcorc@healthpartners.com)
Carle BroMenn Medical Center Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle BroMenn Outpatient Center Bloomington, Illinois Site Public Contact - (Research@Carle.com)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Cancer Institute Normal Normal, Illinois Site Public Contact - (Research@Carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Carson Tahoe Regional Medical Center Carson City, Nevada Site Public Contact - (research@sncrf.org)
Centralia Oncology Clinic Centralia, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Chesapeake Regional Medical Center Chesapeake, Virginia Site Public Contact - (CancerCare@ChesapeakeRegional.com)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (HemonCCTrials@geisinger.edu)
Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Corewell Health Reed City Hospital Reed City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
Cotton O'Neil Cancer Center / Stormont Vail Health Topeka, Kansas
CoxHealth South Hospital Springfield, Missouri
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dartmouth Cancer Center - North Saint Johnsbury, Vermont Site Public Contact - (cancer.research.nurse@hitchcock.org)
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Doctor's Hospital of Laredo Laredo, Texas
Duke University Medical Center Durham, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Durham VA Medical Center Durham, North Carolina Site Public Contact - (VHADURcancertrials@va.gov)
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health - Ely Clinic Ely, Minnesota
Essentia Health - International Falls Clinic International Falls, Minnesota
Essentia Health - Park Rapids Park Rapids, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center-South University Clinic Fargo, North Dakota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Saint Mary's Hospital - Superior Superior, Wisconsin
Essentia Health Sandstone Sandstone, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Lakes Medical Center Wyoming, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Flaget Memorial Hospital Bardstown, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Great Falls Clinic Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
HSHS Sacred Heart Hospital Eau Claire, Wisconsin
HaysMed Hays, Kansas
Heartland Regional Medical Center Saint Joseph, Missouri Site Public Contact - (Trisha.England2@mymlc.com)
Hendrick Medical Center Abilene, Texas
Hennepin County Medical Center Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Hunter Holmes McGuire Veterans Administration Medical Center Richmond, Virginia Site Public Contact - (Regina.McClung@va.gov)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Inspira Medical Center Vineland Vineland, New Jersey
Iowa Methodist Medical Center Des Moines, Iowa
Kingman Regional Medical Center Kingman, Arizona Site Public Contact - (research@sncrf.org)
Knox Community Hospital Mount Vernon, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Lake Regional Hospital Osage Beach, Missouri Site Public Contact - (clinicaltrials@lakeregional.com)
Lakeview Hospital Stillwater, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Lawrence Memorial Hospital Lawrence, Kansas Site Public Contact - (Stephanie.Norris@LMH.ORG)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Louisiana State University Health Science Center New Orleans, Louisiana Site Public Contact - (emede1@lsuhsc.edu)
Low Country Cancer Care Savannah, Georgia Site Public Contact - (Lorraine.OHara@hcahealthcare.com)
Margaret R Pardee Memorial Hospital Hendersonville, North Carolina Site Public Contact - (pardeecancerresearch@unchealth.unc.edu)
Mary Imogene Bassett Hospital Cooperstown, New York Site Public Contact - (CancerClinicalTrials@bassett.org)
Memorial Health University Medical Center Savannah, Georgia Site Public Contact - (Lorraine.OHara@hcahealthcare.com)
Memorial Hospital of Sweetwater County Rock Springs, Wyoming Site Public Contact - (tharris@sweetwatermemorial.com)
Memorial Medical Center-Las Cruces Las Cruces, New Mexico Site Public Contact - (Deborah.Brown@LPNT.net)
Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri
Mercy Health - Perrysburg Hospital Perrysburg, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Health - Saint Anne Hospital Toledo, Ohio Site Public Contact - (Jeffh@columbusccop.org)
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital Fort Smith Fort Smith, Arkansas
Mercy Hospital Oklahoma City Oklahoma City, Oklahoma
Mercy Hospital Saint Louis St Louis, Missouri
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Hospital Springfield Springfield, Missouri
Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri
Minnesota Oncology - Burnsville Burnsville, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monticello Cancer Center Monticello, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Munson Medical Center Traverse City, Michigan Site Public Contact - (crcwm-regulatory@crcwm.org)
New Ulm Medical Center New Ulm, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
North Memorial Medical Health Center Robbinsdale, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Northeast Georgia Medical Center Braselton Braselton, Georgia Site Public Contact - (cancerpatient.navigator@nghs.com)
Northeast Georgia Medical Center-Gainesville Gainesville, Georgia Site Public Contact - (cancerpatient.navigator@nghs.com)
Novant Health Breast Surgery - Greensboro Greensboro, North Carolina Site Public Contact - (pjordan@novanthealth.org)
Novant Health Cancer Institute - Kernersville Kernersville, North Carolina Site Public Contact - (asmarrs@novanthealth.org)
Novant Health Cancer Institute - Mount Airy Mount Airy, North Carolina Site Public Contact - (asmarrs@novanthealth.org)
Novant Health Cancer Institute - Thomasville Thomasville, North Carolina Site Public Contact - (pjordan@novanthealth.org)
Novant Health Colon and Rectal Clinic Clemmons, North Carolina Site Public Contact - (pjordan@novanthealth.org)
Novant Health Forsyth Medical Center Winston-Salem, North Carolina Site Public Contact - (pjordan@novanthealth.org)
OSF Saint Anthony Medical Center Rockford, Illinois
OSF Saint Francis Hospital and Medical Group Escanaba, Michigan Site Public Contact - (WI_research_admin@hshs.org)
Ochsner Medical Center Jefferson New Orleans, Louisiana Site Public Contact - (Elisemarie.curry@ochsner.org)
Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Phelps Health Delbert Day Cancer Institute Rolla, Missouri Site Public Contact - (research@phelpshealth.org)
Princeton Community Hospital Princeton, West Virginia
Regional Cancer Center at Johnson City Medical Center Johnson City, Tennessee Site Public Contact - (charles.mays@balladhealth.org)
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Rice Memorial Hospital Willmar, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Ridgeview Medical Center Waconia, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Rush-Copley Healthcare Center Yorkville, Illinois Site Public Contact - (Cancer.Research@rushcopley.com)
Rush-Copley Medical Center Aurora, Illinois Site Public Contact - (RCMC_Cancer_Research@rush.edu)
SSM Health Dean Medical Group - Baraboo Baraboo, Wisconsin
SSM Health Dean Medical Group - Janesville Janesville, Wisconsin
SSM Health Dean Medical Group - South Madison Campus Madison, Wisconsin
SSM Health Good Samaritan Mount Vernon, Illinois Site Public Contact - (gayla.hall@ssmhealth.com)
SSM Health Saint Louis University Hospital St Louis, Missouri
STCC at DHR Health Institute for Research and Development Edinburg, Texas Site Public Contact - (dhrresearch@dhr-rgv.com)
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon
Saint Anthony Regional Hospital Carroll, Iowa Site Public Contact - (sbenson@iora.org)
Saint Francis Medical Center Cape Girardeau, Missouri Site Public Contact - (sfmc@sfmc.net)
Saint Francis Regional Medical Center Shakopee, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Helena Hospital St. Helena, California
Saint John's Hospital - Healtheast Maplewood, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Saint Joseph Hospital Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph Hospital East Lexington, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Joseph London London, Kentucky Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org)
Saint Luke's Hospital Chesterfield, Missouri Site Public Contact - (Rachel.varner@unitypoint.org)
Saint Luke's Hospital of Duluth Duluth, Minnesota Site Public Contact - (kdean@slhduluth.com)
Saint Mary's Hospital Centralia, Illinois Site Public Contact - (protocols@AllianceNCTN.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Salina Regional Health Center Salina, Kansas Site Public Contact - (mleepers@srhc.com)
Sentara Norfolk General Hospital Norfolk, Virginia
Sentara Princess Anne Hospital Virginia Beach, Virginia Site Public Contact - (djoverto@sentara.com)
Southeastern Medical Oncology Center-Clinton Clinton, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Goldsboro Goldsboro, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southeastern Medical Oncology Center-Jacksonville Jacksonville, North Carolina Site Public Contact - (jfields@cancersmoc.com)
Southern Illinois University School of Medicine Springfield, Illinois
Sovah Health Martinsville Martinsville, Virginia Site Public Contact - (sharon.hubbard@lpnt.net)
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
Strecker Cancer Center-Belpre Belpre, Ohio Site Public Contact - (Jeffh@columbusccop.org)
The Carle Foundation Hospital Urbana, Illinois Site Public Contact - (Research@carle.com)
The Iowa Clinic PC West Des Moines, Iowa
The University of Kansas Cancer Center - Olathe Olathe, Kansas Site Public Contact - (OlatheCCResearch@kumc.edu)
UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa
UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa
UI Healthcare Mission Cancer and Blood - Fort Dodge Fort Dodge, Iowa Site Public Contact - (trials@missioncancer.com)
UP Health System Marquette Marquette, Michigan Site Public Contact - (Dianna.Larson@mghs.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
United Hospital Center Bridgeport, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)
Unity Hospital Fridley, Minnesota
University Health Truman Medical Center Kansas City, Missouri
University of Iowa Healthcare Cancer Services Quad Cities Bettendorf, Iowa Site Public Contact - (katherine-daprile@uiowa.edu)
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
VCU Community Memorial Health Center South Hill, Virginia Site Public Contact - (nemer.elmouallem@vcuhealth.org)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
West Virginia University Healthcare Morgantown, West Virginia Site Public Contact - (cancertrialsinfo@hsc.wvu.edu)

Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer

ctrrecruit@vcu.edu

PHASE2
NCT06388018
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must have had surgery consisting of hysterectomy (total abdominal, laparoscopic or robotic-assisted) and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards (sentinel or full lymphadenectomy). There must be no macroscopic residual disease after surgery * Patients must have histologically confirmed stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed * Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2 * Patients' age must be \>= 18 years * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. A similar process must be followed for sites outside of Canada as per their respective cooperative group's procedures * Patient is able (i.e. sufficiently fluent) and willing to complete the patient reported outcomes (PRO) questionnaires in either English, French or a validated language. The baseline assessment must be completed within required timelines, prior to enrollment. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible * Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits placed on patients being considered for this trial. The patient's city of residence may be required to verify their geographical proximity. (Call the CCTG office (613-533-6430) if questions arise regarding the interpretation of this criterion.) Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up * Patients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial * Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy * SUB-STUDY A: Patients with endometrial carcinoma (endometrioid, serous, clear cell, un-/dedifferentiated, carcinosarcoma, mixed), must have one of the following combinations of International Federation of Gynecology and Obstetrics (FIGO) stage, grade, and lymphovascular invasion (LVI): * Cohort A1: * Stage IA (not confined to polyp), grade 3, pN0, with or without LVI (Pelvic lymph node surgical assessment (sentinel or full lymphadenectomy) is required for grade 3 or stage II. Para-aortic lymphadenectomy is not mandated.) * Stage IB, grade 1 or 2, pNx/N0, with or without LVI * Stage IB, grade 3, pN0, without substantial LVI (Pelvic lymph node surgical assessment (sentinel or full lymphadenectomy) is required for grade 3 or stage II. Para-aortic lymphadenectomy is not mandated.) * Stage II (microscopic), grade 1 or 2, pN0, without substantial LVI (Pelvic lymph node surgical assessment (sentinel or full lymphadenectomy) is required for grade 3 or stage II. Para-aortic lymphadenectomy is not mandated.) (Substantial LVI is defined as \>= 3 foci per College of American Pathologists' reporting guideline) * Cohort A2: * Stage IA (not confined to polyp), grade 3, pNx, with or without LVI * Stage IB, grade 3, pNx, with or without LVI * Stage IB, grade 3, pN0, with substantial LVI (Substantial LVI is defined as \>= 3 foci per College of American Pathologists' reporting guideline) * Stage II (microscopic), grade 1 or 2, pNx, with or without LVI * Stage II (microscopic), grade 1 or 2, pN0, with substantial LVIƒõ * Stage II (microscopic), grade 3, pNx/N0, with or without LVI * Stage II non-microscopic, any grade, pNx/N0, with or without LVI * Stage III, any grade, pNx/N0-2, with or without LVI * Substantial LVI is defined as .3 foci per College of American Pathologists¡¦ reporting guideline * SUB-STUDY A: Patients must have a molecular classification of POLE mutation. * Note: patients in Cohort A2 should have a known POLE pathogenic mutation prior to consenting * SUB-STUDY B: Patients with endometrial carcinoma (endometrioid only), must have one of the following combinations of FIGO stage, grade, and lymphovascular invasion (LVI): * Stage IA (not confined to polyp), grade 3, pN0, with or without LVI (Pelvic lymph node surgical assessment \[sentinel or full lymphadenectomy\] is required for grade 3 or stage II. Para-aortic lymphadenectomy is not mandated) (Substantial LVI is defined as \>= 3 foci per College of American Pathologists' reporting guideline) * Stage IB, grade 1 or 2, pNx/N0, with or without LVI * Stage IB, grade 3, pN0, without substantial LVI (Pelvic lymph node surgical assessment \[sentinel or full lymphadenectomy\] is required for grade 3 or stage II. Para-aortic lymphadenectomy is not mandated) (Substantial LVI is defined as \>= 3 foci per College of American Pathologists' reporting guideline) * Stage II (microscopic), grade 1 or 2, pN0\*, without substantial LVI (Pelvic lymph node surgical assessment \[sentinel or full lymphadenectomy\] is required for grade 3 or stage II. Para-aortic lymphadenectomy is not mandated) (Substantial LVI is defined as \>= 3 foci per College of American Pathologists' reporting guideline) * SUB-STUDY B: Patients must have molecular classification of p53wt/NSMP (based on normal p53 IHC, and absence of pathogenic POLE mutation or MMR deficiency) * SUB-STUDY B: Estrogen receptor positive (\> 10% of the tumour with positive nuclear staining) on IHC
Exclusion Criteria:
* Prior neoadjuvant chemotherapy for current endometrial cancer diagnosis * Prior pelvic radiation * Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for \>= 5 years * Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan) * SUB-STUDY A: Isolated tumour cell(s) identified in lymph node(s) for patients in Cohort A1 * SUB-STUDY B: Abnormal p53 and/or mismatch repair deficiency on immunohistochemistry without pathogenic POLE mutation. * Abnormal p53 can also be determined by TP53 mutations found on DNA testing. * SUB-STUDY B: p53wt/NSMP endometrial carcinoma with a MELF (microcystic, elongated and fragmented) pattern of myoinvasion and/or substantial lymphovascular invasion * SUB-STUDY B: Stage IA (not confined to polyp), grade 3, pN0, with substantial LVI. Stage IB, grade 1 or 2, pNx/N0, with substantial LVI * SUB-STUDY B: Isolated tumour cell(s) identified in lymph node(s)
OTHER: Clinical Observation, PROCEDURE: Computed Tomography, RADIATION: External Beam Radiation Therapy, PROCEDURE: High-Dose-Rate Vaginal Brachytherapy, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, OTHER: Questionnaire Administration, PROCEDURE: X-Ray Imaging
Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8, Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8, Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8
I'm interested
Share via email
Show 61 locations

Study Locations

Hide all locations
Location Contacts
Alaska Women's Cancer Care Anchorage, Alaska Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org)
Ascension Saint Vincent Indianapolis Hospital Indianapolis, Indiana Site Public Contact - (research@stvincent.org)
Asplundh Cancer Pavilion Willow Grove, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Cedars Sinai Medical Center Los Angeles, California
Centro Comprensivo de Cancer de UPR San Juan, Site Public Contact - (Roster@nrgoncology.org)
Duke University Medical Center Durham, North Carolina
Duke Women's Cancer Care Raleigh Raleigh, North Carolina
Emory Saint Joseph's Hospital Atlanta, Georgia
Emory University Hospital Midtown Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute Atlanta, Georgia
Farmington Health Center Farmington, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
First Physicians Group-Sarasota Sarasota, Florida
Florida Cancer Specialists - Sarasota Downtown Sarasota, Florida
Florida Cancer Specialists - Venice Pinebrook Venice, Florida Site Public Contact - (ClinicalTrials@FLCancer.com)
Grady Health System Atlanta, Georgia
Huntington Memorial Hospital Pasadena, California
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
Intermountain Health West End Clinic Billings, Montana
M D Anderson Cancer Center Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson League City League City, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson West Houston Houston, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in Sugar Land Sugar Land, Texas Site Public Contact - (askmdanderson@mdanderson.org)
MD Anderson in The Woodlands Conroe, Texas Site Public Contact - (askmdanderson@mdanderson.org)
Medical College of Wisconsin Milwaukee, Wisconsin
Mount Sinai Chelsea New York, New York Site Public Contact - (CCTO@mssm.edu)
Mount Sinai Hospital New York, New York Site Public Contact - (CCTO@mssm.edu)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania Site Public Contact - (CTO@hmc.psu.edu)
Piedmont Hospital Atlanta, Georgia Site Public Contact - (ORS@piedmont.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Saint Vincent Frontier Cancer Center Billings, Montana
Sarasota Memorial Health Care Center at University Parkway Sarasota, Florida
Sarasota Memorial Hospital Sarasota, Florida
Sarasota Memorial Hospital-Venice N. Venice, Florida
Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey Site Public Contact - (ONCTrialNow@jefferson.edu)
Sinai Hospital of Baltimore Baltimore, Maryland
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
State University of New York Upstate Medical University Syracuse, New York
Sutter Medical Center Sacramento Sacramento, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
UCHealth University of Colorado Hospital Aurora, Colorado
UMass Memorial Medical Center - Memorial Division Worcester, Massachusetts
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
University Medical Center New Orleans New Orleans, Louisiana Site Public Contact - (emede1@lsuhsc.edu)
University of Arizona Cancer Center-North Campus Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona
University of New Mexico Cancer Center Albuquerque, New Mexico
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Utah Sugarhouse Health Center Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
Upstate Cancer Center Radiation Oncology at Oswego Oswego, New York Site Public Contact - (BinghamE@upstate.edu)
Upstate Cancer Center at Verona Verona, New York Site Public Contact - (McDowelE@upstate.edu)
Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Women and Infants Hospital Providence, Rhode Island

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)

Medical Information - medinfo@kitepharma.com

PHASE3
NCT05605899
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:
* Histologically confirmed large B cell lymphoma (LBCL) based on 2016 World Health Organization (WHO) classification by local pathology lab assessment, including of the following: * Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) * High-grade B-cell lymphoma (HGBL) * Note: Transformed DLBCL from follicular lymphoma or from marginal zone lymphoma is eligible if no prior treatment with anthracycline-containing regimen. * High-risk disease defined as an International Prognostic Index (IPI) score of 4 or 5 at initial diagnosis. * Have received only 1 cycle of rituximab plus chemotherapy (R-chemotherapy). * Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function. * Females of childbearing potential must have a negative serum or urine pregnancy test. Key
Exclusion Criteria:
* The following WHO 2016 subcategories by local assessment: * T-cell/histiocyte-rich LBCL * Primary DLBCL of the central nervous system (CNS) * Primary mediastinal (thymic) LBCL * B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma * Burkitt lymphoma * History of Richter's transformation of chronic lymphocytic leukemia * Presence of detectable cerebrospinal fluid (CSF)-malignant cells, brain metastases, or a history of CNS involvement of lymphoma. * Presence of cardiac lymphoma involvement. * Any prior treatment for LBCL other than the 1 cycle of R-chemotherapy. * History of severe immediate hypersensitivity reaction to any of the agents used in this study. * Presence of CNS disorder. History of stroke, transient ischemic attack, or posterior reversible encephalopathy syndrome (PRES) within 12 months prior to enrollment. * History of acute or chronic active hepatitis B or C infection. * Positive for human immunodeficiency virus (HIV) unless taking appropriate anti-HIV medications, with an undetectable viral load by PCR and with a cluster of differentiation 4 (CD4) count \> 200 cells/uL. * Medical conditions or residual toxicities from prior therapies likely to interfere with assessment of safety or efficacy of study treatment. Please refer to protocol for further details. * History of clinically significant cardiac disease within 12 months before enrollment. * History of any medical condition requiring maintenance systemic immunosuppression/systemic disease modifying agents within the last 2 years. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
BIOLOGICAL: Axicabtagene Ciloleucel, DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: Etoposide, DRUG: Rituximab, DRUG: Doxorubicin, DRUG: Vincristine, DRUG: Prednisone
High-risk Large B-cell Lymphoma (LBCL)
I'm interested
Share via email
Show 90 locations

Study Locations

Hide all locations
Location Contacts
ASST degli Spedali Civili di Brescia Brescia, Lombardy
Academisch Medisch Centrum Amsterdam,
Addenbrookes Hospital (Cambridge University Hospitals NHS Foundation Trust) Birmingham,
Avera Cancer Institute Sioux Falls, South Dakota
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia Perugia,
Banner MD Anderson Cancer Center Gilbert, Arizona
CHU Bordeaux-Hopital Haut-Leveque Bordeaux,
CHU Dijon Dijon,
CHU Pontchaillou Rennes CEDEX,
Centre Hospitalier Universitaire de Nice Nice,
Centre Hospitalier Universitaire(CHU) de Toulouse Toulouse,
Centre Leon Berard Lyon,
Centro Hospitalar Universitario Lisboa Norte, E.P.E. - Hospital de Santa Maria Lisbon,
Charite Universitaetsmedizin Berlin Berlin,
Colorado Blood Cancer Institute Denver, Colorado
Columbia University Medical Center New York, New York
Dana-Farber Cancer Institute Boston, Massachusetts
Fred Hutchinson Cancer Center Seattle, Washington
Georgia Cancer Center at Augusta University Augusta, Georgia
Grande Ospedale Metropolitano Bianchi Melacrino Morelli Reggio Calabria,
HELIOS Klinikum Berlin-Buch Berlin,
Henry-Joyce Cancer Center Nashville, Tennessee
Hopital Claude Huriez CHU Lille, Service Maladies du sang Lille cedex,
Hopital Henri MONDOR, APHP Paris,
Hopital Saint Eloi Montpellier,
Hospital Clinico Universitario de Valencia Valencia,
Hospital Universitari Vall d'Hebron Barcelona,
Hospital Universitario 12 de Octubre Madrid,
Hospital Universitario Marqués de Valdecilla Santander,
Hospital Universitario Virgen del Rocio Seville,
Hospital Universitario de Salamanca Salamanca,
IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna,
IRCCS Istituto Clinico Humanitas Rozzano,
Institut Catala d'Oncologia Barcelona,
Instituto Portugues de Oncologia de Lisboa Francisco Gentil - E.P.E. Lisbon,
Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E. Porto,
Intermountain LDS Hospital/Blood and Marrow Transplant/ Acute Leukemia Program Salt Lake City, Utah
Jewish General Hospital Montreal, Quebec
John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey
Juntendo University Hospital Bunkyo-ku, Tokyo
Leiden University Medical Center Leiden,
Maastricht Universitair Medisch Centrum Maastricht,
Mayo Clinic Rochester, Minnesota
Mayo Clinic Cancer Center Outpatient Pharmacy Rochester, Minnesota
Medizinische Universitat Innsbruck Innsbruck,
Medizinische Universität Wien (AKH Wien, Medical University Vienna and General Hospital Vienna) Vienna,
Moffitt Cancer Center Tampa, Florida
Montefiore Medical Center The Bronx, New York
Northwestern Memorial Hospital Chicago, Illinois
Norton Cancer Institute, St. Matthews Campus Louisville, Kentucky
Novant Health Cancer Institute- Hematology Charlotte, North Carolina
Ochsner Clinic Foundation New Orleans, Louisiana
Oncology Hematology Care Clinical Trials, LLC Cincinnati, Ohio
Osaka University Hospital Suita,
Ospedale San Raffaele Milan,
Peter MacCallum Cancer Center Melbourne, Victoria
Princess Margaret Cancer Centre Toronto, Ontario
Prisma Health Cancer Institute Greenville, South Carolina
Roswell Park Cancer Institute Buffalo, New York
Royal Brisbane and Women's Hospital Herston, Queensland
Royal Prince Alfred Hospital Camperdown, New South Wales
Stanford Cancer Institute Stanford, California
Tennessee Oncology, PLLC Nashville, Tennessee
The Ottowa Hospital- General Campus Ottawa,
The University of Kansas Hospital Westwood, Kansas
The University of Texas, MD Anderson Cancer Center Houston, Texas
Tohoku University Hospital Miyagi,
Tokyo Metropolitan Komagome Hospital Bunkyō City,
UC San Diego Moores Cancer Center La Jolla, California
UPMC Hillman Cancer Center Pittsburgh, Pennsylvania
Uniklinikum Duesseldorf, Klinik fuer Haematologie, Onkologie und klinische Immunologie Duesseldorf,
Universitair Medisch Centrum Utrecht Utrecht,
University Hospital, Kyoto Prefectural University of Medicine Kyoto,
University Hospitals Southampton Southampton,
University Medical Center Groningen Groningen,
University of Alabama Hospital Birmingham, Alabama
University of California Los Angeles (UCLA) Los Angeles, California
University of Chicago Medical Center Chicago, Illinois
University of Iowa Iowa City, Iowa
University of MD Greenebaum Comprehensive Cancer Center Baltimore, Maryland
University of Michigan Ann Arbor, Michigan
University of Rochester Medical Center Rochester, New York
University of Texas Southwestern Medical Center Dallas, Texas
Università Cattolica del Sacro Cuore Rome,
Universitätsklinik Erlangen Erlangen,
Universitätsklinikum St. Pölten Sankt Pölten,
Universitätsklinikum bonn, medizinische klinik III Bonn,
Virginia Commonwealth University Richmond, Virginia
Weill Cornell Medical College - NewYork Presbyterian Hospital New York, New York
Zuniklinikum Salzburg, Landeskrankenhaus, Universitatsklinik fur Innere Medizin III der PMU Salzburg,

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ctrrecruit@vcu.edu

PHASE2
NCT05564390
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS. * Participants must be \>= 18 years of age. * Participants must not have received prior anti-cancer therapy for AML or MDS. * Note: Hydroxyurea to control the white blood cell count (WBC) is allowed. * Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction. * Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure. * Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment. * Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy * Note: active hormonal therapy is allowed * Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration. * Participants must agree to have translational medicine specimens submitted. * Participants must be offered the opportunity to participate in specimen banking. * Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP. * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. * Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system. * The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation, DRUG: Azacitidine, OTHER: Best Practice, PROCEDURE: Biopsy Procedure, PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Bone Marrow Biopsy, DRUG: Busulfan, PROCEDURE: Chest Radiography, PROCEDURE: Computed Tomography, DRUG: Cytarabine, DRUG: Daunorubicin Hydrochloride, DRUG: Decitabine and Cedazuridine, PROCEDURE: Echocardiography Test, DRUG: Enasidenib, DRUG: Fludarabine, DRUG: Gemtuzumab Ozogamicin, DRUG: Gilteritinib, DRUG: Liposome-encapsulated Daunorubicin-Cytarabine, DRUG: Melphalan, PROCEDURE: Multigated Acquisition Scan, PROCEDURE: Mutation Carrier Screening, DRUG: Olutasidenib, DRUG: Placebo Administration, PROCEDURE: Positron Emission Tomography, RADIATION: Total-Body Irradiation, DRUG: Venetoclax
Acute Myeloid Leukemia, Myelodysplastic Syndrome
I'm interested
Share via email
Show 307 locations

Study Locations

Hide all locations
Location Contacts
Abbott-Northwestern Hospital Minneapolis, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Alta Bates Summit Medical Center-Herrick Campus Berkeley, California Site Public Contact - (clinicalresearch@sutterhealth.org)
Arthur J E Child Comprehensive Cancer Centre Calgary, Alberta Site Public Contact - (ctsucontact@westat.com)
Augusta University Medical Center Augusta, Georgia Site Public Contact - (ga_cares@augusta.edu)
Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora BayCare Medical Center Green Bay, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Grafton Grafton, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Kenosha South Kenosha, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Racine Racine, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Health Care Germantown Health Center Germantown, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Medical Center in Summit Summit, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Saint Luke's South Shore Cudahy, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora Sinai Medical Center Milwaukee, Wisconsin Site Public Contact - (ncorp@aurora.org)
Aurora West Allis Medical Center West Allis, Wisconsin Site Public Contact - (ncorp@aurora.org)
BJC Outpatient Center at Sunset Hills Sunset Hills, Missouri
Banner University Medical Center - Tucson Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
Baptist Cancer Center-Grenada Grenada, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Golden Triangle Columbus, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baptist Memorial Hospital and Cancer Center-Union County New Albany, Mississippi Site Public Contact - (BCCclintrials@bmhcc.org)
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas Site Public Contact - (burton@bcm.edu)
Ben Taub General Hospital Houston, Texas
Benefis Sletten Cancer Institute Great Falls, Montana Site Public Contact - (mccinfo@mtcancer.org)
Billings Clinic Cancer Center Billings, Montana Site Public Contact - (research@billingsclinic.org)
Bozeman Health Deaconess Hospital Bozeman, Montana Site Public Contact - (mccinfo@mtcancer.org)
CIUSSSEMTL-Hopital Maisonneuve-Rosemont Montreal, Quebec
CSSS Champlain-Charles Le Moyne Greenfield Park, Quebec
Cancer Care Center of O'Fallon O'Fallon, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Care Specialists of Illinois - Decatur Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Cancer Hematology Centers - Flint Flint, Michigan Site Public Contact - (wstrong@ghci.org)
CancerCare Manitoba Winnipeg, Manitoba Site Public Contact - (ctu_web@cancercare.mb.ca)
Carle Cancer Center Urbana, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Effingham Effingham, Illinois Site Public Contact - (Research@carle.com)
Carle Physician Group-Mattoon/Charleston Mattoon, Illinois Site Public Contact - (Research@carle.com)
Carle at The Riverfront Danville, Illinois Site Public Contact - (Research@Carle.com)
Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina
Case Western Reserve University Cleveland, Ohio Site Public Contact - (CTUReferral@UHhospitals.org)
Cedars Sinai Medical Center Los Angeles, California
Centro Comprensivo de Cancer de UPR San Juan, Site Public Contact - (ctsucontact@westat.com)
Community Hospital of Anaconda Anaconda, Montana Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (mccinfo@mtcancer.org)
Community Medical Center Toms River, New Jersey Site Public Contact - (Lennette.Gonzales@rwjbh.org)
Cooper Hospital University Medical Center Camden, New Jersey
Cotton O'Neil Cancer Center / Stormont Vail Health Topeka, Kansas
Crossroads Cancer Center Effingham, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Dana-Farber Cancer Institute Boston, Massachusetts
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire Site Public Contact - (cancer.research.nurse@dartmouth.edu)
Decatur Memorial Hospital Decatur, Illinois Site Public Contact - (morganthaler.jodi@mhsil.com)
Duke University Medical Center Durham, North Carolina
Duluth Clinic Ashland Ashland, Wisconsin Site Public Contact - (CancerTrials@EssentiaHealth.org)
Edward Hines Jr VA Hospital Hines, Illinois
Essentia Health - Deer River Clinic Deer River, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Cancer Center Duluth, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Essentia Health Hibbing Clinic Hibbing, Minnesota
Essentia Health Virginia Clinic Virginia, Minnesota Site Public Contact - (CancerTrials@EssentiaHealth.org)
Fairview Southdale Hospital Edina, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Fred Hutchinson Cancer Center Seattle, Washington
Geisinger Medical Center Danville, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Genesee Hematology Oncology PC Flint, Michigan
Genesys Hurley Cancer Institute Flint, Michigan Site Public Contact - (wstrong@ghci.org)
George E Wahlen Department of Veterans Affairs Medical Center Salt Lake City, Utah
Gundersen Lutheran Medical Center La Crosse, Wisconsin Site Public Contact - (cancerctr@gundersenhealth.org)
Hawaii Cancer Care - Westridge ‘Aiea, Hawaii Site Public Contact - (info@hawaiicancercare.com)
Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii Site Public Contact - (i.webster@hawaiicancercare.com)
HaysMed Hays, Kansas
Heartland Regional Medical Center Saint Joseph, Missouri Site Public Contact - (Trisha.England2@mymlc.com)
Henry Ford Hospital Detroit, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford Medical Center-Columbus Novi, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Henry Ford West Bloomfield Hospital West Bloomfield, Michigan Site Public Contact - (CTOResearch@hfhs.org)
Huntsman Cancer Institute/University of Utah Salt Lake City, Utah Site Public Contact - (cancerinfo@hci.utah.edu)
Hurley Medical Center Flint, Michigan Site Public Contact - (wstrong@ghci.org)
Illinois CancerCare - Washington Washington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Bloomington Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Canton Canton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Carthage Carthage, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Dixon Dixon, Illinois
Illinois CancerCare-Eureka Eureka, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Galesburg Galesburg, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Kewanee Clinic Kewanee, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Macomb Macomb, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Ottawa Clinic Ottawa, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Pekin Pekin, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peoria Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Peru Peru, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Illinois CancerCare-Princeton Princeton, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana Site Public Contact - (iutrials@iu.edu)
Inova Fairfax Hospital Falls Church, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Inova Schar Cancer Institute Fairfax, Virginia Site Public Contact - (Stephanie.VanBebber@inova.org)
Jewish General Hospital Montreal, Quebec
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland Site Public Contact - (jhcccro@jhmi.edu)
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario
Kaiser Permanente Downtown Commons Sacramento, California Site Public Contact - (kpoct@kp.org)
Kaiser Permanente Dublin Dublin, California
Kaiser Permanente Medical Center - Santa Clara Santa Clara, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii Site Public Contact - (shelley.a.clark@kp.org)
Kaiser Permanente San Leandro San Leandro, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fremont Fremont, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Fresno Fresno, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Modesto Modesto, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Oakland Oakland, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Roseville Roseville, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-San Francisco San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Rosa Santa Rosa, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Santa Teresa-San Jose San Jose, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South Sacramento Sacramento, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-South San Francisco South San Francisco, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Vallejo Vallejo, California Site Public Contact - (Kpoct@kp.org)
Kaiser Permanente-Walnut Creek Walnut Creek, California Site Public Contact - (Kpoct@kp.org)
Kaiser San Rafael-Gallinas San Rafael, California Site Public Contact - (Kpoct@kp.org)
Kapiolani Medical Center for Women and Children Honolulu, Hawaii
Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho Site Public Contact - (mccinfo@mtcancer.org)
LSU Health Baton Rouge-North Clinic Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Lawrence Memorial Hospital Lawrence, Kansas Site Public Contact - (Stephanie.Norris@LMH.ORG)
Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania Site Public Contact - (Morgan_M.Horton@lvhn.org)
Lewistown Hospital Lewistown, Pennsylvania Site Public Contact - (HemonCCTrials@geisinger.edu)
Logan Health Medical Center Kalispell, Montana Site Public Contact - (mccinfo@mtcancer.org)
Loyola University Medical Center Maywood, Illinois
MaineHealth Cancer Care and IV Therapy - Brunswick Brunswick, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Cancer Care and IV Therapy - South Portland South Portland, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
MaineHealth Maine Medical Center - Portland Portland, Maine Site Public Contact - (clinicalresearch@mainehealth.org)
Marshfield Medical Center - Minocqua Minocqua, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center - Weston Weston, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Marshfield Marshfield, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org)
Mayo Clinic Hospital in Arizona Phoenix, Arizona
Mayo Clinic in Florida Jacksonville, Florida
Mayo Clinic in Rochester Rochester, Minnesota
Medical College of Wisconsin Milwaukee, Wisconsin
Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen Montvale, New Jersey
Memorial Sloan Kettering Cancer Center New York, New York
Memorial Sloan Kettering Commack Commack, New York
Memorial Sloan Kettering Monmouth Middletown, New Jersey
Memorial Sloan Kettering Nassau Uniondale, New York
Mercy Hospital Coon Rapids, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Mercy Hospital South St Louis, Missouri Site Public Contact - (Danielle.Werle@mercy.net)
Mercy Medical Center - Des Moines Des Moines, Iowa Site Public Contact - (cancerresearch@mercydesmoines.org)
Mercyhealth Hospital and Cancer Center - Janesville Janesville, Wisconsin Site Public Contact - (oncologyclinicaltrials@mhemail.org)
Methodist Medical Center of Illinois Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Mid Coast Hospital Brunswick, Maine Site Public Contact - (ctsucontact@westat.com)
Missouri Baptist Medical Center St Louis, Missouri
Missouri Baptist Sullivan Hospital Sullivan, Missouri
Monmouth Medical Center Long Branch, New Jersey Site Public Contact - (mary.danish@rwjbh.org)
Montefiore Medical Center - Moses Campus The Bronx, New York Site Public Contact - (eskwak@montefiore.org)
Mount Sinai Hospital New York, New York Site Public Contact - (CCTO@mssm.edu)
Nebraska Medicine-Bellevue Bellevue, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
Nebraska Medicine-Village Pointe Omaha, Nebraska
North Shore University Hospital Manhasset, New York
NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois
NorthShore University HealthSystem-Glenbrook Hospital Glenview, Illinois
NorthShore University HealthSystem-Highland Park Hospital Highland Park, Illinois
Northwell Health/Center for Advanced Medicine Lake Success, New York
Northwestern Medicine Cancer Center Delnor Geneva, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois Site Public Contact - (Donald.Smith3@nm.org)
Northwestern Medicine Glenview Outpatient Center Glenview, Illinois
Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois
Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois Site Public Contact - (cancertrials@northwestern.edu)
Northwestern Medicine Orland Park Orland Park, Illinois Site Public Contact - (nctnprogram_rhlccc@northwestern.edu)
Northwestern University Chicago, Illinois Site Public Contact - (cancer@northwestern.edu)
Novant Health Forsyth Medical Center Winston-Salem, North Carolina Site Public Contact - (pjordan@novanthealth.org)
Novant Health New Hanover Regional Medical Center Wilmington, North Carolina
Novant Health Presbyterian Medical Center Charlotte, North Carolina Site Public Contact - (kashah@novanthealth.org)
OSF Saint Francis Medical Center Peoria, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
OSF Saint Joseph Medical Center Bloomington, Illinois Site Public Contact - (andersonj@illinoiscancercare.com)
Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario
Ohio State University Comprehensive Cancer Center Columbus, Ohio Site Public Contact - (Jamesline@osumc.edu)
OptumCare Cancer Care at Charleston Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Fort Apache Las Vegas, Nevada Site Public Contact - (research@sncrf.org)
OptumCare Cancer Care at Seven Hills Henderson, Nevada Site Public Contact - (research@sncrf.org)
Oregon Health and Science University Portland, Oregon Site Public Contact - (trials@ohsu.edu)
Our Lady of The Lake Baton Rouge, Louisiana
Our Lady of the Lake Physician Group Baton Rouge, Louisiana Site Public Contact - (research@ololrmc.com)
Pali Momi Medical Center ‘Aiea, Hawaii
Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Parkland Health Center - Farmington Farmington, Missouri
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania Site Public Contact - (CTO@hmc.psu.edu)
Phoebe Putney Memorial Hospital Albany, Georgia Site Public Contact - (ga_cares@augusta.edu)
Prisma Health Cancer Institute - Butternut Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Easley Easley, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Eastside Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Faris Greenville, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Greer Greer, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Seneca Seneca, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina Site Public Contact - (Kim.Williams3@prismahealth.org)
ProHealth D N Greenwald Center Mukwonago, Wisconsin Site Public Contact - (research.institute@phci.org)
ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin
ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin
Providence Newberg Medical Center Newberg, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Portland Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Saint Vincent Medical Center Portland, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
Providence Willamette Falls Medical Center Oregon City, Oregon Site Public Contact - (CanRsrchStudies@providence.org)
QEII Health Sciences Centre/Nova Scotia Health Authority Halifax, Nova Scotia
Reading Hospital West Reading, Pennsylvania
Regions Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
Rhode Island Hospital Providence, Rhode Island
Rochester General Hospital Rochester, New York Site Public Contact - (tia.derosa@rochestergeneral.org)
Roswell Park Cancer Institute Buffalo, New York Site Public Contact - (askroswell@roswellpark.org)
Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey
Saint Alphonsus Cancer Care Center-Boise Boise, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho Site Public Contact - (stephanie.couch@stjoeshealth.org)
Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho Site Public Contact - (mccinfo@mtcancer.org)
Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon Site Public Contact - (mccinfo@mtcancer.org)
Saint Barnabas Medical Center Livingston, New Jersey Site Public Contact - (joanne.loeb@rwjbh.org)
Saint Luke's Cancer Institute - Boise Boise, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Meridian Meridian, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Luke's Cancer Institute - Nampa Nampa, Idaho Site Public Contact - (eslinget@slhs.org)
Saint Patrick Hospital - Community Hospital Missoula, Montana Site Public Contact - (amy.hanneman@providence.org)
Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls, Wisconsin Site Public Contact - (WI_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin Site Public Contact - (wi_research_admin@hshs.org)
Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri
Salina Regional Health Center Salina, Kansas
San Juan City Hospital San Juan,
Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org)
Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org)
Siteman Cancer Center at Christian Hospital St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center at West County Hospital Creve Coeur, Missouri Site Public Contact - (info@siteman.wustl.edu)
Siteman Cancer Center-South County St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Southern Illinois University School of Medicine Springfield, Illinois
Springfield Clinic Springfield, Illinois
Springfield Memorial Hospital Springfield, Illinois Site Public Contact - (pallante.beth@mhsil.com)
State University of New York Upstate Medical University Syracuse, New York
Straub Clinic and Hospital Honolulu, Hawaii
Swedish Cancer Institute-Edmonds Edmonds, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Cancer Institute-Issaquah Issaquah, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
Swedish Medical Center-First Hill Seattle, Washington Site Public Contact - (PCRC-NCORP@Swedish.org)
The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky
The University of Kansas Cancer Center - Olathe Olathe, Kansas Site Public Contact - (OlatheCCResearch@kumc.edu)
The Valley Hospital - Luckow Pavilion Paramus, New Jersey Site Public Contact - (clinicaltrialsresearch@valleyhealth.com)
ThedaCare Regional Cancer Center Appleton, Wisconsin Site Public Contact - (ResearchDept@thedacare.org)
Thomas Jefferson University Hospital Philadelphia, Pennsylvania Site Public Contact - (ONCTrialNow@jefferson.edu)
Tibor Rubin VA Medical Center Long Beach, California
Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org)
Tufts Medical Center Boston, Massachusetts Site Public Contact - (ContactUsCancerCenter@TuftsMedicalCenter.org)
UCSF Medical Center-Parnassus San Francisco, California
UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa
UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa
UMass Memorial Medical Center - University Campus Worcester, Massachusetts Site Public Contact - (cancer.research@umassmed.edu)
UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Site Public Contact - (cancerclinicaltrials@med.unc.edu)
UW Cancer Center at ProHealth Care Waukesha, Wisconsin Site Public Contact - (Chanda.miller@phci.org)
United Hospital Saint Paul, Minnesota Site Public Contact - (mmcorc@healthpartners.com)
University Health Truman Medical Center Kansas City, Missouri
University of Alabama at Birmingham Cancer Center Birmingham, Alabama Site Public Contact - (tmyrick@uab.edu)
University of Alberta Hospital Edmonton, Alberta Site Public Contact - (pedsoncologyresearch@ahs.ca)
University of Arizona Cancer Center-North Campus Tucson, Arizona Site Public Contact - (UACC-IIT@uacc.arizona.edu)
University of Arkansas for Medical Sciences Little Rock, Arkansas
University of California Davis Comprehensive Cancer Center Sacramento, California
University of Chicago Comprehensive Cancer Center Chicago, Illinois Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu)
University of Illinois Chicago, Illinois
University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa
University of Kansas Cancer Center Kansas City, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center - North Kansas City, Missouri Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Cancer Center-Overland Park Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Clinical Research Center Fairway, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Health System Saint Francis Campus Topeka, Kansas
University of Kansas Hospital-Indian Creek Campus Overland Park, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas Site Public Contact - (KUCC_Navigation@kumc.edu)
University of Kentucky/Markey Cancer Center Lexington, Kentucky
University of Nebraska Medical Center Omaha, Nebraska Site Public Contact - (unmcrsa@unmc.edu)
University of New Mexico Cancer Center Albuquerque, New Mexico Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu)
University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Site Public Contact - (ou-clinical-trials@ouhsc.edu)
University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu)
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania
University of Rochester Rochester, New York
University of Tennessee - Knoxville Knoxville, Tennessee
University of Vermont Medical Center Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Vermont and State Agricultural College Burlington, Vermont Site Public Contact - (rpo@uvm.edu)
University of Virginia Cancer Center Charlottesville, Virginia Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu)
University of Washington Medical Center - Montlake Seattle, Washington
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin Site Public Contact - (clinicaltrials@cancer.wisc.edu)
UofL Health Medical Center Northeast Louisville, Kentucky Site Public Contact - (ctoinfo@louisville.edu)
VCU Massey Comprehensive Cancer Center Richmond, Virginia Site Public Contact - (CTOclinops@vcu.edu)
Valley Health System Ridgewood Campus Ridgewood, New Jersey Site Public Contact - (clinicaltrialsresearch@valleyhealth.com)
Veterans Affairs Connecticut Healthcare System-West Haven Campus West Haven, Connecticut
Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin Site Public Contact - (ncorp@aurora.org)
Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin Site Public Contact - (ncorp@aurora.org)
Wake Forest University Health Sciences Winston-Salem, North Carolina
Washington University School of Medicine St Louis, Missouri Site Public Contact - (info@siteman.wustl.edu)
Wayne State University/Karmanos Cancer Institute Detroit, Michigan Site Public Contact - (ctoadmin@karmanos.org)
Weisberg Cancer Treatment Center Farmington Hills, Michigan Site Public Contact - (ctoadmin@karmanos.org)
William S Middleton VA Medical Center Madison, Wisconsin
Yale University New Haven, Connecticut Site Public Contact - (canceranswers@yale.edu)

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

Medical Information - medicalinfo@vrtx.com

PHASE2
NCT05312879
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:
* APOL1 genotype of G1/G1, G2/G2, or G1/G2 * Proteinuric kidney disease Key
Exclusion Criteria:
* Solid organ or bone marrow transplant * Uncontrolled hypertension * History of diabetes mellitus * Known underlying cause of kidney disease including but not limited to sickle cell disease Other protocol defined Inclusion/Exclusion criteria apply.
DRUG: VX-147, DRUG: Placebo
Proteinuric Kidney Disease
APOL1-mediated kidney disease (AMKD)
I'm interested
Share via email
Show 314 locations

Study Locations

Hide all locations
Location Contacts
A. Alfred Taubman Health Care Center - Nephrology Clinic at Taubman Center Ann Arbor, Michigan
AA Medical Research Center Flint, Michigan
AMR-Miami Coral Gables, Florida
AURA Nord Saint-Ouen,
Advanced Clinical Research of Atlanta Atlanta, Georgia
Alabama Kidney Research Alabaster, Alabama
Ambroise Paré Hospital Paris,
American Clinical Trials LLC - Acworth Acworth, Georgia
American Clinical Trials LLC - Douglasville Douglasville, Georgia
Amicis Research Center - Balboa Granada Hills, California
Amsterdam UMC - Amsterdam Public Health Research Institute Amsterdam,
Ann & Robert H. Lurie Children's Hospital of Chicago - Nephrology Chicago, Illinois
Arlington Nephrology Arlington, Texas
Atlanta VA Healthcare System Decatur, Georgia
Augusta University Medical College of Georgia - Adult Sickle Cell Clinic Augusta, Georgia
Barnes-Jewish Center for Outpatient Health St Louis, Missouri
Barnum Medical Research - Bienville St Natchitoches, Louisiana
Bay Pines Foundation Bay Pines, Florida
Baylor Scott and White Research Institute - Nephrology Dallas, Texas
Beth Israel Deaconess Medical Center - Nephrology Boston, Massachusetts
Bicetre Hospital Le Kremlin-Bicêtre,
Bioluminux Clinical Research New Jersey Hamilton, New Jersey
Boston Medical Center Boston, Massachusetts
Brookview Hills Research Associates Winston-Salem, North Carolina
CHI St. Vincent Heart Clinic Arkansas- Cardiology and Medicine Clinic - Little Rock Little Rock, Arkansas
CHU Dupuytren 2 - Néphrologie, dialyse, transplantations Limoges,
CHU de Guadeloupe Pointe à Pitre,
CNS Healthcare - Memphis Memphis, Tennessee
CSB Group of Nephrology Brazil Salvador,
CTR Oakwater, LLC Orlando, Florida
CUH - Sheridan Pavilion - Three Cooper Plaza Camden, New Jersey
Cardiology, P.C. Birmingham, Alabama
Carolina Nephrology, PA Spartanburg, South Carolina
Cedars-Sinai Medical Center Los Angeles, California
Center for Advanced Kidney Research Saint Clair Shores, Michigan
Center for Specialized Medicine - Nephrology St Louis, Missouri
Centro Cardiovascular Aristides Sotomayor Santa Lucía SAS IPS Cartagena,
Centro de Pesquisa Clinica Professor Salomao Kelner Recife,
Centro de Pesquisa Clinica do Coracao Aracaju,
Children's Hospital of Alabama Birmingham, Alabama
Children's Hospital of Pittsburgh - Nephrology Pittsburgh, Pennsylvania
Children's National Hospital - Nephrology Washington D.C., District of Columbia
Cincinnati VA Medical Center Cincinnati, Ohio
Cleveland Clinic - Main Campus Cleveland, Ohio
Clincept - Veterans Pkwy. Columbus, Georgia
Clindove Research LLC Brooklyn, New York
Clinica de La Costa S.A.S Atlántico,
Clinical & Translational Science Unit (CTSU) - Nephrology Kansas City, Kansas
Clinical Research Strategies - Romano North Main Office Houston, Texas
Clinical Research of Brandon, LLC Brandon, Florida
Cmip-Centro Mineiro de Pesquisa Ltda Juiz de Fora,
Coastal Medical Research Brunswick, Georgia
Columbia Nephrology Associates, PA Columbia, South Carolina
Comlexo Hospitalar Universitário Professor Edgard Santos Salvador,
Cook Children's Medical Center Fort Worth, Texas
Cordova Research Institute Miami, Florida
DaVita Kidney Care - Las Vegas Las Vegas, Nevada
Dallas Nephrology Associates - Dallas Landry Office Dallas, Texas
Dallas Renal Group - Liberty Dallas Dialysis Center Dallas, Texas
Dallas Renal Group - Mansfield Arlington, Texas
Dallas Renal Group- Dallas Dallas, Texas
Davita Clinical Research - El Paso El Paso, Texas
Delray Physician Care Center Delray Beach, Florida
Dom Vicente Scherer Hospital Porto Alegre,
Duke University Hospital - Children's Health Center Durham, North Carolina
Eastern Nephrology Associates - Greenville Office Greenville, North Carolina
Eastern Nephrology Associates - Jacksonville Office Jacksonville, North Carolina
Eastern Nephrology Associates - Kinston Office Kinston, North Carolina
Eastern Nephrology Associates - New Bern Office New Bern, North Carolina
Eastern Nephrology Associates - Wilmington Office Wilmington, North Carolina
Eastside Clinical Research Associates Los Angeles, California
Edward Hines Jr VA Hospital Hines, Illinois
Elixia Pines Hollywood, Florida
Elixia Tampa Tampa, Florida
EmVenio Research - Chicago Chicago, Illinois
EmVenio Research - Mobile Unit - Birmingham Birmingham, Alabama
Emory Childrens Center - Nephrology Atlanta, Georgia
Emory School of Medicine - Renal Division Atlanta, Georgia
Epsom and St Helier University Hospitals NHS Trust Carshalton,
Essential Concepts Research Solutions Palos Hills, Illinois
FDI Clinical Research San Juan,
Faculdade de Medicina de Botucatu - CKD and Hypertension Department Botucatu,
Faculdade de Medicina de Botucatu - Kidney Transplantation Department Botucatu,
Federal University of Goiás (UFG) Goiânia,
Fides Clinical Research Atlanta, Georgia
Frenova-Southwest Houston Houston, Texas
Fundacion Hospitalaria San Vicente de Paul Medellín,
Fundación Valle Del Lili Santiago de Cali,
Fundação Faculdade Regional de Medicina de São José do Rio Preto Sao Jose Rio Preto,
FutureMeds Birmingham Birmingham,
G.V. (Sonny) Montgomery VAMC Jackson, Mississippi
GCM Medical Group, PSC San Juan,
Galileo Medical Research Ltda Juiz de Fora,
General Nephrology Clinic - New York City New York, New York
Genesis Clinical Research Tampa, Florida
Georgia Nephrology - Decatur Decatur, Georgia
Georgia Nephrology - Lawrenceville - Billing Office Lawrenceville, Georgia
Great Ormond Street Hospital For Children London,
Greater Hartford Nephrology Bloomfield, Connecticut
Grossman School of Medicine New York, New York
Guy's Hospital - Endocrinology London,
Hackensack University Medical Center Hackensack, New Jersey
Heart Center Research LLC Huntsville, Alabama
Helen Diller Medical Center at Parnassus Heights San Francisco, California
Henry Ford Health System - Nephrology Detroit, Michigan
Hopital Henri Mondor - Nephrology Créteil,
Hopital Necker Enfants Malades - Nephrology Paris,
Hopital Tenon Paris,
Hopital de la Conception Marseille, Provence-Alpes-Côte d'Azur Region
Horizon Research Group - Coral Gables Coral Gables, Florida
Hospital Ana Nery/SESAB Salvador,
Hospital Clinic de Barcelona - Nephrology Barcelona,
Hospital Curry Cabral - Serviço de Nefrologia Lisbon,
Hospital Nord Michallon - Nephrology Grenoble,
Hospital Nove de Julho - Nephrology São Paulo,
Hospital São Lucas Rio de Janeiro,
Hospital Universitari Vall d´Hebron - Servicio de Pediatria Barcelona,
Hospital Universitario 12 de Octubre - Nephrology Madrid,
Hospital Universitario Virgen Macarena Seville, Andalusia
Hospital das Clínicas da Faculdade de Medicina - Laboratório de Nefrologia Celular, Genética e Molecular São Paulo,
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Monte Alegre,
Hospital de Clínicas de Porto Alegre - Nephrology Porto Alegre,
Hospital do Rim - Fundação Oswaldo Ramos São Paulo,
Houston Medical Research Institute, LLC Houston, Texas
Hôpital de Rangueil Toulouse,
ICM - Instituto do Coração de Marília Marília,
IPECC - Instituto de Pesquisa Clinica de Campinas Campinas,
IU School of Medicine - Nephrology Indianapolis, Indiana
Icahn School of Medicine at Mount Sinai - Nephrology New York, New York
Infigo Clinical Research Sanford, Florida
Inova Clinical Trials and Research Center Tyrone, Georgia
Instituto Pro-Renal Curitiba,
Instituto de Ensino e Pesquisa Clinica do Ceara Fortaleza,
InterMed Consultants - Edina Clinic Edina, Minnesota
Irmandade Da Santa Casa De Misericordia De Sao Paulo São Paulo,
James J. Peters VA Medical Center The Bronx, New York
Javara Inc./Privia Medical Group - Annapolis, MD Annapolis, Maryland
Javara Inc./Privia Medical Group - Fayetteville, GA Fayetteville, Georgia
Javara Inc./Privia Medical Group - Savannah, GA Savannah, Georgia
Javara Inc./Privia Medical Group - Silver Spring, MD - Columbia Pike Silver Spring, Maryland
Jefferson Einstein Philadelphia Hospital - Nephrology Philadelphia, Pennsylvania
Jefferson Health - 33 South 9th Street Philadelphia, Pennsylvania
Jersey Shore University Medical Center Neptune City, New Jersey
Kaiser Permanente Georgia Atlanta, Georgia
Kaiser Permanente Los Angeles Medical Center Los Angeles, California
Kaiser Permanente Sacramento Medical Center Sacramento, California
Kidney Care Center of North Valley Granada Hills, California
Kidney Care and Transplant Services of New England - West Springfield West Springfield, Massachusetts
Kidney Medical Associates, PLLC The Bronx, New York
Kidney Specialists of N Houston, PLLC Shenandoah, Texas
Kidney and Hypertension Center Victorville, California
King's College Hospital - Pulmonology London,
Kings County Hospital Brooklyn, New York
Komfo Anokye Teaching Hospital - Nephrology Kumasi,
LCMC Health Metairie, Louisiana
Lagos State University Teaching Hospital Ikeja,
Lagos University Teaching Hospital Surulere, Lagos
Le Bonheur Children's Hospital - Outpatient Clinic Memphis, Tennessee
Leicester General Hospital Leicester,
Lewis Katz School of Medicine at Temple University - Section of Nephrology Philadelphia, Pennsylvania
Lifespan Clinical Research Center East Providence, Rhode Island
Louis Stokes Cleveland VA Medical Center Cleveland, Ohio
Louisiana Clinical and Translational Science (LA CaTS) Center New Orleans, Louisiana
Louisiana State University Health Shreveport Shreveport, Louisiana
MD Medical Research Oxon Hill, Maryland
Manchester Royal Infirmary - Endocrinology Manchester,
McGuire Research Institute, Inc. (151) Richmond, Virginia
MedBio Trials Miami, Florida
Medical College of Wisconsin - Pulmonology Milwaukee, Wisconsin
Medical University of South Carolina - Pulmonology Charleston, South Carolina
Mediservis del Tolima IPS S.A.S. Ibagué,
Metrolina Nephrology Associates - Freedom Dr Charlotte, North Carolina
Mid and South Essex Hospitals NHS Trust Basildon,
Mid-Atlantic Permanente Research Institute Gaithersburg, Maryland
Milwaukee Nephrologists - Wauwatosa Wauwatosa, Wisconsin
Minneapolis VA Healthcare System Minneapolis, Minnesota
Monroe Research, LLC West Monroe, Louisiana
Montefiore Einstein - Albert Einstein College of Medicine The Bronx, New York
Montefiore Einstein Hospital - Moses Campus The Bronx, New York
Morehouse School of Medicine, Grady Memorial Hospital Atlanta, Georgia
NANI Research LLC - Evergreen Park IL Evergreen Park, Illinois
NANI Research LLC - Fort Wayne IN Fort Wayne, Indiana
NTKDA Lewisville Lewisville, Texas
NYC Health + Hospital/Harlem New York, New York
Nashville General Hospital - Meharry Medical College - Nephrology Nashville, Tennessee
Nashville VA Medical Center Nashville, Tennessee
Nephrology & Hypertension Associates, PC Middlebury, Connecticut
Nephrology Associates Fairhope, Alabama
Nephrology Associates of Tidewater, LTD Virginia Beach, Virginia
Nephrology Associates, P.C. - Columbus Columbus, Mississippi
Nephrology Clinical Trials Center Nashville, Tennessee
Nephrology Consultants, LLC Huntsville, Alabama
Nephrology Physicians, LLC Mishawaka, Indiana
Nephrology and Hypertension Associates - Tupelo Tupelo, Mississippi
Nephrotex Research Group Dallas, Texas
Nevada Kidney Disease and Hypertension Centers Las Vegas, Nevada
New Mexico VA Healthcare System Albuquerque, New Mexico
New York Presbyterian Queens Flushing, New York
Nigerian Institute of Medical Research Lagos,
North Carolina Nephrology P.A. - Cary Cary, North Carolina
North Florida/South Georgia Veterans Health System Gainesville, Florida
Northwest Louisiana Nephrology, LLC Shreveport, Louisiana
Northwestern Medical Group Chicago, Illinois
Nottingham University Hospitals - Children's Clinical Research Facility - Pulmonology Nottingham,
Nova Clinical Research, LLC - Bradenton - 59th St Bradenton, Florida
Ochsner Medical Center - New Orleans New Orleans, Louisiana
Ohio State University - Wexner Medical Center - Nephrology Clinical Trials Unit Columbus, Ohio
Olive Branch Family Medical Center Olive Branch, Mississippi
Omega Research Orlando, LLC - Mercy Dr Orlando, Florida
PUC Trials - Unidade Epicenter Curitiba,
Patient First Clinical Trials Lutherville, Maryland
Pharmacorp Clinical Trials, Inc Charleston, South Carolina
Phoenix Children's Hospital, Inc. - Nephrology Phoenix, Arizona
Praxis Pesquisa Medica Santo André, São Paulo
Premier Clinical Research Overland Park, Kansas
Prime Clinical Research - Mansfield - Regency Parkway Mansfield, Texas
Prime Clinical Research Inc - Lewisville Lewisville, Texas
Prime Health and Wellness Fayette, Mississippi
Prolato Clinical Research Center - Kirby Dr Houston, Texas
Promotora Medica Las Americas S.A. - Clinica Las Americas Medellín,
QUEST Research Institute Farmington Hills, Michigan
Queen Elizabeth Hospital Birmingham Birmingham,
Qway Research Hialeah, Florida
Randomize Now - College Park College Park, Georgia
Recherche GCP Research Montreal,
Reina Sofia University Hospital - Nephrology Córdoba,
Renal Associates Columbus, Georgia
Renal Associates of Alabama, LLC Montgomery, Alabama
Renal Associates of Baton Rouge Baton Rouge, Louisiana
Renal Medicine Associates Albuquerque, New Mexico
Renal Research of Montgomery County, PLLC The Woodlands, Texas
Renal and Transplant Associates of New England, PC Springfield, Massachusetts
Ronald Ralph MD PA Houston, Texas
Rophe Adult and Pediatric Medicine Union City, Georgia
Royal Free Hospital - Nephrology London,
Rutgers Doctors Office Center Newark, New Jersey
SKY Integrative Medical Center Ridgeland, Mississippi
SUNY Downstate Health Sciences University Brooklyn, New York
San Antonio Kidney Disease Center Physicians Group - Medical Center San Antonio, Texas
San Antonio Kidney Disease Center Physicians Group - Westover Hills San Antonio, Texas
Santa Casa de Misericordia de Belo Horizonte Belo Horizonte,
Scott Research, Inc. Laurelton, New York
Shands Hospital - Nephrology Gainesville, Florida
Solano & Terront Servicios Medicos SAS - Unidad Integral de Endocrinologia - UNIENDO Bogotá,
South Florida Nephrology Research Coral Springs, Florida
South Florida Research Miami Springs, Florida
South Florida Research Institute Lauderdale Lakes, Florida
Southeast Kidney Associates East Point, Georgia
Southeast Renal Research Institute Chattanooga, Tennessee
Southwest Family Medicine Associates (SFMA) - Dallas Dallas, Texas
Sparrow Clinical Research Institute Lansing, Michigan
St George's Hospital London - Nephrology London,
St Pancras Clinical Research London,
St. Clair Nephrology Research Roseville, Michigan
St. Louis Children's Hospital - Nephrology St Louis, Missouri
St. Louis Heart and Vascular, P.C. St Louis, Missouri
Synexus Clinical Research - Atlanta (DRS) Atlanta, Georgia
Synexus Clinical Research - Chicago (DRS) Chicago, Illinois
Synexus Clinical Research - Glasgow (DRS) Bellshill,
Synexus Clinical Research - Midlands (DRS) Birmingham,
Synexus Clinical Research - NW Consortium Manchester (DRS) Manchester,
Synexus Clinical Research - New York (DRS) New York, New York
Synexus Clinical Research - Orlando Orlando, Florida
Texas Tech University Health Sciences Center Lubbock, Texas
The Bank Hospital Cantonments,
The George Washington University - GW Medical Faculty Associates Washington D.C., District of Columbia
The Johns Hopkins University - Johns Hopkins Hospital - Nephrology Baltimore, Maryland
The Kirklin Clinic - Nephrology Birmingham, Alabama
The Medical Research Group - Saint Agnes Medical Center Fresno, California
The Rogosin Kidney Center New York, New York
The Royal London Hospital - Nephrology London,
Tidewater Kidney Specialists - Church St. Norfolk, Virginia
Total Research Group, LLC Miami, Florida
Tranquil Clinical Research Webster, Texas
Tufts Medical Center Boston, Massachusetts
UAMS Medical Center - Pulmonology Little Rock, Arkansas
UC - DCI McMillan Research Unit Cincinnati, Ohio
UCI Center for Clinical Research Orange, California
UCLA Division of Nephrology Los Angeles, California
UCLA Lundquist Institute at Harbor-UCLA Medical Center Torrance, California
UChicago Medicine - Comer Children's Hospital Chicago, Illinois
UF Health Cardiovascular Center - Jacksonville Jacksonville, Florida
UH Cleveland Medical Center - Nephrology Cleveland, Ohio
UMMC Grenada Hospital Grenada, Mississippi
UNC Clinical and Translational Research Center Chapel Hill, North Carolina
UTSW Medical Center - Nephrology Dallas, Texas
UVA Health - Nephrology Clinical Research Center Charlottesville, Virginia
UW Medical Center - Montlake - Nephrology Seattle, Washington
Unidade Local de Saude Amadora/Sintra, E.P.E. Amadora,
Unidade Local de Saúde de Loures-Odivelas, E.P.E. Loures,
Unidade Local de Saúde de Santa Maria, E.P.E. - Nephrology Lisbon,
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology Leuven,
Universite Catholique de Louvain - Pulmonology Woluwe-Saint-Lambert, Brussels Capital
University College Hospital Ibadan,
University Medical Center - New Orleans - Nephrology New Orleans, Louisiana
University of Ghana Medical School - Nephrology Accra,
University of Iowa Health Care Medical Center- Nephrology Iowa City, Iowa
University of Maryland Medical Center - General Clinical Research Center Baltimore, Maryland
University of Nigeria Teaching Hospital Enugu,
University of Puerto Rico Rio Piedras,
University of Texas Health Science Center - Nephrology San Antonio, Texas
Université Paris-Descartes / Hôpital Européen Georges Pompidou Paris,
VA New York Harbor Healthcare System New York, New York
Velocity Clinical Research - Hallandale Beach Hallandale, Florida
Veterans Affairs Medical Center - Washington D.C Washington D.C., District of Columbia
Virginia Commonwealth University - Division of Nephrology Richmond, Virginia
Walter Cantídio University Hospital Fortaleza,
Whittier Street Health Center Roxbury, Massachusetts
Women's College Hospital Toronto,
Wythenshawe Hospital - Medicines Evaluation Unit Manchester,
Yale University - Yale Nephrology Clinical Research Clinic New Haven, Connecticut
York Clinical Research, LLC Norfolk, Virginia
Zenos Clinical Research Dallas, Texas
Zucker School of Medicine Great Neck, New York